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The present dissertation is divided in two parts. The first one concerns the investigations on 
cascade reactions initiated by π-activation to synthesize heterocycles and the second one 
describes the studies toward the total synthesis of melohenine B. 
In this thesis, distinction between racemates and enantiomers will be applied according to 
the convention shown below: 
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I) The cascade way to heterocycles 
  
 A cascade reaction, also named a domino reaction is, following the definition given by 
Tietze, “a process involving two or more consecutive reactions in which subsequent 
reactions results as a consequence of the functionality formed by bond formation or 
fragmentation in the previous step”.[1] As such, the cascade reactions have an excellent 
economical and ecological advantage over the traditional multistep processes, as they 
perform several steps in one pot without isolating the reaction intermediates. Because one 
of the most important challenges of modern chemistry is to face the increase in complexity 
of the target molecules, in the meantime reduce the environmental impact related to the 
waste disposal, and the conservation of natural resources,[2] the domino process has been 
the subject of intense investigations in the past few years.[3]  
  
 However, long before public awareness regarding the necessity to reduce the human 
impact on the environment, cascade reactions have been recognized as an efficient method 
to synthesize natural products. Indeed, in 1917, after analysis of the biogenesis of the 
bicyclic tropane structure, Schöpf and Robinson described the first domino reaction, leading 
from succindialdehyde I-1, methylamine I-2 and acetonedicarboxylic acid I-3 to tropinone I-9 
via a double Mannich reaction (Scheme 1).[4] More recently, inspired by the biosynthesis of 
lanosterol, the precursor of steroids,[5] W. S. Johnson devised, in 1971, the synthesis of 
progesterone through a cationic polyolefin cyclization.[6]  
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Scheme 1. The Robinson and Schöpf cascade reaction to tropinone synthesis. 
 
 Different reviews on the subject have tried to classify the domino reactions. The 
method employed by Tietze et al. can be singled out.[3b] The arrangement is based on the 
reaction type of the first two steps of the cascade. Cationic, anionic, radical, pericyclic, redox 
and transition-metal-catalyzed transformations are thus distinguished. The last category, the 
transition-metal-catalyzed reactions, has only recently offered new perspectives for 
generating complex molecules.[7] The great potential of this tool lies in the catalytic amounts 
necessary for the reaction and the novel processes for bond formation with no direct parallel 
in nature. In an impressive example, Oppolzer and coworkers described the synthesis of 
tetracyclic compound I-13 via the palladium-catalyzed reaction of the cycloheptene I-10 
(Scheme 2).[8]  
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Scheme 2. Palladium-catalyzed cascade reaction (Oppolzer et al., 1991).[8] 
 
 In addition, an early example of transition-metal-catalyzed domino process to 
construct natural product was described by Vollhardt et al. described in 1979, in the total 
synthesis of (±)-oestrogen using a cobalt-catalyzed cycloaddition, followed by an 
intramolecular Diels-Alder reaction (Scheme 3).[9] 
 
 
Scheme 3. Cobalt-catalyzed total synthesis of (±)-oestrogen (Vollhardt et al., 1979).[9] 
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 Over the last years, a large number of synthetic routes to obtain heterocyclic 
compounds have applied transition-metal-catalyzed cascade reactions.[10] Due to their ability 
to activate π-systems,[11] especially alkynes,[12] strategies using soft metal cations, such as 
AuI, AuIII, AgI or PtII have been found to be excellent for constructing complex scaffolds. 
Moreover, it appears that these catalysts can be employed easily in simple reaction 
conditions and show a remarkable functional group tolerance.[13] For example, Porco et al 
described in 2004 the synthesis of (±)-azaphilone S-15183a, where the key step is a gold-
catalyzed cycloisomerization of o-alkynylbenzaldehyde I-20 (Scheme 4).[14] 
 
 
Scheme 4. Synthesis of (±)-azaphilone S-15183a (Porco et al., 2004).[14]
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II) Catalyzed cascade reactions, a way toward furan 
compounds 
 
1) Furans, an important class of heterocycles 
 
 Furans correspond to a significant class of five-membered heterocycles. They are 
present as key structural units in a variety of natural products,[15] for example in the 
teubrevin G (I-23) and in pharmaceutical substances like the anti gastric ulcer drug ranitidine 
(I-24) (Zantac®).[16] 
 
                                                         
Figure 1. Presentation of selected furan-containing compounds. 
 
 Moreover, they play a useful synthetic role in total syntheses as intermediates ready 
to be further oxidized, reduced or to undergo a cycloaddition.[17] Therefore, their value has 
pressed chemists to develop methods for their syntheses. Classical ways, such as the Paal-
Knorr synthesis[18] (Scheme 5, Eq 1) or the Feist-Benary[19] synthesis (Scheme 5, Eq 2) are 
frequently employed.  
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Scheme 5. Classical methods for furan synthesis. 
 
 Although these reactions have shown to be useful, the development of new routes 
stays a current issue, in particular efficient methods giving access to highly functionalized 
furans under mild conditions. 
 
 Amongst various examples, methods employing cascade reactions to synthesize 
furans are also depicted. They mostly involve a 5-endo cyclization of an alkynyl or allenyl 
ketone.[20] Thus, Larock and coworkers have introduced a gold-catalyzed process where the 
oxonium ion intermediate is trapped with different nucleophiles to produce trisubstituted 
furans (Scheme 6).[21] 
 
 
Scheme 6. Catalyzed synthesis of trisubstituted furans (Larock et al., 2004).[21] 
 
 Copper catalysts are also efficient in catalyzing the cyclization, as shown by 
Yamamoto et al. with the formation of trisubstituted furans employing alkynyl enones and 
copper(I) bromide.[22] Gevorgyan and coworkers have made use of haloallenyl ketones to 
construct di-, tri-, and tetrasubstituted furans.[23]  In this case, the cascade reaction was 
triggered by gold(III) chloride (Scheme 7). 
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Scheme 7. Gold-catalyzed synthesis of tetrasubstituted furans (Gevorgyan et al, 2005).[23] 
 
 In addition to the above examples, Kirsch and coworkers have developed a domino 
reaction that combines a 5-endo heterocyclization and a pinacol-type rearrangement to 
construct 3(2H)-furanones I-36 (Scheme 8).[24]   
 
 
Scheme 8. Synthesis of 3(2H)-furanones via a cyclization/pinacol-type 1,2-alkyl shift 
sequence (Kirsch et al., 2006).[24]
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2) Cyclization/1,2-migration sequence, new development 
 
2.1) The planned process 
 
 The encouraging results on the 3(2H)-furanone syntheses have inspired us to explore 
further the possibilities of the cascade process heterocyclization/1,2-migration.[25] We 
planned that the designed alkynone I-37, following a similar pathway, could be the right 
substrate to generate 2,3-dihydrofurans I-39. After π-activation, I-37 should thus form an 
oxonium ion intermediate, in which the hydroxyl group outside the newly established cycle 
could induce a 1,2-alkyl migration (Scheme 9).  
 
 
Scheme 9. Planned sequence to 2,3-dihydrofurans. 
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2.2) Results and discussion 
 
2.2.1) Substrate synthesis 
  
 Starting substrates I-37 were prepared as shown in Scheme 10. Reduction of 3-
methylcyclohex-2-enone under Luche conditions[26] followed by diastereoselective 
epoxidation with m-CPBA gave epoxide I-43, which was treated with tert-BuMe2SiCl (TBSCl), 
imidazole, and DMAP in CH2Cl2 to afford silyl ether I-44. By use of the conditions developed 
by Pagenkopf and co-workers,[27] alkynylation of the epoxide at the more hindered carbon 
was possible in varying yields with a range of terminal alkynes. Swern oxidation[28] and 
removal of the silyl group under acidic conditions gave cyclohexanone derivatives I-37. As 
confirmed by NOE signals, the alkynyl side chain and hydroxyl group are trans in the six-
membered ring.1 
 
Scheme 10.  Synthesis of substrates I-37. 
 
2.2.2) An unexpected furan 
  
 When the first experiments with substrate I-37a were conducted to test the 
possibility of the cyclization/1,2-alkyl migration cascade with carbophilic Lewis acids, traces 
of an unexpected furan (I-47a) were detected (Entry 1, Table 1).  
 
                                                          
1
 Haug. T. T Die Totalsynthese von (+)-Chloriolide, Technische Universität München, 2010. 
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Entry Catalyst (5 mol%) Solvent      
(0.05 M) 
Time Temperature (°C) Yielda (%)        
I-47a 
1 AuCl(PPh3)/AgSbF6 CH2Cl2 1h rt traces 
2 AuCl(PMe3)/AgSbF6 CH2Cl2 15 min rt 54 
3 AuCl(PMe3)/AgSbF6 Toluene 1h 100 68 
4 AuCl(PPh3)/AgSbF6 Toluene 20 min 100 35 
5 AuCl(PMe3)/AgOTf Toluene 30 min 100 23 
6 AuCl(PMe3)/AgBF4 Toluene 24h 100 22 
7 PtCl
2
 Toluene 5h 100 74 
8 PtCl
4
 Toluene 2h 100 77 
9 PtCl
4
 iPrOHb/Toluene 45 min 100 83 
10 HBF4 CH2Cl2 5h rt 0 
a: Yield of isolated product after complete consumption of I-37a; b: 1.5 equiv. 
Table 1. Screening of conditions. 
 
 Changing the ligand PPh3 to PMe3 led to the formation of the furan I-47a (Entry 1-2, 
Table 1), or switching to other silver salts gave the same result in various yields: no trace of 
the desired dihydro-furan (I-39 or I-40) was observed (Entry 5-6, Table 1).  
 
 As previously described, polysubstituted furans are interesting target structures, it 
appeared to us that this catalyzed route from the cyclohexanones I-37 can be a new and 
convenient way to access trisubstituted furans with an aldehyde-containing side chain. 
Subsequently several conditions were examined to improve the yield of the domino 
sequence. Changing from gold catalysts to platinium proved to be successful, PtCl4 (5 mol%) 
catalyzed the formation of furan I-47a in toluene at 100°C in 77% (Entry 8, Table 1). The 
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addition of iPrOH remarkably decreased the time needed for complete conversion (Entry 9, 
Table 1).  
 
 To explain the furan formation, a mechanism was proposed (Scheme 11). The 
cascade reaction starts as planned for the formation of the 2,3-dihydrofuran, with the 
activation of the alkyne moiety via coordination of the π-acid. The nucleophilic attack of the 
carbonyl group gives the oxonium ion I-48, which after 1,2 shift, rearranges to the spirocyclic 
intermediate I-50.[25b] Grob-type fragmentation[29] of the cation I-50 produces the furan I-47 
with the aldehyde containing side chain. The protodemetalation, necessary for regeneration 
of the catalyst, is probably facilitated by the presence of isopropanol as external proton 
source.  
 
Scheme 11. Proposed mechanism for the formation of I-47. 
 
 The bicyclic dihydrofuran I-39 was not isolated, instead a bicyclic dihydrofuran with 
acid functionality (I-51a) was found by T. T. Haug, using 10 mol% Cu(OTf)2 in wet DMF at 
80°C (Scheme 12). Klaus-Daniel Umland, a coworker on the project, improved the condition 
for the synthesis of the methyl ester of I-51. He found that the reaction of I-37 with 10 mol% 
CuCl in wet DMPU at 80°C, directly followed by methylation, delivered the bicyclic ester in 
82% yield.  
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Scheme 12. Copper-catalyzed cascade reaction. 
 
 The mechanistic investigations by Klaus-Daniel Umland have shown that contrary to 
the redox neutral platinum catalyst, the oxidative copper catalyst leads to heterocyclization 
and oxidation as described in Scheme 13. 
 
 
Scheme 13. Plausible mechanism for the formation of I-51. 
 
2.2.3) Scope of the platinum-catalyzed cascade reaction 
 
 The optimized reaction conditions were applied to a scope of substrates (Table 2). 
Various trisubstituted furans were obtained in good to excellent yields. The domino process 
proved to be efficient with alkyl- (I-47h), aryl- (I-47a, I-47c, I-47d) and heteroaryl- (I-47b) 
substituted alkynes. It appeared that electron donating groups have a positive effect on the 
yield, perhaps due to a better coordination of the π-system to the platinum catalyst. 
Substrates with trimethylsilylethinyl-, silyloxypropinyl- and silyloxybutinyl-moieties were also 
tested. Unfortunately, the cascade reactions failed in these cases. Furans with methyl 
substituted alkyl-chains were also performed in excellent yields (I-47i and I-47j). 
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Table 2. Substrate scope. 
 
 In conclusion, a novel and highly practical route to access a library of trisubstituted 
furans with an aldehyde-containing side chain was developed thanks to a platinum-catalyzed 
sequence consisting of heterocyclization/1,2-migration.  
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3) The catalyzed propargyl-Claisen rearrangement in cascade 
reactions 
 
 Since the first discovery of [3,3]-sigmatropic rearrangements in 1912 by L. Claisen,[30] 
the method has been a widespread tool for synthetic chemists.[31] The interest generated by 
the Claisen rearrangement gave birth to a plethora of different versions of [3,3]-sigmatropic 
rearrangements, as the Carroll rearrangement,[32] the Eschenmoser rearrangement[33] or the 
Ireland-Claisen rearrangement[34]. More recently, transition-metal catalyzed reactions also 
entered into the game.[35] To name some examples, Overman et al. devised the 
rearrangement of allyltrichloroacetimidate to the corresponding trichloroacetamide using 
mercury salt as the catalyst,[36] or even the palladium-catalyzed Claisen rearrangement 
developed by Van der Baan and Bickelhaupt.[37] A catalyzed propargyl-type-Claisen 
rearrangement was first reported in 1997 by Grissom et al.. They described the reaction of 
propargyl-vinyl-ethers to their resultant allenyl-carbonyl products, employing a silver salt 
(Scheme 14).[38]   
 
 
Scheme 14.  First propargyl-Claisen rearrangement (Grissom et al., 1997).[38] 
 
 Toste and coworkers further developed this process by broadening the substrate 
scope and by providing a mechanism to explain the gold-catalyzed rearrangement for 
propargylic vinyl ethers and propargylic vinyl esters.[39] In the case of propargylic vinyl 
ethers, they showed that the [3,3]-rearrangement is irreversible and proceeds via a 
concerted pathway (Scheme 15). After activation of the starting material I-55 through the π-
complex I-56 the rearrangement is induced, assisted by the formation of a cyclic carbocation 
(cyclization-induced rearrangement). A Grob-type fragmentation of I-57 provides the allene 
complex I-58. Finally, the gold cation is released giving the free allene I-59.  
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Scheme 15. Gold-catalyzed [3,3]-rearrangements of propargyl vinyl ethers (Toste et al., 
2004).[39] 
  
 In 2005, Kirsch and coworkers performed a domino process where the propargyl-
Claisen rearrangement occurs prior to a cyclization reaction. With this approach available, 
they have converted easily accessible propargyl vinyl ether[40] into furans,[41] pyrans,[42] 
pyrroles[43]  and 1,2-dihydropyridines[44] (Scheme 16).  
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Scheme 16. Scope of syntheses with propargyl vinyl ether (Kirsch et al.). 
 
 Moreover, propargyl-vinyl-ethers were also used as a powerful starting material by 
Jiang et al., who demonstrated that the propargyl-Claisen rearrangement can also be 
catalyzed by copper,[45] iron,[46] silver[47] and palladium[48] catalysts to deliver, after a domino 
sequence, tri- and tetra-substituted furans. Interestingly, the propargyl-vinyl-ethers were 
prepared in situ with acceptor activated alkynes and propargylic alcohols under basic 
conditions (Scheme 17). 
 
 
Scheme 17. One-pot Synthesis of polysubstituted furans (Jiang et al., 2009).[45] 
 
CATALYZED CASCADE REACTIONS, A WAY TOWARD FURAN COMPOUNDS 
THE CATALYZED PROPARGYL-CLAISEN REARRANGEMENT IN CASCADE REACTIONS 
 
26 
 
 Tejedor and coworkers showed in a series of works that microwave-assisted cascade 
reactions are also great tools to obtain heterocycles from propargyl-vinyl-ethers.[49]
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3.1) The new sequence 
  
 Bearing in mind that the propargyl-Claisen rearrangement[50] can still play an 
important role in building novel cascade reactions, new propargyl vinyl ethers I-72 were 
designed. On the basis of previous work of Kirsch et al. on propargyl-Claisen rearrangements 
and the published work of Gagosz et al[51] (Scheme 18), the catalyzed sequence depicted in 
Scheme 19 was expected to occur to give compound I-74. We planned that the cascade 
reaction starts with activation of the alkyne group of I-72 through coordination with the 
silver-catalyst, which triggers a silver-catalyzed propargyl-Claisen rearrangement. The newly 
formed allene in I-73 should also be activated by the catalyst, which induces a 5-endo 
heterocyclization of the hydroxy group into the allene delivering the desired product I-74 
(Scheme 19). 
 
 
Scheme 18. Cascade reaction including a propargyl-Claisen rearrangement (Gagosz et al., 
2006).[51] 
 
 
Scheme 19. Proposal of a novel cascade reaction. 
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3.2)  Results and Discussion 
 
3.2.1) Synthesis of the propargyl vinyl ethers 
 
To test this idea, the substrates were synthesized in a four-step synthesis as 
described in Scheme 20.  
 
Scheme 20. Synthesis of substrates for the catalyzed cascade reaction. 
 
Propargylic alcohol I-75 was protected as a THP ether followed by the addition to an 
aldehyde, after which the phosphine catalyzed Michael-type addition to an acetylene[52] 
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gave the propargylic vinyl ether I-78, which was deprotected under mild acidic conditions 
with PPTS to produce the starting material (I-72) requisite for the catalyzed domino reaction.   
 
To broaden the scope of substrates and to shorten their access, a two-step synthesis 
was implemented. The propargyl alcohol I-79 was directly added to the acetylene via the 
phosphine catalyzed Michael-type addition, the final addition to an aldehyde gave the 
desired substrate for the catalysis (Scheme 21). 
 
Scheme 21. Shorter approach to the substrates. 
 
3.2.2) Propargyl-Claisen Rearrangement and Condensation 
 
 With regard to the previous results published in the group, the standard substrate (R1 
= Me, R2 = Et) was first subjected to silver and gold salts as catalysts. To our surprise, an 
unexpected furan appeared to be formed in a good yield, particularly with the silver salts 
(Table 3). 
 
 
 
 
 
 
CATALYZED CASCADE REACTIONS, A WAY TOWARD FURAN COMPOUNDS 
THE CATALYZED PROPARGYL-CLAISEN REARRANGEMENT IN CASCADE REACTIONS 
 
30 
 
 
Entry Cat. (10 mol%) Acid (mol%) Solvent 
(0.1 M) 
Temp. (°C) Time (h) Yielda (%) Z/E 
1 AgSbF4 
 
CH2Cl2 rt 24 74 7/2 
2 AuCl 
 
CH2Cl2 rt 3 23 7/2 
3 (PPh3)AuNTf2 
 
CH2Cl2
b rt 24 32 5/1 
4 AgBF4(CN)2 
 
CH2Cl2 rt 24 32 7/2 
5 AgOTf 
 
CH2Cl2 rt 24 76 4/1 
6 AgOTf SnCl4 (10) CH2Cl2 rt 3 0  
7 AgOTf ZnCl2 (10) CH2Cl2 rt 48 traces  
8 AgOTf tBuCl (20) CH2Cl2 rt 3 9  
9 AgBF4 
 
CH2Cl2 rt 48 88 4/1 
10 AgBF4
c 
 
CH2Cl2 35 24 87 4/1 
11 AgBF4 
 
CH2Cl2 35 1 91 3/1 
12 
  
DCE 60 24 0  
13 DCE 90 48 12 7/1 
14   Toluene 120 (Mw) 5 24, P2  
a: Isolated yield after flash chromatography; b: 0.5 M; c: 2 mol%. 
Table 3. Screening of conditions. 
 
 A possible explanation for the formation of the tetra-substituted furan could reside in 
a sequence propargyl-Claisen rearrangement/condensation. After activation of the alkyne 
moiety in I-72a by coordination with the silver-catalyst, which triggers the propargyl-Claisen 
rearrangement, a condensation of the alcohol into the newly formed ketone probably occurs 
instead of the planned 5-endo heterocyclization. Final protodemetalation and aromatization 
give the tetra-substituted furan I-81a (Scheme 22). 
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Scheme 22. A surprising result. 
 
 As in most cases, only the condensation product was isolated, it appears that the 
condensation is quicker than a possible catalyzed heterocyclization. Lewis acids (SnCl4, 
ZnCl2), or hidden Brønsted acid
[53] were thought to help the condensation of the alcohol into 
the ketone (Entry 6-8, Table 3). Instead, other products were isolated: unfortunately, a 
proper characterization was not completed due to the difficulty of obtaining pure samples. 
Thermic conditions were also tested, and formation of the furan was observed at 90°C. 
However, after 48h at this temperature, only 12% of the product was isolated (Entry 13, 
Table 3). Using microwave and heating the propargylic vinyl ether at 120°C for 5h also gave 
the tetrasubstituted furan in mixture with another product, P2 (Figure 2). The latter probably 
arises from a lactonization subsequent to the propargyl-Claisen rearrangement. 
 
 
Figure 2. Propargyl-Claisen rearrangement and lactonization. 
 
 To our knowledge, no other work has reported this sequence of reaction and since 
polysubstituted furans represent an important building block, further investigations were 
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carried out. Silver(I) tetrafluoroborate (Entry 9, Table 3) emerges to be the best catalyst for 
this reaction. After optimization of the conditions, the polysubstituted furan was produced 
in 87% yield in 24h in dichloromethane at 35°C, with 2 mol% silver(I) tetrafluoroborate (Entry 
10, Table 3). However, the product can only be isolated as a mixture of E and Z isomers. To 
facilitate the analytical analysis, it was decided to reduce the double bond.2 Moreover, it is 
worth noticing that a 10 mol% loading in silver salt delivered the product in 91% yield in 1h 
at 35°C (Entry 11, Table 3). However, since the yields are similar, a low catalyst loading was 
favoured over the reaction time. 
 
3.2.3) Scope of the domino sequence 
 
 The selected reaction conditions were applied to test the scope of substrates. A 
library of tri- and tetra-substituted furans was easily synthesized. Alkyl (Entry 1-2-3, Table 4) 
and aryl (Entry 4-7-8, Table 4) substituted furans were obtained in good yields. Nevertheless, 
a more crowded alkyl substituent reduces the performance of the reaction (Entry 5- 6, Table 
4). Moreover, it seems that the presence of a phenyl moiety in R1 is a drawback for the 
reaction, contrary to its presence in R2. The presence of a donor substituent at the vinyl 
position seems to be of prime importance. Indeed when R3 = H (Entry 9, Table 4) the reaction 
occured very slowly (72 hours) with 6 mol% AgBF4 instead of 2 mol%. Gold (I) chloride was 
also tested with substrate I-72i. Although the complete conversion was accelerated (24 
hours), the yield stayed at 31%. 
 
 
 
 
 
 
 
                                                          
2
 2D-NMR studies on p. 149. 
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Entry Substrate R1 R2 R3 Time (h) Yield
a (%) 
1 I-72a Me Et Me 14 72 
2 I-72b Me nPr Me 14 68 
3 I-72c Me tBu Me 14 66 
4 I-72d Me Ph Me 14 78 
5 I-72e iBu Et Me 14 64 
6 I-72f iBu Ph Me 14 60 
7 I-72g Ph Et Me 14 30 
8 I-72h Ph Ph Me 14 65 
9 I-72i Me Et H 72 33b 
10 I-72j Me Et Ph 22 68 
11 I-72k Et Me Me 18 49 
12 I-72l Ph Me Me 5 25 
13 I-72m 4-F-C6H4 Me Me 21 decomposition 
14 I-72n 4-MeO-C6H4 Me Me 2 decomposition 
15 I-72o Et H Me 21 43c 
16 I-72p Ph H Me 19 36c 
17 I-72q H Et Me 18 53 
18 I-72r H Ph Me 14 60 
a: Isolated yield after flash chromatography; b: 6 mol% AgBF4; c: The hydrogenation of the double bond was 
not performed. 
Table 4. Substrate scope. 
 
 In some cases of poor yields, the products were isolated directly after cyclization, in 
order to define if the hydrogenation of the double bond or the sequence of rearrangement-
condensation was responsible for the result. As illustrated in Table 5, with the exception of 
the entries 1 and 6, the yields were already low after the domino sequence. 
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Entry Subtrate R1 R2      R3          Time (h) Yield
a (%) 
1 I-72f iBu Ph Me 15 75 (Z/E 2 :1) 
2 I-72g Ph Et Me 15 34 (Z/E 3 :1) 
3 I-72k Et Me Me 16 56 (Z/E 2.5 :1) 
4 I-72l Ph Me Me 22 31 (Z/E 3 :1) 
5 I-72q H Et Me 16 45 (Z/E 6 :1) 
6 I-72r H Ph Me 15 70 (Z/E 100 :1) 
a: Isolated yield after flash chromatography. 
Table 5. Scope limitation. 
 
3.2.4) Further developments 
 
 To further explore the functionalization of the furan, an oxidative cleavage was 
performed on the double bond. Using conditions developed by Nicolaou et al.,[54] the 
aldehyde functionalized tetra-substituted furan was introduced (Scheme 23). 
 
 
Schema 23. Oxidative cleavage. 
 
 With these encouraging results, pyrrole synthesis was envisioned using the same 
process. With regard to the mechanism described for the furan formation, a new substrate 
containing a nitrogen moiety was formed. Starting from substrate I-72a, the novel nitrogen 
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building block was produced in two steps: the secondary alcohol was transformed into a 
mesylate, which was then easily substituted by benzylamine (Scheme 24). 
 
Scheme 24. Substrate production for pyrrole synthesis. 
 
 The amino compound was intended to react under the same conditions to give the 
corresponding pyrrole derivative. However, only traces were observed. By submitting I-86a 
to gold(I) chloride in DCE at 50°C, we were able to isolate desired pyrrole I-87a in a good 
yield (80%). The hydrogenation of the double bond delivered I-88a in 81% yield (Scheme 25). 
 
 
Scheme 25. Synthesis of tetrasubstituted pyrrole. 
 
 However, it seems that the benzyl substituent is essential for a good yield. Switching 
from a benzyl to a butyl group, the yield was reduced dramatically to 29%. 
 
 To conclude, a silver-catalyzed cascade reaction was developed and implemented as 
a convenient process to deliver tri- and tetra-substituted furans with the side chain available 
for further functionalization. In addition to the furans, the sequence also gave access to 
polysubstituted pyrroles.  
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4) Summary 
  
As part of the project on the cascade reactions initiated by π-activation, two 
sequences were developed to produce tri- and tetra-substituted furans. 
 
On one hand, by exploring the cascade process of heterocyclization/1,2-migration to 
provide 2,3-dihydrofurans, an unexpected furan was isolated. Nevertheless, as poly-
substituted furans are interesting target structures, the catalyzed route from the 
cyclohexanones I-37 was investigated and a new and convenient way to access tri-
substituted furans with an aldehyde-containing side chain was developed (Scheme 26). The 
sequence is catalyzed by PtCl4 and probably proceeds via a heterocyclization followed by 1,2-
shift ring-contraction and a Grob-type fragmentation.[55] 
 
Scheme 26. Platinum-catalyzed cascade reaction, heterocyclization /1,2-migration.  
 
On the other hand, in the realm of the study on catalyzed propargyl-Claisen rearran-
gements launched in the Kirsch group, a sequence of propargyl-Claisen rearran-
gement/condensation on propargylic vinyl ethers has generated tri- and tetra-substituted 
furans. The domino reaction was effectively catalyzed by AgBF4, and to facilitate the 
analytical analysis, the process was terminated by hydrogenation of the double bond 
(Scheme 27).  
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Scheme 27. Silver-catalyzed propargyl-Claisen rearrangement. 
  
 However, the method presents some limitations in the case of phenyl moiety in R1 or 
in the case of a terminal double bond, where the yields drop dramatically to 30-40%.  
 
 In addition to the furan formation, a pyrrole synthesis was envisioned using the same 
process. Nevertheless, it required 10 mol% AuCl in DCE at 50°C to be effective (Scheme 28). 
N-benzyl pyrrole was isolated in an excellent 80% yield. Unfortunately replacing the benzyl 
group by a butyl group, the yield was reduced to 29%.   
 
Scheme 28. Synthesis of tetrasubstituted pyrrole.
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III) Catalyzed cascade reactions, a way toward pyridine 
derivatives 
 
1) Introduction 
 
 Like furans, pyridines are also a significant class of heterocycles. They are present in 
numerous natural products, active pharmaceuticals and functional materials.[56] To name 
some examples, the alkaloids methyl multijuguinate[57] (I-89) and monasnicotinate A[58] (I-
90), were recently isolated from a Brazilian tree and fermented rice respectively. Pyridine 
derivatives for pharmaceutical uses include, for example, imatinib mesylate (Gleevec)[59] (I-
91) prescribed for chronic myelogenous leukemia or the asthma treatment drug, 
tripelennamine (Pyribenzamine)[60] (I-92). 
 
                         
                                                    
Figure 3. Presentation of selected pyridine-containing compounds. 
 
 Since the first isolation of the pyridine base picoline by Anderson from bone oil in 
1846,[61] and the structure elucidation by Körner[62] (1869) and Dewar[63] (1871), the pyridine 
derivatives have gained in commercial importance. The production by coal tar distillation 
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was no longer adequate and synthetic methods were implemented. Most of them were 
condensation reactions between an amine and a carbonyl compound as the Hantzsch 
pyridine synthesis[64] (Scheme 29, Eq 1) or the [3 + 2+ 1] Kröhnke synthesis[65] (Scheme 29, Eq 
2).  
 
 
Scheme 29. Condensation methods. 
 
 Modern routes do not banish condensation approaches: nevertheless, the current 
trend is the transition-metal-catalyzed process.[66] Amongst several groups, Trost and 
coworkers make use of a ruthenium-catalyzed cascade reaction (Scheme 30, Eq 1).[67] The 
strategy is based on a metal-catalyzed cycloisomerization followed by a 6π–electro-
cyclization. This last stage is a rather common approach to terminate the cascade sequence 
and to provide the pyridine derivatives.[68] For his part, Larock et al. have developed a two-
step synthesis via palladium/copper catalyzed procedure (Scheme 30, Eq 2),[69] and 
Barluenga and coworkers have devised a [4 + 2] route through a gold-catalyzed dehydro-aza-
Diels-Alder reaction (Scheme 30, Eq 3).[70] 
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Scheme 30. Transition-metal catalyzed methods. 
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2) Pyridine synthesis, a novel approach  
 
 Despite the large development of transition-metal-catalyzed or electrophilically 
induced cascade reactions to synthesize N-heterocycles,[71] their application to the pyridine 
synthesis is rather rare. With the desire to rectify this tendency, we decided to launch a 
study on the activity of ene-ynamides toward π-acids to access pyridine derivatives. Keeping 
in mind the previous works achieved in the Kirsch group on enynes,[72] and in particular the 
one, demonstrating that 1,5-enynes can undergo a 6-endo cyclization to reach a large scope 
of polysubstituted benzenes,[73] we believed that N-allyl-ynamides should be the elements of 
choice to produce pyridines. The envisaged cascade sequence is similar to the one applied 
for the polysubstituted benzenes, namely a 6-endo carbocyclization and subsequent 
oxidative aromatization (Scheme 31). 
 
 
Scheme 31. Planned sequence for pyridine synthesis. 
 
  Although methods using ene-ynamides are sparse,[74] two processes based on the 
activation of ene-ynamide π-system have convinced us of the power of this entity.[75] 
Malacria and coworkers demonstrated that 1,6- and 1,7-ene-ynamides can undergo 
platinum-catalyzed cycloisomerization (Scheme 32, Eq 1) via activation of the alkyne and 
[2+2] cycloaddition. In addition, Cossy et al. reported a 1,6-ene-ynamide gold-catalyzed 
cycloisomerization (Scheme 32, Eq 2). 
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Scheme 32. Examples of ene-ynamide applications. 
CATALYZED CASCADE REACTIONS, A WAY TOWARD PYRIDINE DERIVATIVES 
RESULTS AND DISCUSSION 
 
43 
 
3) Results and Discussion 
 
3.1) Substrate synthesis 
 
 Various routes for the synthesis of ene-ynamides are known.[76] Brückner’s 
procedure[76b] was first chosen due to it’s flexibility in obtaining a large variety of substrates 
(Scheme 33). The commercially available tosylamide is formylated, followed by alkylation to 
obtain N-allyl formamide I-121. One must note that the inverse process, i.e. alkylation 
followed by formylation, failed in case of tosyl protection of the amine. Compound I-121 was 
then converted to N-allyl ynamide via a Corey-Fuchs protocol.[77] A final Sonogashira cross-
coupling reaction allowed us to functionalize the terminal acetylene carbon.[78] 
 
Scheme 33. Synthesis of the starting material I-124. 
 
 We also used Hsung’s alternative.[76a] The substrate production was reduced to a 
two-step synthesis (Scheme 34). After alkylation, amide I-126 was converted to ynamide via 
a cross-coupling reaction of the amide with bromo-phenylacetylene using a Cu(II) catalyst. 
 
Scheme 34. Alternative route for the subtrate synthesis. 
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3.2)  Studies on the pyridine synthesis 
 
 Based on the previous work on 1,5-enynes to access benzene derivatives using metal-
free conditions[73] and the attraction for simple reaction conditions, we started our journey 
by testing iodocarbocyclization protocols.[79] Treatment of ene-ynamide I-124 with NIS in 
dichloromethane did not produce the desired pyridine, but a lactam compound I-127 
(Scheme 35).  
 
 
Scheme 35. An unexpected result. 
 
 As shown in Scheme 36, contrary to the anticipated mechanism, NIS seems to 
activate the olefin rather than the alkynyl moiety. The iodonium ion triggered then the 5-exo 
cyclization and the newly formed cationic species was trapped by a nucleophile, here a 
water molecule, and tautomerisation delivered finally I-127.   
 
Scheme 36. A proposed mechanism for the formation of lactam I-127. 
 
 Although this result was not the anticipated one, it could be an interesting road into 
the production of lactam derivatives. However, further investigations in this path revealed 
that the route is not robust since the isolation of I-127 was not reproduced. As the metal-
free pathway was fruitless, transition-metal catalysts were tested (Table 6). 
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Entry Catalyst (5 mol%) Solvent (0.1 M) Temp. (°C) Results 
1 AuCl CH2Cl2 rt  50 SM 
2 AuCl Toluene 80 I-130 
3 (PPh3)AuCl/AgSbF6 CH2Cl2 rt  50 SM 
4 (PPh3)AuCl/AgSbF6 Toluene 80 Decomposition 
5 PtCl2 Toluene 80 Decomposition 
Table 6. Screening of transition-metal catalysts. 
 
 Standard conditions for “π-acids” were employed without significant results. At room 
temperature and slightly higher temperature (50°C), no reactivity was observed. However, 
treatment of N-allyl ynamide I-124 with gold(I) chloride in hot toluene allowed us to isolate a 
new product, ketenimine I-130 (Scheme 37).  
 
 
Scheme 37. Formation of an unwished ketenime.   
 
 An aza-Claisen rearrangement[80] is most likely responsible for this result. The 
formation of ketenimines[81] via a 3-aza-Claisen rearrangement of N-allyl ynamides has 
already been demonstrated by Hsung et al. in the case of thermal or palladium-catalyzed 
conditions.[82] Recognizing this, no further investigation was continued in this direction.  
 
 At this point, substrate I-124 appeared to be unsuitable for the planned pyridine 
synthesis. It was then decided to change the orientation and to start over with a new kind of 
substrate. The novel strategy was based on a propargyl ynamide building block, where 
activation of one of the alkyne moieties should trigger a 6-endo cyclization and oxidative 
aromatization should deliver the pyridine derivative (Scheme 38).  
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Scheme 38. Novel strategy for pyridine synthesis. 
 
 As illustrated in Scheme 39, the synthesis of substrate I-131 proceeded by using 
Hsung’s protocol, which was less effective with a propargyl amide than with an allyl amide. 
 
Scheme 39. Synthesis of substrate I-131. 
 
 Various conditions were screened (Table 7), transition-metal-catalyzed as well as 
metal free conditions. In both cases, the results were clearly unsatisfactory. With transition-
metal catalysts, no reaction occurred at room temperature or at slightly higher temperatures 
(50°C), and heating up to 80°C resulted in decomposition of the starting material. For gold(I) 
chloride (Entry 2, Table 7), a new compound was isolated without complete identification. 
Nevertheless it appeared that the primary alkyne moiety did not react. In the case of metal-
free conditions (Entry 8, Table 7), the diacetylene was reactive toward NIS, unfortunately 
none of the isolated compounds corresponded to a pyridine derivative. 
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Entry Catalyst (5 mol%) Solvent (0.1 M) Temp. (°C) Results 
1 AuCl CH2Cl2 rt 50 SM 
2 AuCl Toluene 80 Primary alkyne still 
present 
3 PtCl2 Toluene
a 80 Decomposition 
4 PtCl4 Toluene
a 80 Decomposition 
5 (PPh3)AuCl/AgSbF6 CH2Cl2 rt SM 
6 (PPh3)AuCl/AgSbF6 Toluene 80 Decomposition 
7 CuI DMF 80 - 
8 NISb CH2Cl2
a rt - 
a: 0.07 M; b: 2 equiv.  
Table 7. Tests on I-131 for pyridine construction. 
 
 In light of these results, the investigations on the subject were stopped. Both 
imagined substrates seemed to be powerless to reach pyridine derivatives. A new modeling 
of the substrate appears necessary, for example new protecting groups for the amine or 
other substituents attached to the π-system. However, the latter also means a reduction of 
the reaction scope. 
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4) Summary 
 
In our effort to develop new strategies for heterocycle synthesis, a cascade sequence 
to access pyridine derivatives was planned. Based on previous works achieved in the Kirsch 
group on enynes,[72] and in particular on the one demonstrating that 1,5-enynes can undergo 
a 6-endo cyclization to reach a large scope of polysubstituted benzenes,[73] N-allyl ynamides 
were formed to provide a library of pyridine backbones (Scheme 40). 
 
 
Scheme 40. Planned sequence for pyridine synthesis. 
 
Unfortunately, as the first tests were carried out, it appeared that substrate I-124 
was not well conceived to produce pyridines. Indeed, the screened conditions did not give 
significant results. They either led to complete recovery of the starting material or complete 
decomposition. In two different cases, products were isolated, nevertheless none of them 
were the expected pyridine derivative. In the first case, contrary to the anticipated 
mechanism, NIS seemed to activate the olefin rather than the alkynyl moiety. Then, as 
planned, the iodonium ion probably triggered the 5-exo cyclization and the newly formed 
cationic species was trapped by a water molecule, tautomerization delivered finally lactam I-
127 (Scheme 41). In the second case, the substrate I-124 with a catalytic presence of gold(I) 
chloride in hot toluene provided a new product, ketenimine I-130, most likely due to an aza-
Claisen rearrangement of the N-allyl-ynamide (Scheme 41). 
 
 
Scheme 41. Formation of undesired products.  
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  At this point, a novel strategy was envisioned based on a propargyl ynamide 
substrate. Similarly, activation of one of the alkyne moieties should trigger a 6-endo 
cyclization and oxidative aromatization should deliver the pyridine derivative (Scheme 42).  
 
 
Scheme 42. Novel strategy for pyridine synthesis. 
 
Various conditions were tried: transition-metal-catalyzed as well as metal free 
conditions. In both cases, no positive result emerged. 
 
 Together, tested substrates and conditions seemed to be powerless to reach pyridine 
derivatives. A new modeling of the substrate appears necessary, like a new protecting group 
for the amine or other substituents attached to the π-system. However, the latter also 
means a reduction of the reaction scope. Consequently, no further investigation has been 
conducted on this project.  
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IV) Experimental part 
 
1) General procedures 
 
Air and water sensitive reactions were performed in flame-dried glassware under an 
argon or nitrogen atmosphere. Air and moisture sensitive reagents were introduced via 
argon or nitrogen pre-filled plastic syringes, dry glass syringes or cannula.  
At low temperature, the reactions were carried out in a dewar filled with ice-water 
(0°C) or acetone/dry ice (-78°C). Under 0°C, reactions were accomplished with a cryostat 
(Thermo Haake, EK90).  
 
1.1) Solvents and reagents 
 
Dichloromethane (CH2Cl2), diethyl ether (Et2O), tetrahydrofuran (THF) were dried 
using a solvent purification system SPS-800 from M.Braun GmbH: 
 CH2Cl2: Merck Emsure®, p. a., 99.8%, <0.03% H2O, Column 2 × MB-KOL-A. 
 Et2O: Merck Emsure®, p. a., 99.7%, <0.03% H2O, Column 1 × MB-KOL-A, 1 × 
MB-KOL-M Typ 2. 
 THF: Merck Emsure®, p. a., 99.8%, <0.03% H2O, Column 2 × MB-KOL-M Typ 
2. 
Other solvents and reagents were purchased dry:  
 Acetonitrile: Acros Organics, Extra Dry, 99.9% over molecular sieves,           
< 0.005% H2O. 
 Dimethylsulfoxide: Sigma-Aldrich, puriss., 99.5% over molecular sieves,     
< 0.01% H2O or Acros Organics, Extra Dry, 99.9% over molecular sieves,           
< 0.005% H2O. 
 Methanol: Acros Organics, Extra Dry, 99.8% over molecular sieves,                    
< 0.005% H2O. 
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 N,N-Dimethylformamide: Sigma-Aldrich, puriss., 99.5% over molecular 
sieves, < 0.01% H2O or Acros Organics, Extra Dry, 99.9% over molecular 
sieves, < 0.005% H2O. 
 Toluene: Acros Organics, Extra Dry, 99.8% over molecular sieves, < 0.005% 
H2O. 
 1,2-dichloroethane: Acros Organics, Extra Dry, 99.8% over molecular 
sieves, < 0.005% H2O. 
 N,N-Diisopropylethylamine: Sigma-Aldrich, puriss., 99.5% over molecular 
sieves, < 0.05% H2O. 
 Pyridine: Acros Organics, Extra Dry, 99.8% over molecular sieves, < 0.005% 
H2O or Sigma-Aldrich, puriss., 99.8% over molecular sieves, < 0.005% H2O 
 Triethylamine: Distillated from molecular sieves and used immediately 
after distillation.  
 
Solvents used for thin layer chromatography (TLC), flash chromatography or work up 
(CH2Cl2, Et2O, THF, ethyl acetate, acetone, ethanol, methanol, pentanes, cyclohexane, 
petroleum ethers) were simply distilled. All other solvents and reagents were purchased 
from Aldrich, Acros, Fluka and Merck and used without further purification. 
 
1.2) Analytical techniques and apparatus 
 
Analytical thin-layer chromatography (TLC)  
TLC was performed with Merck Kieselgel 60 F254, 0.25 mm precoated glass-backed TLC 
plates. TLC plates were visualized using UV254, cerium ammonium molybdate (CAM) solution, 
or potassium permanganate (KMnO4) solution. CAM solution was prepared using 2.0 g 
cerium (IV) sulfate, 25.0 g ammonium heptamolybdate, 50 mL H2SO4 and 300 mL water. 
KMnO4 was prepared using 3 g potassium permanganate, 20.0 g potassium carbonate and 5 
mL 5% sodium hydroxide in 300 mL water.   
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Flash Chromatography 
 Flash chromatography was carried out using 60 silica gel (40-63 µm, 230-400 mesh 
ASTM) available from Merck.  
 
Gas chromatography (GC and GC-MS) 
 GC-MS spectra were recorded on an Agilent gas chromatography, Agilent 
Technologies 7890 A equipped with column HP-5MS (30 m x 250 µm x 0.25 µm), an Agilent 
Technologies 5975C inert MSD with triple-axis detector and helium as the carrier gas.  
 
Infrared spectroscopy (IR) 
 Infrared spectra were recorded on a JASCO IR-4100 spectrometer. Samples were 
analysed neat with attenuated total reflection (ATR). Characteristic bands are reported in 
wave length (cm-1).  
 
Mass Spectroscopy (MS) 
 Mass spectroscopic data were recorded using Finnigan MAT 8200 and an Agilent 
Technologies 5975C (electron ionization, EI 70 eV), or using a MAT 95S and a Bruker 
micrOTOF Agilent 1100 Series (high resolution mass spectroscopy, HRMS).  
 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
1H NMR spectra were obtained on Bruker 600 MHz FT-NMR, 400 Mhz FT-NMR, 500 
MHz FT-NMR, 360 MHz FT-NMR and 250 MHz FT-NMR spectrometers. 13C NMR spectra were 
recorded at 151.1 Mhz, 100.7 MHz, 90.6 MHz or 62.9 Mhz. Chemical shifts are reported in 
ppm relative to solvent signal. Multiplicity is indicated as follows: s (singlet); d (doublet); t 
(triplet); m (multiplet); dd (doublet of doublets).  
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2) Catalyzed cascade reactions, a way toward furan 
compounds 
 
2.1) Cyclization/1,2-migration sequence, new development 
 
3-Methylcyclohex-2-enone (I-41) 
 
 
 
To a solution of ethylacetoacetate (9.20 g, 71.0 mmol) in tBuOH (71 mL) methyl vinyl ketone 
(5.00 g, 71.0 mmol) was added. The solution was cooled to 0°C and tBuOK (599 mg, 5.34 
mmol) was added.The resulting mixture was stirred for 30 minutes, then another portion of 
tBuOK (1.59 g, 14.2 mmol) was incorporated. The reaction mixture was heated to reflux. 
After 20 hours, it was quenched with a 1M solution of HCl and extracted three times with 
EtOAc. The combined organic phase was washed with NaOH (1M) and sat. NaCl-solution, 
dried over Na2SO4 and concentrated under reduced pressure. After distillation, I-41 (5.73 g, 
52.0 mmol, 67%) was obtained as a clear colorless liquid.  
 
TLC: Rf = 0.43 (Pentanes/EtOAc = 8/2) [CAM/UV]  
 
1H NMR (250 MHz, CDCl3)  [ppm] 5.87 (s, 1H), 2.39-2.21 (m, 4H), 2.07-1.89 (m, 5H). 
 
13C NMR(63 MHz, CDCl3)  [ppm] 199.7, 162.7, 126.7, 37.0, 30.9, 24.4, 22.5.  
 
The analytic data are identical to the literature data.[83] 
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3-Methylcyclohex-2-enol (I-42a) 
 
 
 
To a solution of CeCl3
.7H2O (1.68 g, 45.0 mmol) in dry methanol (82 mL) 3-methylcyclohex-2-
enone I-41 (5.0 g, 45.0 mmol) was added. Under ice bath cooling, NaBH4 (1.70 g, 45.0 mmol) 
was slowly introduced. The reaction mixture was allowed to stir at room temperature for 
1 h. Then, it was quenched with water and extracted three times with Et2O. The combined 
organic phase was washed with sat. NaCl-solution, dried over Na2SO4 and concentrated 
under reduced pressure. The crude product I-42a (4.74 g, 42.5 mmol, 94%) was obtained as 
colourless oil. It was directly used for the next step without further purification.  
 
TLC: Rf = 0.43 (Pentanes/EtOAc= 8/2) [CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 5.46 (d, J =1.3 Hz, 1H), 4.14 (s, 1H), 1.87 (d, J = 5.7 Hz, 2H), 
1.80-1.69 (m, 2H), 1.65 (d, J = 0.7 Hz, 3H), 1.59-1.48, m, 2H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 139.1, 124.6, 66.2, 32.0, 30.4, 24.0, 19.3.  
 
The analytical data are identical to the literature data.[84] 
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6-Methyl-7-oxabicyclo[4.1.0]heptan-2-ol(I-43a) 
 
 
 
To a solution of I-42a (7.75 g, 69.1 mmol) in dry CH2Cl2 (461 mL), NaHCO3 (14.5 g, 172 mmol) 
was added. The resulting mixture was cooled to 0°C and m-CPBA (17.9 g, 103 mmol) was 
slowly introduced. The mixture was allowed to warm to room temperature and was stirred 
overnight. The reaction was then quenched with sat. Na2SO3-solution, and extracted three 
times with EtOAc. The combined organic phase was washed with sat. NaHCO3 solution and 
sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced pressure. The crude 
product I-43a (8.53 g, 66.55 mmol, 96%) was obtained as colourless oil. It was directly used 
for the next step without further purification.  
 
TLC: Rf = 0.11 (Pentanes/EA = 8/2) [CAM] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 4.02 (td, J = 5.3, 3.5 Hz, 1H), 3.16 (d, J = 3.3 Hz, 1H), 1.94-
1.80 (m, 1H), 1.73-1.55 (m, 1H), 1.55-1.42 (m, 3H), 1.35 (s, 3H), 1.31-1.20 (m, 1H). 
 
13C NMR(91 MHz, CDCl3)  [ppm] 66.9, 62.7, 62.1, 29.4, 29.1, 24.1, 18.1.  
 
The analytical data are identical to the literature data.[84] 
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6-butyl-7-oxabicyclo[4.1.0]heptan-2-ol (I-43b) 
 
 
 
 
 
 
Following the same procedure as for I-43a, 3-butyl-2-cyclohexen-1-ol (1.5 g, 9.72 mmol) was 
epoxidized with m-CPBA (2.30 g, 14.6 mmol) giving the product I-43b (1.59 g, 9.03 mmol, 
93%). 
 
TLC: Rf = 0.17 (Pentanes/Et2O = 7/3) [CAM] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 4.04-3.91 (m, 1H), 3.13 (d, J = 3.0 Hz, 1H), 2.01-1.80 (m, 
1H), 1.78 (dd, J = 8.4, 4.9 Hz, 1H), 1.74-1.64 (m, 1H), 1.54 (ddd, J = 12.6, 6.4, 3.7 Hz, 5H), 1.42-
1.18 (m, 5H),  0.90 (t, J = 7.1 Hz, 3H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 66.96, 64.40, 61.43, 37.15, 29.06, 26.87, 26.65, 22.70, 
18.25, 13.97. 
 
The analytical data are conformed to the literature.[85] 
 
t-Butyldimethyl((-6-methyl-7-oxabicyclo[4.1.0]heptan-2-yl)oxy)silane(I-44a) 
 
 
 
To a solution of 6-methyl-7-oxabicyclo[4.1.0]heptan-2-ol I-43a (1.00 g, 7.80 mmol) in abs. 
CH2Cl2 (49 mL) at 0°C, were added imidazole (637 mg, 9.36 mmol), TBS-chloride (1.41 g, 9.36 
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mmol) and DMAP (47.6 mg, 390 µmol). The reaction mixture was allowed to warm to room 
temperature and stirred for 5 h. Then the reaction was quenched with water and extracted 
with Et2O, the combined organic phase was washed with sat. NaCl-solution, dried over 
Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (Pentanes/Et2O = 9/1) to obtain the product I-44a (1.64 g, 6.77 mmol, 87%). 
 
TLC: Rf = 0.27 (Pentanes/EtOAc = 99/1) [CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 4.01 (ddd, J = 8.3, 6.1, 2.0 Hz, 1H), 2.96 (d, J = 1.8 Hz, 1H), 
1.85–1.36 (m, 6H), 1.30 (s, 3H), 0.92(s, 9H), 0.11 (s, 3H), 0.09 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 69.7, 63.4, 60.5, 28.2, 27.9, 26.0, 24.3, 20.1, 18.4, -4.37, -
4.41.  
 
The analytical data are identical to the literature data.[86] 
 
t-Butyl((-6-butyl-7-oxabicyclo[4.1.0]heptan-2-yl)oxy)dimethylsilane (I-44b) 
 
 
 
Following the same procedure as for I-44a, I-43b (1.40 g, 8.22 mmol) was protected with 
TBS-chloride (1.49 g, 9.87 mmol). After flash chromatography (Pentanes/Et2O = 99/1), the 
product I-44b (1.74 g, 6.12 mmol, 75%) was obtained. 
 
TLC: Rf = 0.24 (Pentanes/Et2O = 99/1) [CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 4.03-3.92 (m, 1H), 2.94 (d, J = 1.9 Hz, 1H), 1.70 (dd, J = 8.8, 
4.1 Hz, 2H), 1.64-1.14 (m, 10H), 0.91 (s, 12H), 0.11 (s, 3H), 0.09 (s, 3H). 
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13C NMR (63 MHz, CDCl3)  [ppm] 69.8, 63.4, 62.4, 37.7, 26.9, 28.0, 26.0, 25.9, 22.7, 20.4, 
18.2, 14.0, -4.48, -4.52.  
 
MS (EI, 70 eV) m/z (%): 227.17 (100) [M+- tBu], 185 (11), 171 (72), 157 (72), 141 (56), 129 
(31), 115 (20), 105 (17), 93 (36), 75 (100), 67 (27), 41 (26).  
 
HRMS (EI, 70 eV) m/z 227.14585, [227.14619 calcd. for C12H23O2Si (M
+- tBu)]. 
 
General procedure for the epoxide opening(A) [27] 
 
To a solution of alkyne (1.2 equiv.) in abs. Et2O (0.20 M) at 0°C, were slowly added to nBuLi 
(1.2 eq) and AlMe3 (1.1 equiv.), the resulting mixture was allowed to warm to room 
temperature, and then the epoxide (1 equiv.) was introduced. The solution was cooled to -
78°C and BF3.OEt2 (2 equiv.) was slowly added. After 3 h at -78°C, methanol was added; the 
reaction was stirred for 15 minutes, quenched with aq. 20% Na-/K-tartrate-solution and 
glycerine. The resulting mixture was extracted three times with Et2O. The combined organic 
phase was washed with sat. NaCl-solution, dried over Na2SO4 and concentrated under 
reduced pressure. The crude product was purified by flash chromatography. 
 
6-((t-Butyldimethylsilyl)oxy)-2-methyl-2-(phenylethynyl)cyclohexanol(S5a) (I-45a) 
 
 
 
Following procedure A, the epoxide I-44a (750 mg, 3.31 mmol) was reacted with 
phenylacetylene (440 mg, 4.30 mmol). After flash chromatography (Pentanes/Et2O = 99/1), 
the product I-45a (888 mg, 2.57 mmol, 78%) was obtained. 
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TLC: Rf = 0.27 (Pentanes/EtOAc = 99/1) [CAM/UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.41-7.27 (m, 5H), 4.26-4.14 (m, 1H), 3.67 (d, J = 2.7 Hz, 
1H), 2.45 (s, 1H), 1.75-1.32 (m, 9H), 0.91 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 131.4, 128.2, 127.7, 123.7, 94.2, 83.2, 75.9, 71.1, 37.4, 
31.3, 28.1, 25.8, 20.9, 18.1, -4.53, -4.83. 
 
MS (EI, 70 eV) m/z (%): 287 (61) [M+- tBu], 269 (10) [M+- iPr-H2O], 195 (40), 180 (20), 167 
(30), 141 (22), 115 (25), 75 (100).  
 
The analytical data are conformed to the literature.[27] 
 
6-((t-Butyldimethylsilyl)oxy)-2-methyl-2-(thiophen-3-ylethynyl)cyclohexanol (I-45b) 
 
 
 
Following procedure A, the epoxide I-44a (500 mg, 2.06 mmol) was reacted with 3-
ethynylthiophene (267mg, 2.47 mmol). After flash chromatography (Pentanes/Et2O = 99/1), 
the product I-45b (374 mg, 1.07 mmol, 52%) was obtained. 
 
TLC: Rf = 0.50 (Pentanes/Et2O = 99/1) [CAM/UV] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 7.35 (dd, J = 3.0, 1.2 Hz, 1H), 7.27-7.25 (m, 1H), 7.07 (dd, J 
= 5.0, 1.2 Hz, 1H), 4.21-4.14 (m, 1H), 3.67 (d, J = 2.6 Hz, 1H), 2.45 (s, 1H), 1.75-1.45 (m, 8H), 
1.39 (s, 3H), 0.93 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H). 
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13C NMR (91 MHz, CDCl3)  [ppm] 129.9, 127.6, 125.1, 122.6, 93.7, 78.1, 75.8, 71.0, 37.4, 
31.3, 28.1, 25.9, 25.8, 20.9, 18.1, -4.50, -4.79. 
 
MS (EI, 70 eV) m/z (%): 293 (100) [M+- tBu], 275 (8), 247 (14), 201 (55), 186 (16), 167 (16), 
161 (14), 147 (10), 131 (15), 121 (10), 93 (11), 75 (97), 44 (10). 
 
HRMS (EI, 70 eV) m/z 293.1022, [293.1026 calcd. for C15H21O2SSi (M
+- tBu)]. 
 
6-((t-Butyldimethylsilyl)oxy)-2-((4-methoxyphenyl)ethynyl)-2-methylcyclohexanol (I-45c) 
 
 
 
Following procedure A, the epoxide I-44a (495 mg, 2.06 mmol) was reacted with 4-
ethynylanisole (323 mg, 2.47 mmol). After flash chromatography (Pentanes/Et2O = 99/1), the 
product I-45c (458 mg, 1.22 mmol, 60%) was obtained. 
 
TLC: Rf = 0.63 (Pentanes/Et2O = 95/5) [UV/CAM] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 7.35-7.31 (m, 2H), 6.87-6.82 (m, 2H), 4.23-4.16 (m, 1H), 
3.83 (s, 3H), 3.67 (d, J = 2.7 Hz, 1H), 2.45 (s, 1H), 1.70-1.44 (m, 7H), 1.39 (s, 3H), 0.93 (s, 9H), 
0.12 (s, 3H), 0.11 (s, 3H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 159.2, 132.8, 115.8, 113.8, 92.6, 82.9, 76.0, 71.0, 55.3, 
37.4, 31.4, 28.2, 25.9, 21.0, 18.1, -4.51, -4.78. 
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MS (EI, 70 eV) m/z (%): 317 (100) [M+- tBu], 298 (5), 224 (32), 209 (8), 185 (13), 159 (5), 131 
(8), 121 (10), 75 (41), 43 (18). 
 
HRMS (EI, 70 eV) m/z 374.2273, [374.2272 calcd. for C22H34O3Si]. 
 
6-((t-Butyldimethylsilyl)oxy)-2-((3-chlorophenyl)ethynyl)-2-methylcyclohexanol (I-45d) 
 
 
 
Following procedure A, the epoxide I-44a (700 mg, 2.89 mmol) was reacted with 3-chloro-1-
ethynyl-benzene (474 mg, 3.47 mmol). After flash chromatography (Pentanes/Et2O = 99/1), 
the product I-45d (362 mg, 0.95 mmol, 33%) was obtained. 
 
TLC: Rf = 0.60 (Pentanes/Et2O = 99/1) [UV/CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.39 (d, J = 1.8 Hz, 1H), 7.30-7.25 (m, 3H), 4.25-4.07 (m, 
1H), 3.68 (d, J = 2.7 Hz, 1H), 2.47 (s, 1H), 1.66-1.57 (m, 6H), 1.41 (s, 3H), 0.94 (s, 9H), 0.14 (s, 
3H), 0.13 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 134.1, 131.4, 129.6, 129.4, 128.0, 125.4, 95.6, 81.9, 75.7, 
71.1, 37.5, 31.3, 28.1, 25.8, 20.9, 18.1, -4.49, -4.79. 
 
MS (EI, 70 eV). m/z (%): 323 (17), 321 (60) [M+- tBu], 303 (6), 286 (8), 239 (6), 229 (40), 194 
(20), 179 (10), 165 (8), 131 (12), 93 (11), 75 (100). 
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HRMS (EI, 70 eV) m/z 321.1076, [321.1072 calcd. for C17H22O2ClSi (M
+- tBu)]. 
 
6-((t-Butyldimethylsilyl)oxy)-2-(cyclohex-1-en-1-ylethynyl)-2-methylcyclohexanol (I-45f) 
 
 
 
Following procedure A, the epoxide I-44a (500 mg, 2.06 mmol) was reacted with 1-
ethynylcyclohexene (268 mg, 2.47 mmol). After flash chromatography (Pentanes/Et2O = 
99/1), the product I-45f (512 mg, 1.47 mmol, 71%) was obtained. 
 
TLC: Rf = 0.63 (Pentanes/Et2O = 99/1) [CAM/UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 6.04-5.97 (m, 1H), 4.16-4.04 (m, 1H), 3.56 (d, J = 2.8Hz, 
1H), 2.39 (s, 1H), 2.09 (t, J = 5.3 Hz, 4H), 1.67-1.43 (m, 10H), 1.30 (s, 3H), 0.90 (s, 9H), 0.09 (s, 
3H), 0.09 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 133.3, 120.7, 91.3, 84.9, 76.0, 71.0, 37.1, 31.3, 29.6, 28.1, 
25.9, 25.8, 25.5, 22.3, 21.5, 20.9, 18.1, -4.57, -4.83. 
 
MS (EI, 70 eV) m/z (%): 305 (16) [M+- iPr], 291 (4) [M+- tBu], 215 (22), 201 (8), 185 (20), 131 
(22), 109 (28), 93 (16), 75 (100), 55 (23), 43 (23). 
 
HRMS (EI, 70 eV) m/z 305.15710, [305.17804 calcd. for C17H27O2Si (M
+-iPr)]. 
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6-((t-Butyldimethylsilyl)oxy)-2-(hept-1-yn-1-yl)-2-methylcyclohexanol (I-45h) 
 
 
 
Following procedure A, the epoxide I-44a (500 mg, 2.06 mmol) was reacted with heptyne 
(237 mg, 2.47 mmol). After flash chromatography (Pentanes/Et2O = 99/1), the product I-45h 
(430 mg, 1.27 mmol, 62%) was obtained. 
 
TLC: Rf = 0.44 (Pentanes/Et2O = 99/1) [CAM/UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 4.11 (ddd, J = 8.9, 5.7, 2.8 Hz, 1H), 3.52 (d, J = 2.7 Hz, 1H), 
2.38 (s, 1H), 2.16 (t, J = 6.8 Hz, 2H), 1.68- 1.20 (m, 15H), 0.95- 0.85 (m, 12H), 0.09 (s, 3H), 
0.08 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 84.6, 82.9, 76.1, 70.9, 36.7, 31.4, 31.0, 28.8, 28.2, 26.2, 
25.8, 22.2, 20.8, 18.6, 18.1, 14.0, -4.60, -4.85. 
 
MS (EI, 70 eV), m/z (%): 281 (28) [M+- tBu], 263 (5), 199 (26), 189 (87), 133 (31), 119 (40), 95 
(41), 81 (38), 75 (100), 55 (26). 
 
HMRS (EI, 70 eV) m/z 281.19379, [281.19370 calcd. for C16H29O2Si (M
+- tBu)]. 
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2-butyl-6-((t-Butyldimethylsilyl)oxy)-2-((4-methoxyphenyl)ethynyl)cyclohexanol(I-45k) 
 
 
 
Following procedure A, the epoxide I-44b (500 mg, 1.76 mmol) was reacted with 4-
ethynylanisole (278.7 mg, 2.11 mmol). After flash chromatography (Pentanes/Et2O = 99/1), 
the product I-45k (306 mg, 0.734 mmol, 42%) was obtained. 
 
TLC: Rf = 0.79 (Pentanes/Et2O = 95/5) [UV/CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.32 (d, J = 8.9 Hz, 2H), 6.3 (d, J = 8.9 Hz, 2H), 4.17 (td, J = 
8.1, 2.7 Hz, 1H), 3.81 (s, 3H), 3.70 (d, J = 2.8 Hz, 1H), 1.76-1.28 (m, 12H), 1.01-0.86 (m, 11H), 
0.10 (s, 3H), 0.10 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 132.8, 116.0, 113.8, 91.4, 84.1, 74.2, 71.2, 55.3, 41.4, 37.9, 
30.4, 28.6, 26.3, 25.8, 23.2, 20.8, 18.1, 14.1, -4.52, -4.77. 
 
MS (EI, 70 eV). m/z (%): 359 (6) [M+- tBu], 237 (7), 227 (93), 209 (8), 171 (81), 135 (46), 107 
(19), 93 (41), 75 (100), 67 (16), 57 (12). 
 
HRMS (EI, 70 eV) m/z 359.20258, [359.20370 calcd. for C21H31O3Si (M
+- tBu)].  
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2-butyl-6-((t-Butyldimethylsilyl)oxy)-2-(phenylethynyl)cyclohexanol (I-45l) 
 
 
 
Following procedure A, the epoxide I-44b (1.0 g, 3.51 mmol) was reacted with 
phenylacetylene (430 mg, 4.21 mmol). After flash chromatography (Pentanes/Et2O = 99/1), 
the product I-45l (643.5 mg, 1.66 mmol, 47%) was obtained. 
 
TLC: Rf = 0.24 (Pentanes/Et2O = 99/1) [UV/CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.43-7.34 (m, 2H), 7.34-7.28 (m, 3H), 4.17 (td, J = 8.0, 2.8 
Hz, 1H), 4.02-3.94 (m, 1H), 3.71 (d, J = 2.7 Hz, 1H), 2.41 (s, 1H), 1.79-1.46  (m, 8H), 1.44-1.25 
(m, 4H), 0.98-0.90 (m, 12H), 0.11 (s, 3H), 0.10 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 147.3, 131.4, 128.2, 127.6, 93.1, 84.4, 74.1, 71.2, 41.5, 
37.8, 30.3, 28.6, 26.3, 25.8, 23.2, 20.8, 18.1, 14.1, -4.51, -4.77. 
 
MS (EI, 70 eV). m/z (%): 329 (13) [M+-tBu], 243 (28), 227 (93), 185 (8), 171 (43), 157 (47), 151 
(67), 141 (33), 131 (27), 109 (60), 95 (83), 75 (100), 69 (61), 55 (41). 
 
HRMS (EI, 70 eV) m/z 329.19, [329.26 calcd. for C20H29O2Si (M
+-tBu)]. 
 
General procedure for Swern oxidation (B)[28] 
 
To a solution of oxalyl chloride (1.1 equiv.) in abs. CH2Cl2 (5 M) at -78°C, was slowly added a 
solution of DMSO (2.2 equiv.) in abs. CH2Cl2 (12.5 M). The solution was stirred for 30 
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minutes, and then the alcohol (1 equiv.) in abs. CH2Cl2 (3 M) was slowly added dropwise. The 
reaction mixture was stirred for 30 minutes. Finally Et3N (5 equiv.) was slowly added. The 
resulting mixture was allowed to warm to room temperature. After 1 hour, it was quenched 
with water and extracted three times with Et2O. The combined organic phase was washed 
with sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography.  
 
6-((t-Butyldimethylsilyl)oxy)-2-methyl-2-(phenylethynyl)cyclohexanone (I-46a) 
 
 
 
Following procedure B, substrat I-45a (920 mg, 2.67 mmol) was oxidized. After flash 
chromatography (Pentanes/Et2O = 99/1), the product I-46a (897 mg, 2.62 mmol, 98%) was 
obtained. 
 
TLC: Rf = 0.27 (Pentanes/EA = 99/1) [CAM/UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.45-7.28 (m, 5H), 5.02 (dd, J = 12, 6.4 Hz, 1H), 2.22 (dqd, 
J =  8.8, 5.9, 3.2 Hz, 3H), 1.86-1.46 (m, 3H), 1.41 (s, 3H), 0.92 (s, 9H), 0.16 (s, 3H), 0.06 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 206.9, 128.4, 122.8, 91.0, 84.8, 74.3, 46.2, 41.7, 37.8, 25.8, 
23.1, 21.3, 18.6, -4.72, -5.67. 
 
MS (EI, 70 eV) m/z (%): 285 (100) [M+- tBu], 257 (7), 199 (20), 183 (13), 155 (22), 115 (20), 75 
(55). 
 
HRMS (EI, 70 eV) m/z 285.1310, [285.1311 calcd. for C17H21O2Si (M
+- iPr)]. 
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6-((t-Butyldimethylsilyl)oxy)-2-methyl-2-(thiophen-3-ylethynyl)cyclohexanone (I-46b) 
 
 
 
Following procedure B, substrat I-45b (298 mg, 0.85 mmol) was oxidized. After flash 
chromatography (Pentanes/Et2O = 99/1), the product I-46b (232 mg, 0.67 mmol, 78%) was 
obtained. 
 
TLC: Rf = 0.50 (Pentanes/Et2O = 99/1) [CAM/UV] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 7.40 (dd, J = 3.0, 1.1 Hz, 1H), 7.31-7.28 (m, 1H), 7.08 (dd, J 
= 5.0, 1.1 Hz, 1H), 5.01 (dd, J = 12.1, 6.4 Hz, 1H), 2.33-2.13 (m, 3H), 1.88-1.15 (m, 5H), 1.41 (s, 
3H), 0.93 (s, 9H), 0.17 (s, 3H), 0.07 (s, 3H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 206.9, 129.7, 128.4, 125.4, 121.8, 90.5, 79.9, 74.4, 46.2, 
41.7, 37.8, 25.8, 23.1, 21.1, 18.5, -4.69, -5.51. 
 
MS (EI, 70 EV) m/z (%): 291 (74) [M+-tBu], 276 (13), 231 (20), 217 (10), 199 (27), 183 (100), 
161 (15), 141 (10), 115 (14), 75 (55), 61 (11). 
 
HRMS (EI, 70 eV) m/z 333.13480, [333.13391 calcd. for C18H25O2SSi (M
+- Me)]. 
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6-((t-Butyldimethylsilyl)oxy)-2-((4-methoxyphenyl)ethynyl)-2-methylcyclohexanone (I-46c) 
 
 
 
Following procedure B, substrat I-45c (340 mg, 0.93 mmol) was oxidized. After flash 
chromatography (Pentanes/Et2O = 99/1), the product I-46c (247 mg, 0.66 mmol, 73%) was 
obtained. 
 
TLC: Rf = 0.63 (Pentanes/Et2O = 95/5) [UV/CAM] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 7.38-7.31 (m, 2H), 6.92-6.82 (m, 2H), 5.03 (dd, J = 12.1, 
6.4 Hz, 1H), 3.83 (s, 3H), 2.34-2.10 (m, 3H), 1.66 (ddd, J = 29.3, 13.3, 5.9, 3.1 Hz, 4H), 1.41 (s, 
3H), 0.93 (s, 9H), 0.17 (s, 3H), 0.07 (s, 3H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 207.2, 159.5, 132.9, 115.0, 114.0, 89.5, 84.6, 74.4, 55.3, 
46.1, 41.8, 37.8, 25.8, 23.1, 21.1, 18.6, -4.69, -5.53. 
 
MS (EI, 70 EV) m/z (%): 315 (100) [M+- tBu], 300 (9), 287 (30), 269 (7), 241 (10), 213 (11), 185 
(21), 145 (6), 129 (7), 75 (19). 
 
HRMS (EI, 70 eV) m/z 315.1408, [315.1411 calcd. for C18H23O3Si (M
+- tBu)]. 
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6-((t-butyldimethylsilyl)oxy)-2-((3-chlorophenyl)ethynyl)-2-methylcyclohexanone (I-46d) 
 
 
 
Following procedure B, substrat I-45d (349 mg, 0.92 mmol) was oxidized. After flash 
chromatography (Pentanes/Et2O = 99/1), the product I-46d (281 mg, 0.75 mmol, 81%) was 
obtained. 
 
TLC: Rf = 0.60 (Pentanes/Et2O = 99/1) [UV/CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.43-7.37 (m, 1H), 7.37-7.26 (m, 3H), 4.99 (dd, J = 12.0, 
6.4 Hz, 1H), 2.36-2.08 (m, 3H), 1.89-1.59 (m, 3H), 1.43 (s, 3H), 0.94 (s, 9H), 0.18 (s, 3H), 0.08 
(s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 206.5, 134.2, 131.4, 129.6, 129.6, 128.6, 124.5, 92.3, 83.4, 
74.5, 46.2, 41.8, 37.8, 25.8, 23.0, 21.1, 18.5, -4.68, -5.48. 
 
MS (EI, 70 eV) m/z (%): 322 (32), 319 (100) [M+- tBu], 269 (12), 245 (6), 189 (15), 75 (28), 59 
(6). 
  
HRMS (EI, 70 eV) m/z 319.0912, [319.0912 calcd. for C17H20O2ClSi (M
+- tBu)]. 
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6-((t-Butyldimethylsilyl)oxy)-2-(cyclohex-1-en-1-ylethynyl)-2-methylcyclohexanone (I-46f) 
 
 
 
Following procedure B, substrat I-45f (444 mg, 1.27 mmol) was oxidized. After flash 
chromatography (Pentanes/Et2O = 99/1), the product I-46f (365 mg, 1.05 mmol, 83%) was 
obtained. 
 
TLC: Rf = 0.50 (Pentanes/Et2O = 99/1) [CAM/UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 6.05 (dd, J = 4.0, 2.0 Hz, 1H), 4.95 (dd, J = 11.2, 6.4 Hz, 
1H), 2.28-1.99 (m, 6H), 1.80-1.40 (m, 8H), 1.32 (s, 3H), 1.04-0.83 (m, 9H), 0.14 (s, 3H), 0.04 (s, 
3H). 
 
13C NMR (63 MHz, CDCl3) ppm] 207.2, 134.5, 120.3, 88.2, 85.6, 74.2, 46.0, 41.8, 31.8, 29.3, 
25.8, 25.6, 23.2, 22.3, 21.4, 21.0, 18.5, -4.73, -5.57. 
 
MS (EI, 70 EV) m/z (%): 289 (100) [M+- tBu], 239 (6), 215 (6), 187 (8), 159 (8), 143 (5), 129 (8), 
105 (12), 91 (12), 75 (28), 59 (8), 41 (8). 
 
HRMS (EI, 70 eV) m/z 289.16232, [289.16238 calcd. for C17H25O2Si (M
+- tBu)]. 
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6-((t-Butyldimethylsilyl)oxy)-2-(hept-1-yn-1-yl)-2-methylcyclohexanone (I-46h) 
 
 
 
Following procedure B, substrat I-45h (397.6 mg, 1.17 mmol) was oxidized. After flash 
chromatography (Pentanes/Et2O = 99/1), the product I-46h (274.6 mg, 0.816 mmol, 70%) 
was obtained. 
 
TLC: Rf = 0.44 (Pentanes/Et2O = 99/1) [CAM/UV] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 4.96 (dd, J =12.1, 6.5Hz, 1H), 2.28 -1.98 (m, 5H), 1.77-1.27 
(m, 12H), 0.96 -0.88 (m, 12H), 0.16 (s, 3H), 0.05 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 207.7, 85.1, 81.9, 74.1, 45.5, 41.8, 37.8, 31.1, 28.5, 25.8, 
23.4, 22.2, 21.0, 18.7, 18.5, 14.0, -4.75, -5.61. 
 
MS (EI, 70 eV), m/z (%): 279 (100) [M+- tBu], 222 (13), 205 (16), 187 (9), 105 (11), 75 (40), 55 
(10). 
 
HMRS (EI, 70 eV) m/z 279.17819, [279.17858 calcd. for C16H27O2Si (M
+- tBu)]. 
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2-butyl-6-((t-Butyldimethylsilyl)oxy)-2-((4-methoxyphenyl)ethynyl)cyclohexanone (I-46k) 
 
 
 
Following procedure B, substrat I-45k (214 mg, 0.490 mmol) was oxidized. After flash 
chromatography (Pentanes/Et2O = 99/1), the product I-46k (132.6 mg, 0.305 mmol, 62%) 
was obtained. 
 
TLC: Rf = 0.79 (Pentanes/Et2O = 95/5) [UV/CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.33 (d, J = 8.9 Hz, 2H), 6.85 (d, J = 8.9 Hz, 2H), 5.04 (dd, J 
= 12.0, 6.2 Hz, 1H), 3.82 (s, 3H), 2.33-2.07 (m, 3H), 2.00-1.59 (m, 3H), 1.00-1.30 (m, 6H), 0.97-
0.83 (m, 12H), 0.15 (s, 3H), 0.05 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 207.2, 159.5, 132.8, 115.2, 113.9, 88.6, 85.8, 74.6, 55.3, 
50.3, 39.7, 37.9, 35.5, 26.8, 25.8, 23.2, 20.9, 18.5, 14.0, -4.69, -5.53. 
 
MS (EI, 70 eV). m/z (%): 357 (100) [M+- tBu], 329 (25), 300 (16), 225 (29), 183 (14), 171 (12), 
121 (14), 95 (12), 75 (76), 57 (18). 
 
HRMS (EI, 70 eV) m/z 399.23480, [399.23500 calcd.for C24H35O3Si (M
+- Me)]. 
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2-butyl-6-((t-Butyldimethylsilyl)oxy)-2-(phenylethynyl)cyclohexanone (I-46l) 
 
 
 
Following procedure B, substrat I-45l (580 mg, 1.50 mmol) was oxidized. After flash 
chromatography (Pentanes/Et2O = 99/1), the product I-46l (372.8 mg, 0.969 mmol, 65%) was 
obtained. 
 
TLC: Rf = 0.24 (Pentanes/Et2O = 99/1) [UV/CAM] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 7.44-7.39 (m, 2H), 7.37-7.31 (m, 3H), 5.05 (dd, J = 12.1, 
6.3 Hz, 1H), 2.32-2.15 (m, 3H), 2.00-1.87 (m, 1H), 1.80 (ddd, J = 16.7, 8.9, 5.3 Hz, 1H), 1.72 (d, 
J = 3.6 Hz, 1H), 1.60-1.51 (m, 2H), 1.50-1.33 (m, 4H), 0.99-0.90 (m, 12H), 0.17 (s, 3H), 0.07 (s, 
3H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 207.1, 131.5, 128.3, 128.2, 123.0, 90.1, 85.0, 74.6, 50.4, 
39.7, 37.9, 35.4, 26.8, 25.8, 23.2, 20.9, 18.5, 14.0, -4.68, -5.51. 
 
MS (EI, 70 eV) m/z (%): 327 (100) [M+-tBu], 271 (10), 225 (8), 197 (8), 141 (7), 129 (6), 91 (7), 
75 (23), 43 (8). 
 
HRMS (EI, 70 eV) m/z 327.17719, [327.17749 calcd. for C20H27O2Si (M
+-tBu)]. 
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General prodecure for deprotection(C) 
 
To a solution of MeOH:conc. HCl (9:1; 0.1 M), the ketone was added. After 1h, the reaction 
mixture was quenched with sat. NaHCO3 solution and extracted three times with Et2O. The 
combined organic phase was washed with sat. NaCl-solution, dried over Na2SO4 and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography. 
 
6-hydroxy-2-methyl-2-(phenylethynyl)cyclohexanone (I-37a) 
 
 
 
Following procedure C, substrat I-46a (1.23 g, 3.58 mmol) was deprotected. After flash 
chromato-graphy(Pentanes/EtOAc = 9/1), product I-37a (743 mg, 3.25 mmol, 91%) was 
obtained. 
 
TLC: Rf = 0.58 (Pentanes/EtOAc = 9/1) [CAM/UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.45-7.28 (m, 5H), 4.96-4.81 (m, 1H), 3.45 (d, J = 4.4Hz, 
1H), 2.49 (ddt, J = 13.1, 6.4, 3.2 Hz, 1H), 2.24 (tt, J = 12.1, 6.0 Hz, 2H), 1.85-1.71 (m, 1H), 1.68- 
1.52 (m, 2H), 1.47 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 209.4, 131.6, 128.3, 122.5, 89.9, 84.9, 72.6, 45.5, 42.5, 
37.6, 22.9, 20.3. 
 
MS (EI, 70 eV) m/z (%): 228 (53) [M+], 213 (82), 199 (41), 183 (44), 141 (51), 129 (100), 115 
(46). 
EXPERIMENTAL PART 
CATALYZED CASCADE REACTIONS, A WAY TOWARD FURAN COMPOUNDS 
 
75 
 
HRMS (EI, 70 eV) m/z 228.1147, [228.1150 calcd. for C15H16O2]. 
 
6-hydroxy-2-methyl-2-(thiophen-3-ylethynyl)cyclohexanone (I-37b) 
 
 
 
Following procedure C, substrat I-46b (200 mg, 0.57 mmol) was deprotected. After flash 
chromatography (Pentanes/Et2O = 9/1), the product I-37b (113 mg, 0.48 mmol, 84%) was 
obtained. 
 
TLC: Rf = 0.14 (Pentanes/Et2O = 99/1) [CAM/UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.40-7.35 (m, 1H), 7.27 (dd, J = 5.0, 3.0 Hz, 1H), 7.08 (d, J = 
5.0 Hz, 1H), 4.93-4.78 (m, 1H), 3.45 (d, J = 4.2 Hz, 1H), 2.48 (ddd, J = 12.8, 6.7, 3.3 Hz, 1H), 
2.23 (dd, J = 13.2, 5.3 Hz, 2H),1.85-1.71 (m, 1H), 1.57 (ddd, J = 12.7, 10.5, 3.7 Hz, 2H), 1.45 (s, 
3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 209.4, 155.9, 129.8, 128.8, 125.4, 89.6, 80.1, 72.6, 45.5, 
42.4, 37.6, 22.9, 20.3. 
 
MS (EI, 70 EV) m/z (%): 234 (29) [M+], 219 (68) [M+- Me], 216 (14) [M+- H2O], 205 (24), 189 
(28), 173 (36), 161 (86), 147 (54), 135 (100), 121 (26), 115 (17), 97 (33), 91 (22), 77(12), 40 
(37). 
 
HRMS (EI, 70 eV) m/z 234.0709, [234.0709 calcd. for C13H14O2S (M
+)]. 
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6-hydroxy-2-((4-methoxyphenyl)ethynyl)-2-methylcyclohexanone (I-37c) 
 
 
 
Following procedure C, substrat I-46c (180 mg, 0.48 mmol) was deprotected. After flash 
chromatography (Pentanes/Et2O = 9/1), product I-37c (93 mg, 0.36 mmol, 75%) was 
obtained. 
 
TLC: Rf = 0.25 (Pentanes/EtOAc = 9/1) [CAM/UV] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 7.38–7.32 (m, 2H), 6.88–6.82 (m, 2H), 4.94–4.86 (m, 1H), 
3.83 (s, 3H), 3.47 (d, J = 4.4 Hz, 1H), 2.54–2.44 (m, 1H), 2.30–2.17 (m, 2H), 1.84–1.75 (m, 1H), 
1.64–1.54 (m, 2H), 1.47 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 209.6, 159.7, 133.0, 114.6, 113.9, 88.6, 84.9, 72.5, 55.3, 
45.4, 42.5, 37.6, 25.8, 22.9. 
 
MS (EI, 70 EV) m/z (%): 258 (92) [M+], 243 (100), 229 (29), 213 (22), 199 (34), 185 (72), 171 
(34), 159 (100), 145 (32), 135 (48), 121 (51), 115 (33). 
 
HRMS (EI, 70 eV) m/z 258.1250, [258.1256 calcd. for C16H18O3]. 
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2-((3-chlorophenyl)ethynyl)-6-hydroxy-2-methylcyclohexanone (I-37d) 
 
 
 
Following procedure C, substrat I-46d (261 mg, 0.69 mmol) was deprotected. After flash 
chromatography (Pentanes/EA = 9/1), the product I-37d (146 mg, 0.56 mmol, 80%) was 
obtained. 
 
TLC: Rf = 0.28 (Pentanes/EtOAc = 9/1) [UV/CAM] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 7.41 (d, J = 1.6 Hz, 1H), 7.33 (t, J = 1.9 Hz, 1H), 7.31 (t, J = 
1.9 Hz, 1H), 7.30-7.27 (m, 1H), 4.93-4.80 (m, 1H), 3.45 (d, J = 4.4 Hz, 1H), 2.51 (ddd, J = 12.7, 
6.8, 3.3 Hz, 1H), 2.34-2.14 (m, 2H), 1.87-1.77 (m, 1H), 1.67-1.60 (m, 1H), 1.53 (dd, J = 12.5, 
4.1 Hz, 1H), 1.48 (s, 3H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 209.1, 134.2, 131.5, 129.7, 129.6, 128.7, 124.2, 91.3, 83.7, 
72.7, 45.5, 42.4, 37.6, 22.8, 20.4. 
 
MS (EI, 70 eV) m/z (%): 262 (26) [M+], 247 (45), 233 (22), 227 (20), 205 (27), 199 (37), 189 
(37), 177 (26), 163 (44), 155 (38), 143 (100), 139 (55), 128 (47), 125 (39), 115 (30), 111 (17), 
101 (13), 77 (19), 55 (27), 43 (29). 
 
HRMS (EI, 70 eV) m/z 262.0744, [262.0755 calcd. for C15H15O2Cl]. 
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2-(cyclohex-1-en-1-ylethynyl)-6-hydroxy-2-methylcyclohexanone (I-37f) 
 
 
 
Following procedure C, substrat I-46f (300 mg, 0.87 mmol) was deprotected. After flash 
chromatography (Pentanes/Et2O = 9/1), the product I-37f (161 mg, 0.69 mmol, 80%) was 
obtained. 
 
TLC: Rf = 0.14 (Pentanes/Et2O = 9/1) [UV/CAM] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 6.09 (d, J = 1.8Hz, 1H), 4.92-4.74 (m, 1H), 3.47 (dd, J = 
17.2, 5.4 Hz, 1H), 2.45 (ddt, J = 9.8, 6.3, 2.9 Hz, 1H), 2.24-2.05 (m, 6H), 1.74 (ddd, J = 16.4, 
7.6, 4.6 Hz, 1H), 1.61 (ddd, J = 14.0, 8.1, 2.9 Hz, 5H), 1.54-1.34 (m, 4H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 209.8, 135.2, 120.1, 87.3, 86.9, 72.4, 45.3, 42.5, 37.6, 29.2, 
25.6, 23.0, 22.2, 21.4, 20.3. 
 
MS (EI, 70 EV) m/z (%): 232 (55) [M+], 216 (90), 203 (24), 189 (35) [M+-iPr], 175 (41) [M+- 
tBu], 159 (38), 145 (44), 131 (43), 117 (39), 105 (92), 91 (100), 75 (67), 57 (40), 42 (92).  
 
HMRS (EI, 70 eV) m/z 232.1458, [232.1458 calcd. for C15H20O2]. 
 
 
 
 
 
EXPERIMENTAL PART 
CATALYZED CASCADE REACTIONS, A WAY TOWARD FURAN COMPOUNDS 
 
79 
 
2-(hept-1-yn-1-yl)-6-hydroxy-2-methylcyclohexanone (I-37h) 
 
 
 
Following procedure C, substrat I-46h (200 mg, 0.59 mmol) was deprotected. After flash 
chromatography (Pentanes/Et2O = 9/1), the product I-37h (92 mg, 0.41 mmol, 69%) was 
obtained. 
 
TLC: Rf = 0.24 (Pentanes/Et2O = 99/1) [CAM/UV] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 4.87-4.72 (m, 1H), 3.44 (d, J = 4.4 Hz, 1H), 2.52-2.33 (m, 
1H), 2.24-1.99 (m, 4H), 1.77-1.64 (m, 1H), 1.60-1.20 (m, 11H), 0.90 (t, J = 6.9 Hz, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 210.2, 85.6, 80.9, 72.3, 44.8, 42.5, 37.6, 31.0, 28.4, 23.2, 
22.1, 20.2, 18.7, 14.0. 
 
MS (EI, 70 eV) m/z (%): 222 (14) [M+], 207 (8), 176 (15), 166 (48) [M+- tBu], 147 (30), 137 
(30), 121 (50), 105 (80), 94 (84), 79 (100), 67 (53), 55 (85), 53 (37), 41 (86). 
 
HMRS (EI, 70 eV) m/z 222.1622, [222.1620 calcd. for C14H22O2]. 
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2-butyl-6-hydroxy-2-((4-methoxyphenyl)ethynyl)cyclohexanone (I-37k) 
 
 
 
Following procedure C, substrat I-46k (161 mg, 0.388 mmol) was deprotected. After flash 
chromatography (Pentanes/Et2O = 9/1), product I-37ka (90.2 mg, 0.300 mmol, 77%) was 
obtained. 
 
TLC: Rf = 0.17 (Pentanes/Et2O = 9/1) [UV/CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.41-7.28 (m, 2H), 6.89-6.79 (m, 2H), 4.89 (ddd, J = 11.8, 
6.9, 4.5 Hz, 1H), 3.82 (s, 3H), 3.48-3.43 (m, 1H), 2.47 (ddd, J = 12.6, 6.7, 3.2 Hz, 1H), 2.35-2.14 
(m, 2H), 2.05-1.88 (m, 1H), 1.87-1.70 (m, 1H), 1.66-1.32 (m, 6H), 1.23 (dd, J = 13.0, 6.0 Hz, 
1H), 0.95 (t, J = 7.0 Hz, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 209.9, 159.7, 133.0, 114.8, 113.9, 87.6, 86.2, 72.7, 55.3, 
49.7, 40.6, 37.9, 35.4, 26.8, 23.1, 20.2, 14.0. 
 
MS (EI, 70 eV) m/z (%): 300 (34) [M+], 265 (7), 258 (17), 243 (50) [M+- nBu], 227 (32), 213 
(16), 205 (42), 201 (26), 185 (23), 171 (25), 159 (34), 145 (21), 135 (44), 121 (100), 108 (25), 
91 (15), 69 (15), 57 (35), 43 (32). 
 
HRMS (EI, 70 eV) m/z 300.1720, [300.1720 calcd. for C19H24O3]. 
 
 
 
EXPERIMENTAL PART 
CATALYZED CASCADE REACTIONS, A WAY TOWARD FURAN COMPOUNDS 
 
81 
 
2-butyl-6-hydroxy-2-(phenylethynyl)cyclohexanone (I-37l) 
 
 
Following procedure C, substrat I-46l (344 g, 0.894 mmol) was deprotected. After flash 
chromatography (Pentanes/Et2O = 9/1), product I-37l (186.4 mg, 0.689 mmol, 77%) was 
obtained. 
 
TLC: Rf = 0.14 (Pentanes/Et2O = 9/1) [UV/CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.47-7.37 (m, 2H), 7.37-7.28 (m, 3H), 4.97-4.81 (m, 1H), 
3.45 (s, 1H), 2,48 (ddd, J = 12.6, 6.7, 3.3 Hz, 1H), 2.38-2.16 (m, 2H), 2.13-1.86 (m, 1H), 1.79 
(ddd, J = 8.0, 6.5, 3.6 Hz, 1H), 1.67-1.25 (m, 7H), 0.95 (t, J = 7.3 Hz, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 209.7, 131.6, 128.3, 122.7, 89.1, 86.3, 72.8, 49.7, 40.6, 
37.9, 35.3, 26.8, 23.1, 20.2, 14.0. 
 
MS (EI, 70 eV) m/z (%): 270 (8) [M+], 228 (15), 213 (34) [M+- tBu], 200 (21), 197 (15), 167 
(21), 155 (27), 148 (85), 128 (81), 115 (53), 96 (81), 81 (91), 70 (60), 55 (100). 
 
HRMS (EI, 70 eV) m/z 270.1614, [270.1614 calcd. for C18H22O2]. 
 
General procedure for the furan synthesis.(D) 
 
To 1-hydroxy-2-alkynyl carbonyl substrate in toluene (0.05 M), PtCl4 (5 mol%) and 
isopropanol (1.5 equiv.) were added. The solution was stirred at 100°C. The reaction 
advancement was controlled by TLC. Finally it was quenched with water and extracted three 
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times with Et2O. The combined organic phase was washed with sat. NaCl-solution, dried over 
Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash 
chromatography.  
 
4-(3-methyl-5-phenylfuran-2-yl)butanal (I-47a) 
                    
 
Following procedure D, substrate I-37a (40 mg, 0.18 mmol) gave after flash chromatography 
(Pentanes/Et2O = 9/1), the furan I-47a (33 mg, 0.14 mmol, 83%). 
 
TLC: Rf = 0.40 (Pentanes/Et2O = 8/2) [CAM/UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 9.75 (s, 1H), 7.62 (dd, J = 5.2, 3.3 Hz, 2H), 7.41-7.30 (m, 
2H), 7.23 (ddd, J = 9.3, 6.0, 4.4 Hz, 1H), 6.45 (s, 1H), 2.70 (t, J = 7.1Hz, 2H), 2.49 (td, J = 7.2, 
1.4 Hz, 2H), 2.10-1.96 (m, 5H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 202.1, 151.3, 149.8, 131.1, 128.6, 126.8, 123.3, 116.9, 
108.3, 43.0, 25.1, 21.1, 9.9. 
 
MS (EI, 70 eV) m/z (%): 228 (25) [M+], 200 (20) [M+-CO], 184 (36) [M+- C2H4O], 171 (100) [M
+- 
C3H5O], 158 (8), 128 (18), 105 (25). 
 
HMRS (EI, 70 eV) m/z 228.1149, [228.1150 calc. for C15H16O]. 
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Entry H C COSY (
1H-1H) HMBC (1H-13C) 
1 9.75 (s, 1H) 202.1 2 2, 3 
2 2.49 (td, 2H) 42.9 1, 3 1, 3, 4 
3 2.10‐1.96 (m, 2H) 21.1 2, 4 1, 2, 4, 5 
4 2.70 (t, 2H) 25.0 3 2, 3, 5, 6, 8 
5  149.8   
6  116.9   
7 2.00 (s, 3H) 9.9  5, 6, 8 
8 6.45 (s, 1H) 108.3  4, 5, 6, 7, 9 
9  151.3   
10  131.1   
11 7.62 (dd, 2H) 123.3 12 9, 12, 13 
12 7.41‐7.30 (m, 2H) 128.6 11, 13 9, 10, 11, 13 
13 7.23 (ddd, 1H) 126.8 12 10, 11, 12 
 
4-(3-methyl-5-(thiophen-3-yl)furan-2-yl)butanal (I-47b) 
 
 
 
Following procedure D, substrate I-37b (41 mg, 0.18 mmol) gave after flash chromatography 
(Pentanes/Et2O = 9/1), the furan I-47b (36 mg, 0.15 mmol, 86%). 
 
TLC: Rf = 0.14 (Pentanes/Et2O = 99/1) [CAM/UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 9.76 (s, 1H), 7.39-7.21 (m, 3H), 6.27 (s, 1H), 2.67 (t, J = 7.1 
Hz, 2H), 2.48 (td, J = 7.2, 1.5 Hz, 2H), 2.07-1.93 (m, 5H). 
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13C NMR (91 MHz, CDCl3)  [ppm] 202.1, 149.0, 148.6, 132.8, 126.0, 124.5, 117.8, 116.5, 
108.0, 43.0, 25.0, 21.2, 9.8. 
 
MS (EI, 70 EV) m/z (%): 234 (17) [M+], 206 (12) [M+-CO], 190 (26) [M+- C2H4O], 177 (100) [M
+- 
C3H5O]. 
 
HRMS (EI, 70 eV) m/z 234.07054, [234.07018 calc. for C13H14O2S]. 
 
4-(5-(4-methoxyphenyl)-3-methylfuran-2-yl)butanal (I-47c) 
 
 
 
Following procedure D, substrate I-37c (40 mg, 0.16 mmol) gave after flash chromatography 
(Pentanes/Et2O = 9/1), the furan I-47c (36 mg, 0.14 mmol, 88%). 
 
TLC: Rf = 0.47 (Pentanes/EtOAc = 9/1) [CAM/UV] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 9.76 (s, 1H), 7.65-7.48 (m, 2H), 6.96-6.87 (m, 2H), 6.32 (s, 
1H), 3.84 (s, 3H), 2.69 (t, J = 7.1 Hz, 2H), 2.50 (td, J = 7.2, 1.6 Hz, 2H), 2.07-2.00 (m, 2H), 1.99 
(s, 3H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 202.2, 158.7, 151.4, 149.0, 124.7, 124.3, 116.8, 114.1,  
106.7, 55.3, 43.0, 25.1, 21.2, 9.9. 
 
MS (EI, 70 EV) m/z (%): 258 (16) [M+], 214 (13) [M+- C2H4O], 201 (100) [M
+- C3H5O], 135 (11). 
 
HRMS (EI, 70 eV) m/z 258.12527, [258.12505 calc. for C16H18O3]. 
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4-(5-(3-chlorophenyl)-3-methylfuran-2-yl)butanal (I-47d) 
 
 
 
Following procedure D, substrate I-37d (40 mg, 0.15 mmol) gave after flash chromatography 
(Pentanes/Et2O = 9/1), the furan I-47d (31 mg, 0.12 mmol,77%). 
 
TLC: Rf = 0.26 (Pentanes/Et2O = 9/1) [UV/CAM] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 9.77 (s, 1H), 7.59 (t, J = 1.8 Hz, 1H), 7.51-7.45 (m, 1H), 
7.35-7.24 (m, 1H), 7.19 (ddd, J = 8.0, 2.0, 1.1 Hz, 1H), 6.49 (s, 1H), 2.70 (t, J = 7.2 Hz, 2H), 2.51 
(td, J = 2.2, 1.5 Hz, 2H), 2.09-1.95 (m, 5H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 202.0, 150.5, 149.9, 134.6, 132.7, 129.9, 126.6, 123.2, 
121.3, 117.2, 109.5, 43.0, 25.1, 21.1, 9.9. 
 
MS (EI, 70 eV) m/z (%): 262 (23) [M+], 234 (15) [M+-CO], 218 (54) [M+- C2H4O], 205 (100) [M
+- 
C3H5O], 191 (7), 149 (9), 141 (12), 111 (10), 57 (8), 44 (34). 
 
HRMS (EI, 70 eV) m/z 262.0748, [262.0755 calc. for C15H15O2Cl]. 
 
 
 
 
 
 
 
 
EXPERIMENTAL PART 
CATALYZED CASCADE REACTIONS, A WAY TOWARD FURAN COMPOUNDS 
 
86 
 
4-(3-methyl-5-(4-(trifluoromethoxy)phenyl)furan-2-yl)butanal (I-47e) 
 
 
 
Following procedure D, substrate I-37e (41 mg, 0.13 mmol) gave after flash chromatography 
(Pentanes/Et2O = 9/1), the furan I-47e (23 mg, 0.07 mmol, 56%). 
 
TLC: Rf = 0.30 (Pentanes/Et2O = 9/1) [UV/CAM]  
 
1H NMR (360 MHz, CDCl3)  [ppm] 9.77 (s, 1H), 7.65-7.58 (m, 2H), 7.26-7.18 (m, 2H), 6.46 (s, 
1H), 2.71 (t, J = 7.1 Hz, 2H), 2.51 (td, J = 7.2, 1.5 Hz, 2H), 2.09-1.99 (m, 5H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 202.0, 150.4, 150.1, 147.8, 129.9, 124.5? 121.3, 117.2, 
109.0, 43.0, 25.1, 21.1, 9.9. 
 
MS (EI, 70 eV) m/z (%): 312 (16) [M+], 284 (12) [M+-CO], 268 (38) [M+- C2H4O], 255 (100) [M
+- 
C3H5O], 189 (5). 
 
HRMS (EI, 70 eV) m/z 312.0967, [312.0968 calc. for C16H15O3F3]. 
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4-(5-(cyclohex-1-en-1-yl)-3-methylfuran-2-yl)butanal (I-47f) 
 
 
 
Following procedure D, substrate I-37f (40 mg, 0.17 mmol) gave after flash chromatography 
(Pentanes/Et2O = 9/1), the furan I-47f (17 mg, 0.07 mmol, 41%). 
 
TLC: Rf = 0.68 (Pentanes/EtOAc = 9/1) [CAM/UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 9.72 (s, 1H), 6.28-6.09 (m, 1H), 5.94 (s, 1H), 2.61 (t, J = 7.1 
Hz, 2H), 2.45 (td, J = 7.3, 1.6 Hz, 2H), 2.29-2.12 (m, 4H), 2.03-1.92 (m, 2H), 1.91 (s, 3H),  1.76-
1.58 (m, 4H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 202.2, 153.0, 148.4, 127.2, 121.1, 116.0, 106.9, 43.0, 25.1, 
25.0, 24.8, 22.4, 22.3, 21.2, 9.8. 
 
MS (EI, 70 EV) m/z (%): 248 (12), 232 (16) [M+], 205 (34), 191 (18), 175 (63) [M+- C3H5O], 163 
(36), 149 (26), 137 (28), 125 (40), 109 (50), 91 (43), 81 (46), 71 (47), 55 (64), 43 (100) 
 
HRMS (EI, 70 eV) m/z 232.14581, [232.14578 calc. for C15H20O2]. 
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4-(5-cyclopropyl-3-methylfuran-2-yl)butanal (I-47g) 
 
 
 
Following procedure D, substrate I-37g (49 mg, 0.26 mmol) gave after flash chromatography 
(Pentanes/Et2O = 9/1), the furan I-47g (23 mg, 0.12 mmol, 47%). 
 
TLC: Rf = 0.59 (Pentanes/EtOAc = 9/1) [CAM/UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 9.70 (s, 1H), 5.72 (s, 1H), 2.56 (t, J = 7.1 Hz, 2H), 2.42 (td, J 
= 7.2, 1.6 Hz, 2H), 1.94 (dd, J = 14.4, 7.3 Hz, 2H), 1.87 (s, 3H), 1.78 (ddd, J = 13.3, 6.6, 4.2 Hz, 
1H), 0.82 (ddd, J = 12.0, 5.2, 3.3 Hz, 2H), 0.73-0.59 (m, 2H). 
 
3C NMR (63 MHz, CDCl3)  [ppm] 202.2, 154.9, 147.5, 115.2, 106.6, 43.0, 25.0, 21.3, 9.8, 8.6, 
6.4. 
 
MS (EI, 70 eV) m/z (%): 192 (20) [M+], 164 (5) [M+-CO], 148 (27) [M+- C2H4O], 135 (100) [M
+- 
C3H5O], 91 (10), 55 (6). 
 
HRMS (EI, 70 eV) m/z 192.1140, [192.1145 calc. for C12H16O2]. 
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4-(3-methyl-5-pentylfuran-2-yl)butanal (I-47h) 
 
 
 
Following procedure D, substrate I-37h (37 mg, 0.16 mmol) gave after flash chromatography 
(Pentanes/Et2O = 9/1), the furan I-47h (24 mg, 0.11 mmol, 65%). 
 
TLC: Rf = 0.59 (Pentanes/EtOAc = 9/1) [CAM/UV] 
 
1H NMR (360 MHz, CDCl3)  [ppm] 9.72 (s, 1H), 5.76 (s, 1H), 2.59 (t, J = 7.1 Hz, 2H), 2.53 (t, J = 
7.6 Hz, 2H), 2.44 (t, J = 7.2 Hz, 2H), 1.96 (dd, J = 14.4, 7.2 Hz, 2H), 1.90 (s, 3H),  1.67-1.58 (m, 
2H), 1.45-1.26 (m, 4H), 0.91 (t, J = 6.7Hz, 3H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 202.4, 154.1, 147.6, 115.0, 107.8, 43.0, 31.4, 28.0, 27.8, 
25.0, 22.4, 21.3, 14.0, 9.8. 
 
MS (EI, 70 eV) m/z (%): 222 (18) [M+], 178 (27) [M+- C2H4O], 165 (100) [M
+- C3H5O], 137 (13), 
121 (66), 109 (10). 
 
HRMS (EI, 70 eV) m/z 222.16129, [222.16143 calc. for C14H22O2].  
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2-methyl-4-(3-methyl-5-phenylfuran-2-yl)butanal (I-47i) 
 
 
 
Following procedure D, substrate I-37i (27 mg, 0.11 mmol) gave after flash chromatography 
(Pentanes/Et2O = 9/1), the furan I-47i (22 mg, 0.09 mmol, 93%). 
 
TLC: Rf = 0.48 (Pentanes/Et2O = 9/1) [UV/CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 9.61 (s, 1H), 7.70-7.56 (m, 2H), 7.35 (t, J = 7.6 Hz, 2H), 
7.30-7.16 (m, 1H), 6.45 (s, 1H), 2.71 (t, J = 13.1, 6.1 Hz, 1H), 2.27-2.06 (m, 2H), 1.99 (s, 3H), 
1.75 (td, J = 14.1, 7.1Hz, 1H), 1.29-1.08 (m, 4H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 204.5, 151.3, 149.8, 131.1, 128.6, 126.7, 123.3, 116.8, 
108.3, 45.6, 29.8, 23.3, 13.3, 9.9. 
 
MS (EI, 70 eV) m/z (%): 242 (15) [M+], 214 (19) [M+-CO], 184 (33) [M+- C3H6O], 171 (100) [M
+- 
C4H7O], 128 (12), 105 (7), 77 (8), 44 (36). 
 
HRMS (EI, 70 eV) m/z 242.13006, [242.13013 calc. for C16H18O2]. 
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4-(3-methyl-5-phenylfuran-2-yl)pentanal (I-47j) 
 
 
 
Following procedure D, substrate I-37j (19 mg, 0.08 mmol) gave after flash chromatography 
(Pentanes/Et2O = 9/1), the furan I-47j (15 mg, 0.06 mmol, 78%). 
 
TLC: Rf = 0.66 (Pentanes/EA = 9/1) [UV/CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 9.69 (s, 1H), 7.69-7.54 (m, 2H), 7.38 (t, J = 7.7 Hz, 2H), 7.24 
(t, J = 7.3 Hz, 1H), 6.46 (s, 1H), 2.95 (dq, J = 13.8, 6.9 Hz, 1H), 2.47-2.35 (m, 2H), 2.10-1.90 (m, 
5H), 1.36 (d, J = 7.0 Hz, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 202.2, 152.7, 151.2, 131.1, 128.6, 126.8, 123.3, 116.4, 
108.3, 42.1, 30.9, 28.4, 19.7, 9.8. 
 
MS (EI, 70 eV) m/z (%): 242 (17) [M+], 214 (7) [M+- CO], 198 (19) [M+- C2H4O], 185 (100) [M
+- 
C3H5O], 171 (6) [M
+- C4H7O], 158 (6), 141 (7), 128 (8), 105 (13), 77 (12), 55 (7), 44 (62). 
 
HRMS (EI, 70 eV) m/z 242.1299, [242.1301 calc. for C16H18O2]. 
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4-(3-butyl-5-(4-methoxyphenyl)furan-2-yl)butanal (I-47k) 
 
 
 
Following procedure D, substrate I-37k (40 mg, 0.14 mmol) gave after flash chromatography 
(Pentanes/Et2O = 9/1), the furan I-47k (31 mg, 0.10 mmol, 77%). 
 
TLC: Rf = 0.27 (Pentanes/Et2O = 9/1) [UV/CAM] 
 
1H NMR (500 MHz, CDCl3)  [ppm] 9.78 (d, J = 1.4 Hz, 1H), 7.57-7.53 (m, 2H), 6.94-6.90 (m, 
2H), 6.36 (s, 1H), 3.85 (s, 3H), 2.70 (t, J = 7.2 Hz, 2H), 2.52 (td, J = 7.3, 1.5 Hz, 2H), 2.37- 2.32 
(m, 2H), 2.03 (p, J = 7.2 Hz, 2H), 1.54 (ddd, J = 12.6, 8.7, 6.4 Hz, 2H), 1.38 (dd, J = 15.0, 7.4 Hz, 
2H), 0.95 (t, J = 7.3 Hz, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 202.2, 158.6, 151.5, 148.7, 124.7, 124.3, 122.1, 114.0, 
105.5, 55.3, 43.0, 32.7, 25.1, 24.4, 22.4, 21.3, 13.9. 
 
MS (EI, 70 eV) m/z (%): 300 (43) [M+], 272 (16) [M+-CO], 256 (15 )[M+- C2H4O], 243 (100) [M
+- 
C3H5O], 227 (11), 215 (19), 201 (33), 135 (18), 57 (9), 43 (15). 
 
HRMS (EI, 70 eV) m/z 300.17142, [300.17200 calc. for C19H24O3].  
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4-(3-butyl-5-phenylfuran-2-yl)butanal (I-47l) 
 
 
 
Following procedure D, substrate I-37l (40 mg, 0.15 mmol) gave after flash chromatography 
(Pentanes/Et2O = 9/1), the furan I-47l (25 mg, 0.09 mmol, 63%). 
 
TLC: Rf = 0.30 (Pentanes/Et2O = 9/1) [UV/CAM] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 9.77 (s, 1H), 7.61 (dd, J = 8.4, 1.2 Hz, 2H), 7.49-7.30 (m, 
2H), 7.30-7.12 (m, 1H), 6.48 (s, 1H), 2.69 (t, J = 7.2 Hz, 2H), 2.51 (td, J = 7.3, 1.5 Hz, 2H), 2.34 
(t, J = 7.4 Hz, 2H), 2.02 (p, J = 7.3 Hz, 2H), 1.61-1.45 (m, 2H), 1.45-1.25 (m, 2H), 0.94 (t, J = 7.2 
Hz, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 202.1, 151.4, 149.5, 131.1, 128.5, 126.7, 123.2, 122.2, 
107.0, 43.0, 32.7, 25.1, 24.4, 22.3, 21.3, 13.9. 
 
MS (EI, 70 eV) m/z (%): 270 (20) [M+], 242 (18) [M+-CO], 226 (25) [M+- C2H4O], 213 (100) [M
+- 
C3H5O], 197 (18), 185 (20), 171 (54), 158 (9), 141 (9), 105 (20), 77 (10), 43 (14). 
 
HRMS (EI, 70 eV) m/z 270.16126, [270.16143 calc.for C18H22O2]. 
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2.2) Propargyl-Claisen Rearrangement 
 
2-(but-3-yn-2-yloxy)tetrahydro-2H-pyran (I-76a) 
 
 
 
(Procedure A)[87] 
 
At rt, a few drops of concentrated hydrochloric acid were added to a mixture of 3-butyn-2-ol 
(5.00 g, 71.3 mmol) and dihydropyran (6.60 g, 78.5 mmol), the mixture was stirred at rt for 
1.5 h. It was dried with MgSO4, and after filtration the crude product was purified by 
distillation (Bp: 65-70°C (15 mbar)) to give the product (6.01 g, 42.2 mmol, 59%) as a 
diastereoisomeric mixture.  
 
TLC: Rf = 0.83 (Cyclohexane/EtOAc = 1/1) [CAM] 
 
1H NMR (600 MHz, CDCl3)  ppm] 4.97 – 4.91 (m, 0.85H), 4.77 (t, J = 3.4 Hz, 0.15H), 4.55 (qd, 
J = 6.7, 1.9 Hz, 0.85H), 4.46 (qd, J = 6.6, 2.1 Hz, 0.15H), 4.03 – 3.96 (m, 0.15H), 3.82 (ddd, J = 
11.3, 8.5, 3.1 Hz, 0.85H), 3.53 (dt, J = 6.5, 4.7 Hz, 1.10H), 2.42 (d, J = 2.1 Hz, 0.15H), 2.37 (d, J 
= 2.0 Hz, 0.80H), 1.89 – 1.79 (m, 1.15H), 1.75 (ddt, J = 12.2, 9.0, 3.0 Hz, 1.0H), 1.65 – 1.50 (m, 
3.80H), 1.48 (d, J = 6.7 Hz, 2.65H), 1.44 (d, J = 6.6 Hz, 0.50H). 
 
 13C NMR (101 MHz, CDCl3) δ [ppm] (97.3, 96.1), (84.7, 83.9), (72.6, 72.0), (62.7, 62.42, 
62.37), 60.8, (30.71, 30.67), (25.6, 25.5), (22.2, 22.0), (19.6, 19.3).  
 
The analytical data are identical to the literature data.[87] 
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6-((tetrahydro-2H-pyran-2-yl)oxy)hept-4-yn-3-ol (I-77a) 
 
 
 
(Procedure B)[87] 
 
At -78°C, nBuLi (9.3 mL, 23.2 mmol, 2.5 M in hexanes) was slowly added to a solution of 2-
(but-3-yn-2-yloxy)tetrahydro-2H-pyran I-76a (3.0 g, 21.1 mmol) in dry THF (21.1 mL, 1 M). 
The mixture was stirred at -78°C for 2 h and then propanal (1.40 g, 24.0 mmol) was added 
dropwise, the solution was stirred for 2h. After allowing the mixture to warm to room 
temperature, it was quenched with sat. NH4Cl-solution and extracted three times with Et2O. 
The combined organic phase was washed with sat. NaCl-solution, dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by flash chromatography 
(Cyclohexane/EtOAc = 4/1) to obtain the product (3.83 g, 18.0 mmol, 86%) as a 
diastereoisomeric mixture. 
 
TLC: Rf = 0.26 (Cyclohexane/EtOAc = 4/1) [CAM]. 
 
1H NMR (600 MHz, CDCl3)  ppm] 4.90 (t, J = 3.5 Hz, 0.80H), 4.75 (t, J = 3.4 Hz, 0.20H), 4.56 
(qd, J = 6.7, 1.4 Hz, 0.80H), 4.47 (qd, J = 6.6, 1.5 Hz, 0.20H), 4.33 (dd, J = 11.0, 5.5 Hz, 1H), 
3.96 (ddd, J = 12.8, 7.8, 3.1 Hz, 0.20H), 3.79 (ddd, J = 11.3, 8.5, 3.2 Hz, 0.80H), 3.49 (ddt, J = 
10.2, 6.9, 5.2 Hz, 1.0H), 1.87 – 1.47 (m, 9H), 1.43 (d, J = 6.7 Hz, 2.45H), 1.40 (d, J = 6.6 Hz, 
0.60H), 0.98 (td, J = 7.4, 3.0 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] (97.4, 96.05), (85.71, 85.68), (84.92, 84.88), (63.92, 
62.91), (62.68, 62.67), 61.0, (31.12, 31.09) (30.82, 30.75), (25.7, 25.6), (22.4, 22.2), (19.7, 
19.4), (9.60, 9.59). 
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The analytical data are identical to the literature data.[87] 
 
(E)-ethyl 3-((6-((tetrahydro-2H-pyran-2-yl)oxy)hept-4-yn-3-yl)oxy)but-2-enoate (I-78a) 
 
 
 
(Procedure C)[88] 
 
At rt, P(nBu)3 (191 mg, 0.942 mmol) was added dropwise to the solution of propargyl alcohol 
I-77a (1.0 g, 4.71 mmol) and ethyl 2-butynoate (581.0 mg, 5.18 mmol) in dry CH2Cl2 (15.7 mL, 
0.3 M). The mixture was stirred at room temperature for 24 h, and then concentrated under 
reduced pressure. The residue was purified by flash chromatography (Cyclohexane/EtOAc = 
9/1) to obtain the product (1.48 g, 4.50 mmol, 95%) as a diastereoisomeric mixture. 
 
TLC: Rf = 0.42 (Cyclohexane/EtOAc = 4/1) [CAM]  
 
1H NMR (400 MHz, CDCl3)  ppm] 5.23 (d, J = 1.9 Hz, 0.15H), 5.22 (d, J = 3.0 Hz, 0.85H), 4.90 
– 4.84 (m, 0.85H), 4.77 (t, J = 3.2 Hz, 0.15H), 4.63 – 4.55 (m, 1H), 4.55 – 4.48 (m, 1H), 4.18 – 
4.09 (m, 2H), 3.96 (dd, J = 14.2, 6.2 Hz, 0.20H), 3.82 (ddd, J = 10.9, 7.3, 3.4 Hz, 0.80H), 3.49 
(td, J = 10.9, 4.6 Hz, 1H), 2.29 (d, J = 1.5 Hz, 3H), 1.90 – 1.80 (m, 3H), 1.63 – 1.49 (m, 5H), 1.45 
(d, J = 6.7 Hz, 2.30H), 1.42 (dd, J = 6.7, 1.4 Hz, 0.70H), 1.26 (td, J = 7.1, 1.4 Hz, 3H), 1.03 (t, J = 
7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] (170.60, 170.56), 168.1, (96.3, 96.2), 93.3, (87.4, 87.2), 
(81.5, 81.3), (69.0, 68.9), (62.9, 62.8), (60.92, 60.88), 59.5, 30.7, (28.74, 28.71), (25.59, 
25.58), (22.05, 21.98), (19.8, 19.7), 19.2, 14.6, (9.63, 9.59). 
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MS (EI) m/z (%):  281.1 (20), 222.1 (78) [M+-nPr], 161.0 (42), 151.0 (59), 85.1 (100). 
 
HRMS (ESI) m/z 347.1829 [347.1829 calcd. for C18H28O5Na (M
++Na+)]. 
 
(E)-ethyl 3-((6-hydroxyhept-4-yn-3-yl)oxy)but-2-enoate (I-72a) 
 
 (Procedure D)[89] 
 
At rt, PPTS (466 mg, 1.86 mmol) was added to a solution of THP-protected alcohol I-78a 
(3.05 g, 9.28 mmol) in dry MeOH (37 mL, 0.25 M). The mixture was heated to 40°C and 
stirred for 24 h. It was quenched with sat. NaHCO3-solution and extracted three times with 
Et2O. The combined organic phase was washed with sat. NaCl-solution, dried over Na2SO4 
and concentrated under reduced pressure. The residue was purified by flash 
chromatography (Cyclohexane/EtOAc = 4/1) to obtain the product (1.01 g, 4.20 mmol, 45%). 
 
TLC: Rf = 0.27 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (600 MHz, CDCl3)  ppm] 5.22 (s, 1H), 4.59 (q, J = 6.4 Hz, 1H), 4.55 (t, J = 6.3 Hz, 1H), 
4.22 – 4.12 (m, 2H), 2.32 (s, 3H), 1.88 (dtd, J = 14.0, 7.2, 2.6 Hz, 3H), 1.48 (d, J = 6.6 Hz, 3H), 
1.30 (t, J = 7.1 Hz, 3H), 1.06 (t, J = 7.4 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 170.4, 167.9, 93.2, 89.0, 80.7, 68.7, 59.4, 58.3, 28.6, 24.2, 
19.0, 14.4, 9.5. 
 
MS (EI) m/z (%): 240.0 (5) [M+], 222.1 (54) [M+-H2O], 165.0 (100) [M
+-EtCH2O2], 161.0 (85), 
151.1 (75), 123 (60), 107 (51), 91.1 (58), 79 (58). 
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HRMS (ESI) m/z 263.1255 [263.1254 calcd. for C13H20O4Na (M
++Na+)]. 
 
7-((tetrahydro-2H-pyran-2-yl)oxy)oct-5-yn-4-ol (I-77b) 
 
 
 
Following procedure B, propargyl alcohol I-76a (500 mg, 3.51 mmol) was added to butanal 
(288.9 mg, 4.01 mmol). After flash chromatography (Cyclohexane/EtOAc = 4/1), the product 
(513.1 mg, 2.27 mmol, 65%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.29 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  ppm] 4.91 (t, J = 3.4 Hz, 0.85H), 4.77 (t, J = 3.4 Hz, 0.15H), 4.62 – 
4.54 (m, 0.85H), 4.53 – 4.45 (m, 0.25H), 4.40 (dd, J = 11.5, 5.9 Hz, 1H), 3.97 (dd, J = 14.4, 6.1 
Hz, 0.20H), 3.86 – 3.77 (m, 0.80H), 3.56 – 3.48 (m, 1H), 1.88 – 1.41 (m, 14H), 0.97 – 0.91 (m, 
3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 96.0, 85.9, 84.7, 62.6, 62.4, 60.9, (40.09, 40.05), 30.7, 
25.6, 22.3, 19.6, 18.6, 13.9. 
 
The analytical data are identical to the literature data.[87] 
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(E)-ethyl 3-((7-((tetrahydro-2H-pyran-2-yl)oxy)oct-5-yn-4-yl)oxy)but-2-enoate (I-78b) 
 
 
 
Following procedure C, propargyl alcohol I-77b (316.1 mg, 1.40 mmol) was added to ethyl 2-
butynoate (156.0 mg, 1.40 mmol). After flash chromatography (Cyclohexane/EtOAc = 9/1), 
the product (287.0 mg, 0.85 mmol, 61%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.4 (Cyclohexane/EtOAc= 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  ppm] 5.23 (d, J = 2.1 Hz, 0.15H), 5.22 (d, J = 3.1 Hz, 0.85H), 4.90 
– 4.83 (m, 0.15H), 4.77 (t, J = 3.3 Hz, 0.85H), 4.61 – 4.53 (m, 1.90H), 4.50 – 4.44 (m, 0.10H), 
4.18 – 4.07 (m, 2H), 3.82 (ddd, J = 10.9, 7.4, 3.3 Hz, 1H), 3.55 – 3.44 (m, 1H), 2.28 (d, J = 1.6 
Hz, 3H), 1.89 – 1.66 (m, 4H), 1.63 – 1.46 (m, 6H), 1.44 (d, J = 6.7 Hz, 3H), 1.26 (td, J = 7.1, 1.4 
Hz, 3H), 0.99 – 0.91 (m, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] (170.63, 170.57), 168.1, (96.3, 96.2), 93.3, (87.3, 87.1), 
(81.7, 81.5), 67.5, (62.95, 62.81), (60.93, 60.89), 59.5, (37.48, 37.45), 30.7, (25.60, 25.58), 
(22.1, 22.0), (19.8, 19.7), 19.2, (18.54, 18.56), 14.6, 13.8. 
 
MS (EI) m/z (%): 236.0 (59) [M+-THPOH], 165.0 (67), 161.0 (41), 85.0 (100), 55.0 (53).  
 
HRMS (ESI) m/z 361.1986 [361.1985 calcd. for C19H30O5Na (M
++Na+)]. 
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(E)-ethyl 3-((7-hydroxyoct-5-yn-4-yl)oxy)but-2-enoate (I-72b) 
 
 
 
Following procedure D, THP-protected alcohol I-78b (227.3 mg, 0.680 mmol) was 
deprotected. After flash chromatography (Cyclohexane/EtOAc = 9/1), the product (60 mg, 
0.236 mmol, 35%) was obtained. 
 
TLC: Rf = 0.13 (Cyclohexane/EtOAc = 9/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  ppm] 5.20 (s, 1H), 4.56 (q, J = 6.3 Hz, 2H), 4.19 – 4.09 (m, 2H), 
2.28 (s, 3H), 1.95 – 1.74 (m, 3H), 1.54 – 1.46 (m,2H), 1.44 (d, J = 6.6 Hz, 3H), 1.27 (t, J = 7.1 
Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.6, 168.1, 93.3, 89.1, 81.1, 67.5, 59.6, 58.5, 37.5, 24.3, 
19.2, 18.5, 14.6, 13.7.  
 
MS (EI) m/z (%): 254.1 (2) [M+], 236.1 (35) [M+-H2O], 211.1 (51) [M
+-C2H3O], 181.1 (36) [M
+-
CO2Et], 165.0 (100) [M
+- PrCH2O2], 137.0 (46), 91.0 (46).  
 
HRMS (ESI) m/z 277.1410 [277.1410 calcd. for C14H22O4Na (M
++Na+)]. 
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2,2-dimethyl-6-((tetrahydro-2H-pyran-2-yl)oxy)hept-4-yn-3-ol (I-77c) 
 
 
 
Following procedure B, propargyl alcohol I-76a (500 mg, 3.51 mmol) was added to 
pivaldehyde (345.4 mg, 4.01 mmol). After flash chromatography (Cyclohexane/EtOAc = 4/1), 
the product (265.0 mg, 1.10 mmol, 31%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.32 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (600 MHz, CDCl3)  ppm] 4.92 (t, J = 3.4 Hz, 0.85H), 4.78 (s, 0.15H), 4.59 (qd, J = 6.7, 
1.4 Hz, 0.85H), 4.51 (qd, J = 6.6, 4.5 Hz, 0.15H), 4.03 (d, J = 6.0 Hz, 1H), 3.98 (ddd, J = 11.8, 
9.1, 2.9 Hz, 0.15H), 3.82 (ddd, J = 11.1, 8.3, 3.1 Hz, 0.85H), 3.55 – 3.48 (m, 1H), 1.87 – 1.80 
(m, 1H), 1.73 (ddd, J = 15.7, 13.5, 8.8 Hz, 2H), 1.63 – 1.50 (m, 4H), 1.46 (dd, J = 6.7, 1.2 Hz, 
2.70H), 1.43 (d, J = 6.6 Hz, 0.50H), 0.99 (d, J = 3.7 Hz, 9H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] (95.91, 95.88), 85.5, 84.2, 71.3, 71.3, 62.5, 60.8, 35.8, 
30.5, 25.4, 25.2, 25.2, 22.1, 19.5. 
 
The analytical data are identical to the literature data.[90] 
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(E)-ethyl 3-((2,2-dimethyl-6-((tetrahydro-2H-pyran-2-yl)oxy)hept-4-yn-3-yl)oxy)but-2-
enoate (I-78c) 
 
 
 
Following procedure C, propargyl alcohol I-77c (255.6 mg, 1.06 mmol) was added to ethyl 2-
butynoate (118.9 mg, 1.06 mmol). After flash chromatography (Cyclohexane/EtOAc = 9/1), 
the product (359.9 mg, 1.02 mmol, 96%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.51 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  ppm] 5.26 (s, 0.15H), 5.24 (d, J = 1.6 Hz, 0.85H), 4.87 (td, J = 4.9, 
2.9 Hz, 0.85H), 4.78 (t, J = 3.3 Hz, 0.15H), 4.62 – 4.56 (m, 0.90H), 4.48 (qd, J = 6.7, 1.5 Hz, 
0.15H), 4.19 (d, J = 1.2 Hz, 1H), 4.18 – 4.06 (m, 2H), 3.86 – 3.78 (m, 1H), 3.54 – 3.44 (m, 1H), 
2.30 (d, J = 1.7 Hz, 3H), 1.82 (dt, J = 9.6, 5.6 Hz, 1H), 1.77 – 1.65 (m, 1H), 1.63 – 1.48 (m, 4H), 
1.45 (d, J = 6.7 Hz, 3H), 1.29 – 1.23 (m, 3H), 1.02 (d, J = 0.9 Hz, 9H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] (171.00, 171.95), 168.1, (96.4, 96.3), 93.3, (88.1, 87.9), 
(80.3, 80.1), 76.3, (63.0, 62.9), (61.00, 60.96), 59.4, 35.7, 30.7, (25.76, 25.73), (25.61, 25.59), 
(22.1, 22.0), (19.9, 19.8), 19.0, 14.6. 
 
HRMS (ESI) m/z 375.2140 [375.2142 calcd. for C20H32O5Na (M
++Na+)]. 
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(E)-ethyl 3-((6-hydroxy-2,2-dimethylhept-4-yn-3-yl)oxy)but-2-enoate (I-72c) 
 
 
 
Following procedure D, THP-protected alcohol I-78c (302 mg, 0.851 mmol) was deprotected. 
After flash chromatography (Cyclohexane/EtOAc = 9/1), the product (132 mg, 0.492 mmol, 
57 %) was obtained. 
 
TLC: Rf = 0.1 (Cyclohexane/EtOAc = 9/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  ppm] 5.22 (s, 1H), 4.57 (p, J = 6.2 Hz, 1H), 4.21 – 4.19 (m, 1H), 
4.17 – 4.11 (m, 2H), 2.30 (s, 3H), 1.89 (s, 1H), 1.46 (d, J = 6.6 Hz, 3H), 1.27 (t, J = 7.1 Hz, 3H), 
1.02 (s, 9H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.9, 168.1, 93.3, 89.8, 79.7, 76.2, 59.5, 58.5, 35.7, 25.7, 
24.4, 19.0, 14.6. 
 
MS (EI) m/z (%): 250.1 (36) [M+-H2O], 189.1 (86), 179.0 (36), 165.0 (100) [M
+-tBuCH2O2], 
137.1 (58), 91.0 (43). 
 
HRMS (ESI) m/z 291.1572 [291.1567 calcd. for C15H24O4Na (M
++Na+)]. 
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1-phenyl-4-((tetrahydro-2H-pyran-2-yl)oxy)pent-2-yn-1-ol (I-77d) 
 
 
 
Following procedure B, propargyl alcohol I-76a (500 mg, 3.51 mmol) was added to 
benzaldehyde (425.6 mg, 4.01 mmol). After flash chromatography (Cyclohexane/EtOAc = 
4/1), the product (779.4 mg, 2.99 mmol, 85%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.27 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (600 MHz, CDCl3)  ppm] 7.56 (d, J = 7.5 Hz, 2H), 7.41 (dd, J = 10.5, 4.3 Hz, 2H), 7.36 
(t, J = 7.3 Hz, 1H), 5.53 (d, J = 6.0 Hz, 1H), 4.97 (dd, J = 4.5, 2.5 Hz, 0.85H), 4.82 (t, J = 3.4 Hz, 
0.15H), 4.68 (qd, J = 6.7, 1.3 Hz, 0.85H), 4.60 – 4.55 (m, 0.15H), 4.02 – 3.96 (m, 0.15H), 3.89 – 
3.79 (m, 0.85H), 3.57 – 3.51 (m, 1H), 2.25-2.19 (m, 1H), 1.90 – 1.82 (m, 1H), 1.80 – 1.73 (m, 
1H), 1.64-1.55 (m, 4H), 1.53 (dd, J = 6.7, 1.2 Hz, 2.65H), 1.49 (dd, J = 6.6, 1.7 Hz, 0.45H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 140.7, 128.8, 128.7, 128.6, 126.8, 126.8, 96.1, 86.9, 84.4, 
64.8, 62.7, 61.0, 30.7, 25.6, 22.2, 19.6. 
 
The analytical data are identical to the literature data.[87] 
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(E)-ethyl 3-((1-phenyl-4-((tetrahydro-2H-pyran-2-yl)oxy)pent-2-yn-1-yl)oxy)but-2-enoate (I-
78d) 
 
 
 
Following procedure C, propargyl alcohol I-77d (300 mg, 1.15 mmol) was added to ethyl 2-
butynoate (128.9 mg, 1.15 mmol). After flash chromatography (Cyclohexane/EtOAc = 9/1), 
the product (310.2 mg, 0.83 mmol, 72%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.51 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  ppm] 7.46 (dd, J = 7.7, 1.7 Hz, 2H), 7.40 – 7.32 (m, 3H), 5.64 (s, 
0.15H), 5.62 (s, 0.85H), 5.34 (d, J = 4.4 Hz, 1H), 4.85 (td, J = 5.0, 2.8 Hz, 0.85H), 4.75 (dd, J = 
6.0, 3.2 Hz, 0.15H), 4.67 – 4.57 (m, 0.85H), 4.50 – 4.47 (m, 0.15H), 4.17 – 4.07 (m, 2H), 3.84 – 
3.75 (m, 1H), 3.46 (tt, J = 17.3, 5.8 Hz, 1H), 2.30 (d, J = 2.0 Hz, 3H), 1.84 – 1.74 (m, 1H), 1.73 – 
1.62 (m, 1H), 1.53 – 1.41 (m, 7H), 1.25 (q, J = 6.9 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] (170.4, 170.3), 167.9, 137.0, 129.1, 128.8, (128.55, 
128.53), (127.52, 127.49), (96.4, 96.3), 94.0, (89.6, 89.5), (80.6, 80.4), (69.8, 69.7), (63.0, 
62.8), (61.02, 60.97), 59.6, 30.7, (25.57, 25.56), (22.0, 21.9), (19.8, 19.7), 19.3, 14.6. 
 
MS (EI) m/z (%): 270.1 (100) [M+-THPOH], 181.0 (29), 153.0 (41).  
 
HRMS (ESI) m/z 395.1827 [395.1829 calcd. for C22H28O5Na (M
++Na+)]. 
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(E)-ethyl 3-((4-hydroxy-1-phenylpent-2-yn-1-yl)oxy)but-2-enoate (I-72d) 
 
 
 
Following procedure D, THP-protected alcohol I-78d (200 mg, 0.537 mmol) was deprotected. 
After flash chromatography (Cyclohexane/EtOAc = 9/1), the product (67.5 mg, 0.234 mmol, 
44%) was obtained. 
 
TLC: Rf = 0.10 (Cyclohexane/EtOAc = 9/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  ppm] 7.49 (dd, J = 7.9, 1.7 Hz, 2H), 7.42 – 7.38 (m, 3H), 5.66 (d, J 
= 0.8 Hz, 1H), 5.34 (s, 1H), 4.65 – 4.57 (m, 1H), 4.16 (tdd, J = 7.1, 3.5, 2.0 Hz, 2H), 2.34 (s, 3H), 
1.90 (s, 1H), 1.50 – 1.46 (m, 3H), 1.32 – 1.25 (m, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.3, 167.9, 136.9, 129.2, 128.9, 128.8, 127.4, 94.1, 
80.1, 69.7, 59.7, 58.6, 24.2, 19.3, 14.6. 
 
MS (EI) m/z (%): 270.1 (100) [M+-H2O], 181.0 (27) [M
+-PhCO], 153.0 (44). 
 
HRMS (ESI) m/z 311.1254 [311.1254 calcd. for C17H20O4Na (M
++Na+)]. 
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2-((5-methylhex-1-yn-3-yl)oxy)tetrahydro-2H-pyran (I-76b) 
 
 
 
Following procedure A, 5-Methyl-1-hexyn-3-ol (1.0 g, 8.92 mmol) was protected with 
dihydropyran (0.825 g, 9.81 mmol). After distillation (T = 65-75°C, 1 mmHg), the product 
(1.02 g, 5.19 mmol, 58%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.51 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  ppm] 4.99 (t, J = 3.3 Hz, 0.85H), 4.95 (dd, J = 4.8, 2.8 Hz, 0.15H), 
4.48 (ddd, J = 7.7, 6.8, 2.0 Hz, 0.85H), 4.31 (td, J = 7.2, 2.1 Hz, 0.15H), 4.03 (qd, J = 8.7, 4.2 Hz, 
0.15H), 3.81 (ddd, J = 11.7, 8.7, 3.2 Hz, 0.90H), 3.57 – 3.49 (m, 1H), 2.43 (d, J = 2.1 Hz, 0.15H), 
2.36 (d, J = 2.0 Hz, 0.85H), 1.91 (dd, J = 13.5, 6.8 Hz, 1H), 1.79 – 1.67 (m, 2H), 1.59 (dt, J = 
20.7, 6.8 Hz, 6H), 0.94 (dt, J = 7.9, 3.9 Hz, 6H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 95.6, 83.3, 73.2, 63.5, 62.5, 44.8, 30.7, 25.6, 24.8, 22.8, 
22.6, 19.5. 
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL PART 
CATALYZED CASCADE REACTIONS, A WAY TOWARD FURAN COMPOUNDS 
 
108 
 
8-methyl-6-((tetrahydro-2H-pyran-2-yl)oxy)non-4-yn-3-ol (I-77e) 
 
 
Following procedure B, propargyl alcohol I-76b (500 mg, 2.55 mmol) was added to propanal 
(168.7 mg, 2.90 mmol). After flash chromatography (Cyclohexane/EtOAc = 4/1), the product 
(503.6 mg, 1.98 mmol, 78%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.50 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (600 MHz, CDCl3)  ppm] 5.09 (s, 0.15H), 4.97 (s, 0.85H), 4.55 (q, J = 5.4 Hz, 0.10H), 
4.53 – 4.49 (m, 0.90H), 4.35 (d, J = 5.9 Hz, 1H), 4.04 – 3.99 (m, 0.10H), 3.80 (ddd, J = 11.8, 
9.1, 3.0 Hz, 0.85H), 3.56 – 3.50 (m, 1H), 1.89 (dd, J = 13.5, 6.7 Hz, 1H), 1.80 (d, J = 5.6 Hz, 1H), 
1.77 – 1.65 (m, 4H), 1.65 – 1.49 (m, 6H), 1.00 (t, J = 7.4 Hz, 3H), 0.94 (dd, J = 9.2, 6.7 Hz, 6H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] (95.51, 95.49), (86.3, 86.2), (84.30, 84.25), (63.90, 63.88), 
(63.65, 63.64), (62.40, 62.38), (44.95, 44.94), (31.09, 31.06), 30.7, 25.6, (24.88, 24.87), 22.9, 
22.6, 19.4, (9.52, 9.50).    
 
MS (EI) m/z (%): 152.1 (3) [M+-THPOH], 95.1 (15), 85.0 (100) [THP], 84.0 (17), 57.0 (32), 55.0 
(31).  
 
HRMS (ESI) m/z 277.1777 [277.1774 calcd. for C15H26O3Na (M
++Na+)]. 
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(E)-ethyl 3-((8-methyl-6-((tetrahydro-2H-pyran-2-yl)oxy)non-4-yn-3-yl)oxy)but-2-enoate (I-
78e) 
 
 
 
Following procedure C, propargyl alcohol I-77e (490 mg, 1.93 mmol) was added to ethyl 2-
butynoate (237.7 mg, 2.12 mmol). After flash chromatography (Cyclohexane/EtOAc = 9:1), 
the product (549.9 mg, 1.50 mmol, 78%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.63 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  ppm] 5.24 (s, 0.10H), 5.22 (s, 0.90H), 4.92 (dt, J = 6.9, 3.6 Hz, 
0.90H), 4.82 – 4.75 (m, 0.20H), 4.61 (t, J = 5.3 Hz, 0.10H), 4.52 (td, J = 6.6, 3.1 Hz, 1.90H), 4.17 
– 4.07 (m, 2H), 3.80 (dd, J = 13.6, 6.3 Hz, 1H), 3.57 – 3.46 (m, 1H), 2.32 (t, J = 2.3 Hz, 0.5H), 
2.29 (d, J = 1.7 Hz, 2.5H), 1.92 – 1.47 (m, 11H), 1.26 (td, J = 7.1, 1.4 Hz, 3H), 1.03 (t, J = 7.4 Hz, 
3H), 0.96 – 0.90 (m, 6H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.4, 167.9, (95.73, 95.65), 93.2, (86.7, 86.5), (82.0, 
81.8), 68.8, 63.7, (62.5, 62.4), 59.3, 44.4, 30.5, 28.6, 25.5, 24.8, 22.6, (19.5, 19.4), 19.0, 14.4, 
(9.5, 9.4).  
 
MS (EI) m/z (%): 264.1 (22) [M+-THPOH], 221.1 (51) [M+-THPOH-nPr], 207.0 (25), 175.0 (26), 
85.0 (100).  
 
HRMS (ESI) m/z 389.2303 [389.2298 calcd. for C21H34O5Na (M
++Na+)]. 
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(E)-ethyl 3-((6-hydroxy-8-methylnon-4-yn-3-yl)oxy)but-2-enoate (I-72e) 
 
 
 
Following procedure D, THP-protected alcohol I-78e (450 mg, 1.23 mmol) was deprotected. 
After flash chromatography (Cyclohexane/EtOAc = 9/1), the product (239.6 mg, 0.849 mmol, 
67%) was obtained. 
 
TLC: Rf = 0.16 (Cyclohexane/EtOAc = 9/1) [CAM] 
 
1H NMR (600 MHz, CDCl3)  [ppm] 5.20 (s, 1H), 4.52 (t, J = 6.3 Hz, 1H), 4.45 (t, J = 6.7 Hz, 1H), 
4.19 – 4.09 (m, 2H), 2.29 (d, J = 2.1 Hz, 3H), 1.91 – 1.79 (m, 3H), 1.73 (s, 1H), 1.66 – 1.60 (m, 
1H), 1.59 – 1.52 (m, 1H), 1.27 (td, J = 7.1, 1.8 Hz, 3H), 1.03 (t, J = 7.4 Hz, 3H), 0.99 – 0.88 (m, 
6H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 170.5, 168.0, 93.4, 88.7, 81.6, 68.9, 61.2, 59.5, (46.83, 
46.80), 28.8, 25.0, (22.68, 22.66), 22.6, 19.1, 14.6, 9.6. 
 
MS (EI) m/z (%): 282.1 (4) [M+], 264.2 (36) [M+-H2O], 221.1 (100) [M
+-H2O-nPr], 207.0 (65) 
[M+-EtCH2O2], 179.0 (86), 151.0 (71).  
 
HRMS (ESI) m/z 305.1721 [305.1723 calcd. for C16H26O4Na (M
++Na+)]. 
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6-methyl-1-phenyl-4-((tetrahydro-2H-pyran-2-yl)oxy)hept-2-yn-1-ol (I-77f) 
 
 
 
Following procedure B, propargyl alcohol I-76b (500 mg, 2.55 mmol) was added to 
benzaldehyde (308.2 mg, 2.90 mmol). After flash chromatography (Cyclohexane/EtOAc = 
4/1), the product (558.8 mg, 2.20 mmol, 86%) was obtained. 
 
TLC: Rf = 0.25 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.54 (dd, J = 8.2, 6.8 Hz, 2H), 7.43 – 7.31 (m, 3H), 5.50 (s, 
1H), 4.99 (d, J = 2.6 Hz, 1H), 4.66 – 4.54 (m, 1H), 3.92 – 3.75 (m, 1H), 3.62 – 3.45 (m, 1H), 2.20 
(s, 1H), 1.99 – 1.48 (m, 9H), 1.05 – 0.90 (m, 6H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 134.4, 128.6, 128.4, 126.7, (95.50, 95.48), 86.2, 84.9, 
64.7, 63.6, (62.30, 62.29), 44.7, 30.5, 25.5, 24.7, 22.7, 22.4, 19.3. 
 
MS (EI) m/z (%): 199.1 (70), 157.0 (47), 105.0 (86) [PhCO], 85 (100), 55 (52).  
 
HRMS (ESI) m/z 325.1771 [325.1774 calcd. for C19H26O3Na (M
++Na+)]. 
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(E)-ethyl 3-((6-methyl-1-phenyl-4-((tetrahydro-2H-pyran-2-yl)oxy)hept-2-yn-1-yl)oxy)but-2-
enoate (I-78f) 
 
 
 
Following procedure C, propargyl alcohol I-77f (565 mg, 2.22 mmol) was added to ethyl 2-
butynoate (273.6 mg, 2.44 mmol). After flash chromatography (Cyclohexane/EtOAc = 9/1), 
the product (667.0 mg, 1.61 mmol, 72%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.39 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.49 (dd, J = 7.7, 1.6 Hz, 2H), 7.40 – 7.36 (m, 3H), 5.65 (s, 
1H), 5.39 (d, J = 2.6 Hz, 1H), 4.96 – 4.88 (m, 1H), 4.58 (tdd, J = 7.3, 3.5, 1.6 Hz, 1H), 4.15 (ddd, 
J = 10.2, 7.0, 3.4 Hz, 2H), 3.81 (t, J = 9.4 Hz, 1H), 3.56 – 3.45 (m, 1H), 2.33 (s, 3H), 1.93 – 1.85 
(m, 1H), 1.75 – 1.47 (m, 8H), 1.28 (t, J = 7.1 Hz, 3H), 0.97 – 0.88 (m, 6H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.4, 167.9, 137.0, 129.1, 128.8, (127.6, 127.5), (96.0, 
95.9), 94.1, (89.2, 89.1), (81.2, 81.0), (69.8, 69.8), (63.9, 63.9), (62.7, 62.6), 59.6, (44.5, 44.5), 
30.7, 25.6, 24.9, 22.8, 22.6, 19.2, 14.6, 13.8. 
 
MS (EI) m/z (%): 199.0 (84), 157.0 (53), 105.0 (86) [PhCO], 85 (100), 55 (54).  
 
HRMS (ESI) m/z 437.2299 [437.2298 calcd. for C25H34O5Na (M
++Na+)]. 
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(E)-ethyl 3-((4-hydroxy-6-methyl-1-phenylhept-2-yn-1-yl)oxy)but-2-enoate (I-72f) 
 
 
 
Following procedure D, THP-protected alcohol I-78f (565 mg, 2.22 mmol) was deprotected. 
After flash chromatography (Cyclohexane/EtOAc = 9/1), the product (667 mg, 1.61 mmol, 
72%) was obtained. 
 
TLC: Rf = 0.16 (Cyclohexane/EtOAc = 9/1) [CAM] 
 
1H NMR (600 MHz, CDCl3)  [ppm] 7.52 (d, J = 7.1 Hz, 2H), 7.46 – 7.38 (m, 3H), 5.69 (s, 1H), 
5.39 (s, 1H), 4.53 (t, J = 7.1 Hz, 1H), 4.18 (qd, J = 7.1, 2.7 Hz, 2H), 2.37 (s, 3H), 1.87 (td, J = 
13.6, 6.8 Hz, 1H), 1.81 (s, 1H), 1.69 (dtd, J = 10.6, 7.3, 3.3 Hz, 1H), 1.65 – 1.59 (m, 1H), 1.31 (t, 
J = 7.1 Hz, 3H), 0.96 (dd, J = 11.9, 6.2 Hz, 6H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 170.1, 167.7, 136.8, 129.0, 128.7, 127.3, 94.0, 90.5, 80.6, 
69.6, 61.1, 59.5, 46.5, 24.8, 22.5, 19.1, 14.4. 
 
MS (EI) m/z (%): 312.1 (8) [M+-H2O], 273.0 (45), 251.0 (22), 227.0 (100) [M
+-C8H7], 91.0 (19).  
 
HRMS (ESI) m/z 353.1723 [353.1723 calcd. for C20H26O4Na (M
++Na+)]. 
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2-((1-phenylprop-2-yn-1-yl)oxy)tetrahydro-2H-pyran (I-76c) 
 
 
 
Following procedure A, 1-Phenyl-2-propyn-1-ol (1.0 g, 7.57 mmol) was protected with 
dihydropyran (0.700 g, 8.32 mmol). After flash chromatography (Cyclohexane/EtOAc = 9/1), 
the product (1.14 g, 5.26 mmol, 69%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.55 (Cyclohexane/EtOAc = 9/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.61 – 7.55 (m, 1H), 7.52 – 7.46 (m, 1H), 7.41 – 7.30 (m, 
3H), 5.52 (d, J = 2.1 Hz, 0.70H), 5.43 (d, J = 2.3 Hz, 0.30H), 5.20 (t, J = 3.1 Hz, 0.70H), 4.57 (t, J 
= 3.4 Hz, 0.30H), 4.06 – 3.98 (m, 0.30H), 3.90 – 3.81 (m, 0.70H), 3.63 – 3.53 (m, 1H), 2.60 (d, J 
= 2.3 Hz, 0.30H), 2.58 (d, J = 2.2 Hz, 0.70H), 1.96 – 1.46 (m, 6H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 138.6, 128.8, 128.6, 128.4, 127.7, 127.5, (96.0, 95.8), 
(83.1, 81.8), (75.3, 74.3), (67.3, 66.7), (62.3, 62.2), (30.4, 30.3), (25.6, 25.5), (19.2, 19.0). 
 
6-phenyl-6-((tetrahydro-2H-pyran-2-yl)oxy)hex-4-yn-3-ol (I-77g) 
 
 
 
Following procedure B, propargyl alcohol I-76c (500 mg, 2.31 mmol) was added to propanal 
(152.9 mg, 2.64 mmol). After flash chromatography (Cyclohexane/EtOAc = 4/1), the product 
(458.3 mg, 1.67 mmol, 72%) was obtained as a diastereoisomeric mixture. 
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TLC: Rf = 0.24 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (600 MHz, CDCl3)  [ppm] 7.55 (d, J = 7.3 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.37 (q, J = 
6.8 Hz, 2H), 7.32 (dd, J = 8.4, 6.2 Hz, 1H), 5.55 (s, 0.65H), 5.46 (s, 0.25H), 5.30 (s, 0.25H), 5.17 
(s, 0.65H), 4.56 (t, J = 3.4 Hz, 0.30H), 4.41 (t, J = 6.4 Hz, 0.70H), 4.04 – 3.98 (m, 0.30H), 3.88 – 
3.81 (m, 0.70H), 3.61 – 3.57 (m, 0.70H), 3.57 – 3.52 (m, 0.30H), 1.93 – 1.47 (m, 9H), 1.02 (td, 
J = 7.4, 1.8 Hz, 2.20H), 1.00 – 0.97 (m, 0.80H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 138.9 128.7, 128.6, 128.3, 127.7, 127.5, 95.6, (88.30, 
88.27), 82.8, 66.8, 64.0, (62.3, 62.2), (31.04, 31.01), 30.5, (25.60, 25.55), 19.2, 9.6. 
 
MS (EI) m/z (%): 172.0 (73) [M+-THPOH], 114.9 (66), 85.1 (63), 57.0 (100).  
 
HRMS (ESI) m/z 297.1461 [297.1461 calcd. for C17H22O3Na (M
++Na+)]. 
 
(E)-ethyl 3-((6-phenyl-6-((tetrahydro-2H-pyran-2-yl)oxy)hex-4-yn-3-yl)oxy)but-2-enoate (I-
78g) 
 
 
 
Following procedure C, propargyl alcohol I-77g (448 mg, 1.63 mmol) was added to ethyl 2-
butynoate (200.7 mg, 1.80 mmol). After flash chromatography (Cyclohexane/EtOAc = 9/1), 
the product (425.7 mg, 1.10 mmol, 67%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.33 (Cyclohexane/EtOAc = 9/1) [CAM] 
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1H NMR (400 MHz, CDCl3)  [ppm] 7.57 – 7.51 (m, 1H), 7.47 – 7.43 (m, 1H), 7.39 – 7.28 (m, 
3H), 5.56 (s, 0.70H), 5.45 (s, 0.30H), 5.30 – 5.24 (m, 1H), 5.14 – 5.10 (m, 0.70H), 4.64 – 4.54 
(m, 1.20H), 4.24 – 4.06 (m, 2H), 4.03 – 3.95 (m, 0.30H), 3.91 – 3.83 (m, 0.70H), 3.63 – 3.51 
(m, 1H), 2.30 (d, J = 3.9 Hz, 2.20H), 2.28 (d, J = 5.8 Hz, 0.70H), 1.94 – 1.47 (m, 8H), 1.31 – 1.23 
(m, 3H), 1.04 (ddd, J = 7.6, 7.0, 1.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] (170.44, 170.39) 167.8, 138.3, (128.48, 128.41), 128.2, 
(127.5, 127.4), (95.8, 95.7), 93.3, (85.1, 84.9), (84.0, 83.8), 68.8, (66.72, 66.70), (62.3, 62.2), 
59.3, 30.3, 28.6, 25.4, 19.1, 19.0, 14.4, 9.5. 
 
HRMS (ESI) m/z 409.1987 [409.1985 calcd. for C23H30O5Na (M
++Na+)]. 
 
(E)-ethyl 3-((6-hydroxy-6-phenylhex-4-yn-3-yl)oxy)but-2-enoate (I-72g) 
 
 
 
Following procedure D, THP-protected alcohol I-78g (370 mg, 0.957 mmol) was deprotected. 
After flash chromatography (Cyclohexane/EtOAc = 9/1), the product (180.2 mg, 0.596 mmol, 
62%) was obtained. 
 
TLC: Rf = 0.11 (Cyclohexane/EtOAc = 9/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.52 (dd, J = 8.1, 1.2 Hz, 2H), 7.40 – 7.30 (m, 3H), 5.50 (s, 
1H), 5.26 (s, 1H), 4.59 (td, J = 6.3, 1.1 Hz, 1H), 4.21 – 4.07 (m, 2H), 2.30 (d, J = 2.3 Hz, 4H), 
1.91 (p, J = 7.2 Hz, 2H), 1.27 (td, J = 7.1, 1.3 Hz, 3H), 1.05 (td, J = 7.4, 1.5 Hz, 3H). 
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13C NMR (101 MHz, CDCl3) δ [ppm] 170.5, 168.0, 140.3, 128.8, 128.6, 126.8, 126.8, 93.5, 
87.0, 83.6, 68.9, 64.7, 59.6, 28.7, 19.1, 14.6, 9.7. 
 
MS (EI) m/z (%): 280.9 (38), 227.0 (26) [M+-EtCH2O2], 207.0 (100), 105 (43) [PhCO], 73 (41). 
 
HRMS (ESI) m/z 325.1411 [325.1410 calcd. for C18H22O4Na (M
++Na+)]. 
 
1,4-diphenyl-4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-yn-1-ol (I-77h) 
 
 
Following procedure B, propargyl alcohol I-76c (500 mg, 2.31 m mol) was added to 
benzaldehyde (279.7 mg, 2.64 mmol). After flash chromatography (Cyclohexane/EtOAc = 
4/1), the product (553.0 mg, 1.72 mmol, 74%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.29 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.66 – 7.46 (m, 4H), 7.46 – 7.30 (m, 6H), 5.62 (s, 1H), 5.56 
(s, 1H), 5.19 (d, J = 3.0 Hz, 1H), 3.96 – 3.79 (m, 1H), 3.70 – 3.39 (m, 1H), 2.34 (s, 1H), 1.95 – 
1.73 (m, 2H), 1.73 – 1.49 (m, 4H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 140.6, 138.7, 128.8, 128.6, 128.4, 127.7, 127.5, (126.84, 
126.82), 95.8, 87.0, 84.7, 66.9, 64.9, 62.3, (30.44, 30.39), (25.6, 25.5), 19.2. 
 
MS (EI) m/z (%): 222.0 (50) [M+-THPOH], 191.1 (50), 105.0 (100) [PhCO], 77.0 (84) [Ph].  
 
HRMS (ESI) m/z 345.1457 [345.1461 calcd. for C21H22O3Na (M
++Na+)]. 
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(E)-ethyl 3-((1,4-diphenyl-4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-yn-1-yl)oxy)but-2-enoate 
(I-78h) 
 
 
 
Following procedure C, propargyl alcohol I-77h (550 mg, 1.71 mmol) was added to ethyl 2-
butynoate (210.8 mg, 1.88 mmol). After flash chromatography (Cyclohexane/EtOAc = 9/1), 
the product (498.5 mg, 1.15 mmol, 67%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.49 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.58 – 7.44 (m, 4H), 7.43 – 7.30 (m, 6H), 5.72 (s, 1H), 5.62 
(s, 0.75H), 5.50 (s, 0.25H), 5.44 (d, J = 3.0 Hz, 0.75H), 5.41 (d, J = 1.3 Hz, 0.25H), 5.13 (dd, J = 
6.5, 3.2 Hz, 1H), 4.23 – 4.14 (m, 2H), 3.90 – 3.81 (m, 1H), 3.61 – 3.52 (m, 1H), 2.35 (d, J = 4.4 
Hz, 2H), 2.33 (d, J = 6.1 Hz, 1H), 1.89 – 1.48 (m, 6H), 1.31 – 1.27 (m, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.3, 167.8, 138.3, 136.8, 129.2, 128.9, 128.6, 128.5, 
127.6, (127.58, 127.56), (96.1, 96.0), 94.2, (87.5, 87.4), (83.2, 83.0), 69.8, 66.9, (62.5, 62.4), 
59.6, (31.0, 30.5), 25.6, 21.2, (19.3, 19.2), (14.6, 14.3). 
 
MS (EI) m/z (%): 332.1 (100) [M+-THPOH], 285.1 (38), 215.1 (46), 105.0 (23) [PhCO], 77.0 (14) 
[Ph].  
 
HRMS (ESI) m/z 457.1990 [457.1985 calcd. for C27H30O5Na (M
++Na+)]. 
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(E)-ethyl-3-((4-hydroxy-1,4-diphenylbut-2-yn-1-yl)oxy)but-2-enoate (I-72h) 
 
 
 
Following procedure D, THP-protected alcohol I-78h (486 mg, 1.12 mmol) was deprotected. 
After flash chromatography (Cyclohexane/EtOAc = 9/1), the product (153.9 mg, 0.440 mmol, 
39%) was obtained. 
 
TLC: Rf = 0.24 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (600 MHz, CDCl3)  [ppm] 7.52 (dd, J = 9.0, 4.2 Hz, 4H), 7.44 – 7.31 (m, 6H), 5.73 (s, 
1H), 5.55 (s, 1H), 5.41 (s, 1H), 4.20 – 4.12 (m, 2H), 2.35 (d, J = 3.6 Hz, 3H), 2.26 (s, 1H), 1.28 (t, 
J = 7.2 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ 170.3, 167.8, 140.1, 136.8, 129.2, 128.9, 128.8, 128.7,127.48, 
127.47, 126.89, 126.88, 94.3, 89.0, 82.7, 69.7, 64.8, 59.7, 19.2, 14.6. 
 
MS (EI) m/z (%): 332.1 (12) [M+-H2O], 303.1 (31.3), 281.0 (39), 207 (100) [M
+-C8H7].  
 
HRMS (ESI) m/z 373.1413 [373.1410 calcd. for C22H22O4Na (M
++Na+)]. 
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(E)-ethyl 3-((6-((tetrahydro-2H-pyran-2-yl)oxy)hept-4-yn-3-yl)oxy)acrylate (I-78i) 
 
 
 
Following procedure C, propargyl alcohol I-77a (200 mg, 0.94 mmol) was added to ethyl 
propiolate (101.4 mg, 1.03 mmol). After flash chromatography (Cyclohexane/EtOAc = 9/1), 
the product (271.6 mg, 0.88 mmol, 93%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.44 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.59 (dd, J = 12.5, 0.7 Hz, 1H), 5.34 (d, J = 12.5 Hz, 1H), 
4.86 (d, J = 2.0 Hz, 1H), 4.59 (q, J = 6.7 Hz, 1H), 4.51 (t, J = 6.3 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 
3.81 (ddd, J = 10.9, 7.8, 3.2 Hz, 1H), 3.50 (dd, J = 10.1, 5.0 Hz, 1H), 1.89 – 1.78 (m, 3H), 1.74 
(d, J = 13.0 Hz, 1H), 1.66 – 1.49 (m, 4H), 1.45 (d, J = 6.7 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H), 1.01 
(t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 167.6, (160.4, 160.3), (98.72, 98.69), (96.14, 96.06), 
(88.1, 87.9), (80.8, 80.7), (72.6, 72.5), (62.7, 62.6), 60.7, 59.8, (30.52, 30.50), (28.6, 28.5), 
25.4, (21.90, 21.87), (19.54, 19.49), 14.3, (9.28, 9.26).  
 
MS (EI) m/z (%): 281.0 (61) [M+-Et], 252.9 (40), 207.0 (100) [M+-THPOH], 134.9 (45), 85.0 
(59), 73.0 (54).  
 
HRMS (ESI) m/z 333.1674 [333.1672 calcd. for C17H26O5Na (M
++Na+)]. 
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(E)-ethyl 3-((6-hydroxyhept-4-yn-3-yl)oxy)acrylate (I-72i) 
 
 
 
Following procedure D, THP-protected alcohol I-78i (1 g, 3.22 mmol) was deprotected. After 
flash chromatography (Cyclohexane/EtOAc = 9/1), the product (585.6 mg, 2.59 mmol, 80%) 
was obtained. 
 
TLC: Rf = 0.22 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.59 (d, J = 12.5 Hz, 1H), 5.35 (d, J = 12.5 Hz, 1H), 4.58 (dd, 
J = 9.3, 3.9 Hz, 1H), 4.52 (t, J = 6.4 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 1.90 (s, 1H), 1.89 – 1.80 
(m, 2H), 1.46 (d, J = 6.6 Hz, 3H), 1.27 (t, J = 7.1 Hz, 3H), 1.02 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 167.9, 160.5, 98.9, 90.1, 80.4, 72.8, 60.0, 58.4, 28.7, 24.3, 
14.5, 9.5. 
 
MS (EI) m/z (%): 208.0 (16) [M+-H2O], 180.1 (37) [M
+-C2H6O], 151.0 (100) [M
+-EtCH2O2], 91.0 
(47), 79.0 (38).  
 
HRMS (ESI) m/z 249.1097 [249.1097 calcd. for C12H18O4Na (M
++Na+)]. 
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(E)-ethyl 3-phenyl-3-((6-((tetrahydro-2H-pyran-2-yl)oxy)hept-4-yn-3-yl)oxy)acrylate (I-78j) 
 
 
 
Following procedure C, propargyl alcohol I-77a (200 mg, 0.94 mmol) was added to ethyl 
phenylpropiolate (181.1 mg, 1.03 mmol). After flash chromatography (Cyclohexane/EtOAc = 
9/1), the product (356.3 mg, 0.92 mmol, 98%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.44 (Cyclohexane/EtOAc= 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.64 – 7.57 (m, 2H), 7.45 – 7.37 (m, 3H), 5.71 (d, J = 2.3 
Hz, 1H), 4.97 (td, J = 6.2, 1.5 Hz, 1H), 4.76 (dt, J = 6.7, 4.1 Hz, 1H), 4.52 (qd, J = 6.7, 1.5 Hz, 
1H), 4.23 (qd, J = 7.2, 0.5 Hz, 2H), 3.85 – 3.77 (m, 1H), 3.58 – 3.43 (m, 1H), 2.04 – 1.93 (m, 
2H), 1.81 (dt, J = 15.2, 10.9 Hz, 2H), 1.60 – 1.48 (m, 4H), 1.37 (d, J = 6.7 Hz, 3H), 1.34 (t, J = 7.1 
Hz, 3H), 1.12 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 165.9, 165.3, 135.8, 130.4, 128.6, 127.8, (103.4, 103.3), 
(96.1, 96.0), (87.3, 87.2), (81.0, 80.9), 73.0, (62.75, 62.69), (60.85, 60.82), 60.0, (30.70, 
30.66), 28.9, 25.6, (22.1, 22.0), (19.8, 19.7), 14.5, 9.6. 
 
MS (EI) m/z (%): 284.1 (82) [M+-THPOH], 213.1 (48), 105 (100) [PhCO], 77 (52). 
 
HRMS (ESI) m/z 409.1988 [409.1985 calcd. for C23H30O5Na (M
++Na+)]. 
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(E)-ethyl 3-((6-hydroxyhept-4-yn-3-yl)oxy)-3-phenylacrylate (I-72j) 
 
 
 
Following procedure D, THP-protected alcohol I-78j (666.8 mg, 1.73 mmol) was deprotected. 
After flash chromatography (Cyclohexane/EtOAc = 9/1), the product (138.6 mg, 0.458 mmol, 
27%) was obtained. 
 
TLC: Rf = 0.10 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.61 – 7.57 (m, 2H), 7.43 – 7.36 (m, 3H), 5.73 (s, 1H), 4.87 
(tdd, J = 6.1, 3.0, 1.6 Hz, 1H), 4.44 (q, J = 6.6 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 1.99 – 1.91 (m, 
2H), 1.60 (s, 1H), 1.35 – 1.30 (m, 6H), 1.10 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 165.6, 165.5, 135.7, 130.4, 128.6, 127.7, 104.0, 89.7, 
81.6, 73.0, 60.1, 58.3, 28.9, 24.3, 14.5, 9.5. 
 
MS (EI) m/z (%): 284.0 (100) [M+-H2O], 237.1 (35), 222.9 (34), 207.1 (44), 105.0 (69) [PhCO].  
 
HRMS (ESI) m/z 325.1407 [325.1410 calcd. for C18H22O4Na (M
++Na+)]. 
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(E)-ethyl 3-(but-3-yn-2-yloxy)but-2-enoate (I-80a) 
 
 
 
Following procedure C, 3-butyn-2-ol (500 mg, 7.13 mmol) was added to ethyl 2-butynoate 
(288.7 mg, 1.43 mmol). After flash chromatography (Cyclohexane/EtOAc = 9/1), the E 
product (918 mg, 5.03 mmol, 71%) and Z product (139.2 mg, 11%) were isolated. 
 
TLC: Rf = 0.63 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 5.21 (s, 1H), 4.70 – 4.64 (m, 1H), 4.19 – 4.09 (m, 2H), 2.52 
(d, J = 2.0 Hz, 1H), 2.29 (s, 3H), 1.58 (d, J = 6.6 Hz, 3H), 1.27 (t, J = 7.1 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.2, 167.9, 93.5, 81.6, 74.7, 63.3, 59.6, 21.9, 19.2, 14.6. 
 
The analytical data are identical to the literature data.[91]  
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(E)-ethyl 3-((5-hydroxyhept-3-yn-2-yl)oxy)but-2-enoate (I-72k) 
 
 
 
Following procedure B, vinyl propargyl alcohol I-80a (207.4 mg, 1.14 mmol) was added to 
propanal (79.3 mg, 1.37 mmol). After flash chromatography (Cyclohexane/EtOAc = 4/1), the 
product (101.3 mg, 0.42 mmol, 37%) was obtained as a diastereoisomeric mixture.  
 
TLC: Rf = 0.25 (Cyclohexane/EtOAc= 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 5.20 (s, 1H), 4.71 (qd, J = 6.6, 1.3 Hz, 1H), 4.35 (dd, J = 
11.3, 5.5 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 2.29 (s, 3H), 1.79 (d, J = 5.6 Hz, 1H), 1.75 – 1.67 (m, 
2H), 1.56 (d, J = 6.6 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H), 0.99 (td, J = 7.4, 0.5 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.3, 168.0, 93.5, 87.5, 82.8, 63.8, 63.6, 59.5, 30.9, 22.0, 
19.2, 14.6, 9.4. 
 
MS (EI) m/z (%): 222.0 (44) [M+-H2O], 179.0 (73), 165.0 (76) [M
+-EtCH2O2], 153.1 (76), 152.0 
(73), 137.0 (100), 57.0 (70) [EtCHO]. 
 
HRMS (ESI) m/z 263.1254 [263.1254 calcd. for C13H20O4Na (M
++Na+)]. 
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(E)-ethyl 3-((5-hydroxy-5-phenylpent-3-yn-2-yl)oxy)but-2-enoate (I-72l) 
 
 
 
Following procedure B, vinyl propargyl alcohol I-80a (200 mg, 1.10 mmol) was added to 
benzaldehyde (140.1 mg, 1.32 mmol). After flash chromatography (Cyclohexane/EtOAc = 
4/1), the product (139.6 mg, 0.48 mmol, 44%) was obtained as a diastereoisomeric mixture.  
 
TLC: Rf = 0.23 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.52 (ddd, J = 5.8, 1.7, 0.7 Hz, 2H), 7.40 – 7.32 (m, 3H), 
5.50 (d, J = 6.3 Hz, 1H), 5.24 (d, J = 1.8 Hz, 1H), 4.81 – 4.74 (m, 1H), 4.19 – 4.09 (m, 2H), 2.31 
– 2.28 (m, 3H), 2.25 (d, J = 6.2 Hz, 1H), 1.60 (d, J = 6.6 Hz, 3H), 1.27 (td, J = 7.1, 1.5 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.3, 168.0, 140.2, 128.8, 128.7, 126.9, 126.8, 93.6, 
86.2, 84.5, 64.7, 63.6, 59.6, 21.9, 19.2, 14.6. 
 
MS (EI) m/z (%): 227.0 (21), 115.0 (16), 105.9 (20), 104.9 (100) [PhCO], 77.0 (54) [Ph]. 
 
HRMS (ESI) m/z 311.1256 [311.1254 calcd. for C17H20O4Na (M
++Na+)]. 
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(E)-ethyl 3-((5-(4-fluorophenyl)-5-hydroxypent-3-yn-2-yl)oxy)but-2-enoate (I-72m) 
 
 
 
Following procedure B, vinyl propargyl alcohol I-80a (200 mg, 1.10 mmol) was added to 4-
fluorobenzaldehyde (163.5 mg, 1.32 mmol). After flash chromatography (Cyclohexane/ 
EtOAc = 4/1), the product (115.3 mg, 0.376 mmol, 34%) was obtained as a diastereoisomeric 
mixture. 
 
TLC: Rf = 0.25 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.52 – 7.45 (m, 2H), 7.04 (td, J = 8.7, 0.9 Hz, 2H), 5.47 (s, 
1H), 5.22 (d, J = 2.7 Hz, 1H), 4.76 (q, J = 6.6 Hz, 1H), 4.21 – 4.08 (m, 2H), 2.31 (s, 1H), 2.29 (d, J 
= 2.5 Hz, 3H), 1.59 (d, J = 6.6 Hz, 3H), 1.27 (td, J = 7.1, 1.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.3, 167.9, 164.1, 161.7, 136.2, 128.7, 115.7, 115.5, 
93.6, 86.1, 84.7, 64.0, 63.6, 59.7, 21.9, 19.2, 14.6. 
 
MS (EI) m/z (%): 149.0 (100), 123.0 (79) [pF-PhCHO], 120.0 (79), 95.0 (55) [pF-Ph], 75.0 (28), 
53.0 (31). 
 
HRMS (ESI) m/z 329.1156 [329.1160 calcd. for C17H19FO4Na (M
++Na+)]. 
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(E)-ethyl 3-((5-hydroxy-5-(4-methoxyphenyl)pent-3-yn-2-yl)oxy)but-2-enoate (I-72n) 
 
 
 
Following procedure B, vinyl propargyl alcohol I-80a (200 mg, 1.10 mmol) was added to 
anisaldehyde (170.4 mg, 1.25 mmol). After flash chromatography (Cyclohexane/EtOAc = 
4/1), the product (88.1 mg, 0.277 mmol, 25%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.15 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3) 7.44 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 5.44 (s, 1H), 5.24 (d, 
J = 3.1 Hz, 1H), 4.77 (q, J = 6.6 Hz, 1H), 4.20 – 4.09 (m, 2H), 3.81 (s, 3H), 2.30 (d, J = 3.3 Hz, 
3H), 2.15 (s, 1H), 1.60 (d, J = 6.6 Hz, 3H), 1.30 – 1.24 (m, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.3, 168.0, 159.9, 132.6, 128.3, 114.1, 93.6, 86.4, 84.3, 
64.3, 63.6, 59.6, 55.5, 21.9, 19.2, 14.6. 
 
HRMS (ESI) m/z 341.1351 [341.1359 calcd. for C18H22O5Na (M
++Na+)]. 
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(E)-ethyl 3-(prop-2-yn-1-yloxy)but-2-enoate (I-80b) 
 
 
 
Following procedure C, 2-propyn-1-ol (500 mg, 8.92 mmol) was added to ethyl 2-butynoate 
(360.9 mg, 1.78 mmol). After flash chromatography (Cyclohexane/EtOAc = 9/1), the E 
product (1.20 g, 7.14 mmol, 80 %) and Z product (217.2 mg, 1.29 mmol, 14%) were isolated. 
 
TLC: Rf = 0.8 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 5.10 (s, 1H), 4.49 (d, J = 2.4 Hz, 2H), 4.14 (q, J = 7.1 Hz, 
2H), 2.55 (t, J = 2.4 Hz, 1H), 2.31 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.8, 167.6, 92.8, 91.8, 76.3, 59.7, 55.8, 18.9, 14.5.  
 
The analytical data are identical to the literature data.[92] 
 
(E)-ethyl 3-((4-hydroxyhex-2-yn-1-yl)oxy)but-2-enoate (I-72o) 
 
 
 
Following procedure B, vinyl propargyl alcohol I-80b (200 mg, 1.19 mmol) was added to 
propanal (83.1 mg, 1.43 mmol). After flash chromatography (Cyclohexane/EtOAc = 4/1), the 
product (101.6 mg, 0.449 mmol, 38%) was obtained as a diastereoisomeric mixture.  
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TLC: Rf = 0.17 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 5.08 (s, 1H), 4.52 (d, J = 1.6 Hz, 2H), 4.38 (t, J = 6.3 Hz, 1H), 
4.14 (q, J = 7.1 Hz, 2H), 2.31 (s, 3H), 1.88 (s, 1H), 1.79 – 1.69 (m, 2H), 1.29 – 1.24 (m, 3H), 
1.01 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.9, 167.7, 92.8, 89.0, 78.4, 63.8, 59.7, 56.2, 30.8, 19.0, 
14.5, 9.5.  
 
MS (EI) m/z (%): 208.1 (16) [M+-H2O], 180.0 (16) [M
+-EtOH], 151.0 (100) [M+-EtCH2O2], 138.0 
(21), 123.0 (25), 57.0 (23) [EtCHO]. 
 
HRMS (ESI) m/z 249.1104 [249.1097 calcd. for C12H18O4Na (M
++Na+)]. 
 
(E)-ethyl 3-((4-hydroxy-4-phenylbut-2-yn-1-yl)oxy)but-2-enoate (I-72p) 
 
 
 
Following procedure B, vinyl propargyl alcohol I-80b (200 mg, 1.19 mmol) was added to 
benzaldehyde (153.8 mg, 1.43 mmol). After flash chromatography (Cyclohexane/EtOAc = 
4/1), the product (105.8 mg, 0.386 mmol, 32%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.17 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.53 (dd, J = 8.1, 1.3 Hz, 2H), 7.37 (tdd, J = 8.7, 4.6, 2.3 Hz, 
3H), 5.52 (s, 1H), 5.11 (s, 1H), 4.57 (d, J = 1.7 Hz, 2H), 4.14 (q, J = 7.1 Hz, 2H), 2.31 (s, 3H), 
1.61 (s, 1H), 1.27 (t, J = 7.1 Hz, 3H). 
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13C NMR (101 MHz, CDCl3) δ [ppm] 170.9, 167.7, 140.1, 128.8, 128.7, 126.8, 92.8, 87.8, 80.2, 
64.7, 59.7, 56.2, 19.0, 14.5.  
 
HRMS (ESI) m/z 297.1099 [297.1097 calcd. for C16H18O4Na (M
++Na+)]. 
 
2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran (I-76d) 
 
 
 
Following procedure A, 2-propyn-1-ol (3.0 g, 53.5 mmol) was protected with dihydropyran 
(4.95 g, 58.9 mmol). After distillation, the product (6.62 g, 47.2 mmol, 88%) was obtained as 
a diastereoisomeric mixture. 
 
TLC: Rf = 0.70 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 4.82 (t, J = 3.4 Hz, 1H), 4.26 (qd, J = 15.7, 2.4 Hz, 2H), 3.88 
– 3.79 (m, 1H), 3.57 – 3.49 (m, 1H), 2.40 (t, J = 2.4 Hz, 1H), 1.90 – 1.69 (m, 2H), 1.68 – 1.49 
(m, 4H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 97.0, 79.9, 74.1, 62.2, 54.1, 30.4, 25.5, 19.2. 
 
The analytical data are identical to the literature data.[93] 
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6-((tetrahydro-2H-pyran-2-yl)oxy)hex-4-yn-3-ol (I-77q) 
 
 
 
Following procedure B, propargyl alcohol I-76d (1.0 g, 7.13 mmol) was added to propanal 
(497.0 mg, 8.56 mmol). After flash chromatography (Cyclohexane/EtOAc = 4/1), the product 
(1.14 g, 5.73 mmol, 80%) was obtained. 
 
TLC: Rf = 0.12 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 4.81 (t, J = 3.3 Hz, 1H), 4.39 – 4.33 (m, 1H), 4.31 (d, J = 1.7 
Hz, 1H), 4.29 – 4.23 (m, 1H), 3.88 – 3.79 (m, 1H), 3.56 – 3.49 (m, 1H), 1.93 (s, 1H), 1.78 – 1.68 
(m, 3H), 1.68 – 1.49 (m, 5H), 1.01 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 96.9, 87.0, 81.0, 63.9, 62.2, 54.4, 30.9, 30.4, 25.5, 19.2, 
9.6.  
 
MS (EI) m/z (%): 140.1 (1) [M+-EtCHO], 85 (60) [THP], 84 (71), 83.0 (45), 55 (100). 
 
HRMS (ESI) m/z 221.1153 [221.1148 calcd. for C11H18O3Na (M
++Na+)]. 
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(E)-ethyl 3-((6-((tetrahydro-2H-pyran-2-yl)oxy)hex-4-yn-3-yl)oxy)but-2-enoate (I-78q) 
 
 
 
Following procedure C, propargyl alcohol I-77q (400 mg, 2.02 mmol) was added to ethyl 2-
butynoate (249.5 mg, 2.22 mmol). After flash chromatography (Cyclohexane/EtOAc = 9/1), 
the product (516.4 mg, 1.66 mmol, 82%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.45 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 5.21 (d, J = 2.0 Hz, 1H), 4.80 (dd, J = 6.0, 2.8 Hz, 1H), 4.52 
(td, J = 6.3, 1.3 Hz, 1H), 4.30 (s, 2H), 4.19 – 4.07 (m, 2H), 3.84 (ddd, J = 11.3, 7.2, 3.1 Hz, 1H), 
3.58 – 3.47 (m, 1H), 2.29 (d, J = 0.8 Hz, 3H), 1.96 – 1.82 (m, 2H), 1.67 – 1.49 (m, 6H), 1.27 (t, J 
= 7.1 Hz, 3H), 1.03 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] (170.63, 170.59), 168.1, (96.91, 96.86), 93.3, (83.4, 83.3), 
(82.8, 82.7), 68.9, (62.3, 62.2), 59.5, (54.26, 54.18), (30.42, 30.41), 28.7, 25.5, 19.3, (19.21, 
19.16), 14.6, 9.7. 
 
MS (EI) m/z (%): 208.1 (100) [M+-THPOH], 179.0 (71), 137.0 (38), 85 (88) [THP], 55 (29).  
 
HRMS (ESI) m/z 333.1676 [333.1672 calcd. for C17H26O5Na (M
++Na+)]. 
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(E)-ethyl 3-((6-hydroxyhex-4-yn-3-yl)oxy)but-2-enoate (I-72q) 
 
 
 
Following procedure D, THP-protected alcohol I-78q (300 mg, 0.97 mmol) was deprotected. 
After flash chromatography (Cyclohexane/EtOAc = 9/1), the product (132.9 mg, 0.59 mmol, 
61 %) was obtained. 
 
TLC: Rf = 0.24 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3)  [ppm] 5.19 (s, 1H), 4.53 (t, J = 6.3 Hz, 1H), 4.31 (dd, J = 6.3, 1.5 
Hz, 2H), 4.14 (tdd, J = 10.9, 7.1, 3.8 Hz, 2H), 2.29 (s, 3H), 1.91 – 1.83 (m, 2H), 1.61 (t, J = 6.3 
Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H), 1.04 (t, J = 7.4 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 170.6, 168.0, 93.3, 85.3, 82.7, 68.8, 59.6, 51.2, 28.8, 19.2, 
14.6, 9.6.  
 
MS (EI) m/z (%): 150.9 (92) [M+-EtCH2O2], 91.0 (93), 79.0 (91), 76.9 (100), 52.9 (92).  
 
HRMS (ESI) m/z 249.1105 [249.1097 calcd. for C12H18O4Na (M
++Na+)]. 
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1-phenyl-4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-yn-1-ol (I-77r) 
 
 
 
Following procedure B, propargyl alcohol I-76d (1.0 g, 7.13 mmol) was added to 
benzaldehyde (909.0 mg, 8.56 mmol). After flash chromatography (Cyclohexane/EtOAc = 
4/1), the product (1.15 mg, 4.67 mmol, 65%) was obtained. 
 
TLC: Rf = 0.16 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.58 – 7.50 (m, 2H), 7.42 – 7.29 (m, 3H), 5.52 (d, J = 5.5 
Hz, 1H), 4.82 (t, J = 3.4 Hz, 1H), 4.42 – 4.27 (m, 2H), 3.88 – 3.79 (m, 1H), 3.57 – 3.47 (m, 1H), 
2.28 (d, J = 23.0 Hz, 1H), 1.90 – 1.68 (m, 2H), 1.67 – 1.51 (m, 4H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 140.6, 128.8, 128.6, 126.8, 97.1, 85.8, 83.0, 64.8, 62.2, 
54.5, 30.4, 25.5, 19.2. 
 
MS (EI) m/z (%): 143.9 (24) [M+-THPOH], 115.0 (69) [CH2OTHP], 105.0 (97) [PhCO], 84.0 (83), 
77.0 (100) [Ph], 55.0 (100). 
 
HRMS (ESI) m/z 269.1148 [269.1148 calcd. for C15H18O3Na (M
++Na+)]. 
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(E)-ethyl 3-((1-phenyl-4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-yn-1-yl)oxy)but-2-enoate     
(I-78r) 
 
 
 
Following procedure C, propargyl alcohol I-77r (400 mg, 1.62 mmol) was added to ethyl 2-
butynoate (200.6 mg, 1.79 mmol). After flash chromatography (Cyclohexane/EtOAc = 9/1), 
the product (291.7 mg, 0.81 mmol, 50%) was obtained as a diastereoisomeric mixture. 
 
TLC: Rf = 0.47 (Cyclohexane/EtOAc = 9/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.50 (dd, J = 7.8, 1.7 Hz, 2H), 7.43 – 7.36 (m, 3H), 5.67 (s, 
1H), 5.36 (d, J = 2.7 Hz, 1H), 4.80 (q, J = 3.4 Hz, 1H), 4.35 (t, J = 1.4 Hz, 2H), 4.20 – 4.10 (m, 
2H), 3.88 – 3.79 (m, 1H), 3.54 – 3.47 (m, 1H), 2.34 (d, J = 0.6 Hz, 3H), 1.87 – 1.77 (m, 1H), 1.76 
– 1.67 (m, 1H), 1.65 – 1.57 (m, 2H), 1.55 – 1.48 (m, 2H), 1.28 (t, J = 7.1 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 170.4, 167.9, 137.0, 129.1, 128.9, 127.5, (97.05, 97.02), 
94.0, 85.6, 82.0, 69.8, (62.3, 62.2), 59.6, (54.4, 54.3), 30.4, 25.5, 19.3, 19.2, 14.6. 
 
MS (EI) m/z (%): 144.0 (100), 115.0 (82) [CH2OTHP], 105.0 (41) [PhCO], 85.0 (33), 55.0 (27). 
 
HRMS (ESI) m/z 381.1671 [381.1672 calcd. for C21H26O5Na (M
++Na+)]. 
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(E)-ethyl 3-((4-hydroxy-1-phenylbut-2-yn-1-yl)oxy)but-2-enoate (I-72r) 
 
 
 
Following procedure D, THP-protected alcohol I-78r (282.9 mg, 0.789 mmol) was 
deprotected. After flash chromatography (Cyclohexane/EtOAc = 9/1), the product (142.9 mg, 
0.52 mmol, 66%) was obtained. 
 
TLC: Rf = 0.17 (Cyclohexane/EtOAc = 9/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3)  [ppm] 7.54 – 7.48 (m, 2H), 7.45 – 7.35 (m, 3H), 5.67 (s, 1H), 5.33 
(s, 1H), 4.36 (s, 2H), 4.16 (tdd, J = 11.0, 7.1, 3.7 Hz, 2H), 2.34 (s, 3H), 1.66 (s, 1H), 1.29 (t, J = 
7.1 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 170.3, 167.9, 136.9, 129.2, 128.9, 127.3, 94.1, 87.4, 81.9, 
69.6, 59.7, 51.3, 19.3, 14.5.  
 
MS (EI) m/z (%): 151.8 (38) [M+-PhCHO-H2O], 105.0 (100) [PhCO], 77.0 (100) [Ph]. 
 
HRMS (ESI) m/z 297.1109 [297.1097 calcd. for C16H18O4Na (M
++Na+)]. 
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(E)-ethyl 3-((6-(benzylamino)hept-4-yn-3-yl)oxy)but-2-enoate (I-86a) 
 
 
 
At 0°C, Et3N (98.39 mg, 1.665 mmol) and MsCl (142.97 mg, 1.248 mmol, 4 M in CH2Cl2) were 
added to vinyl propargyl alcohol I-72a (200 mg, 0.832 mmol) in CH2Cl2 (1.66 mL, 0.5 M). The 
reaction mixture was stirred at 0°C for 2 h. CH2Cl2 was added and the organic phase was 
washed with sat. NaHCO3-solution and sat. NaCl-solution, dried over Na2SO4 and 
concentrated under reduced pressure. At rt, the crude product was dissolved in MeCN 
(0.8 mL, 1 M) and benzylamine (178.3 mg, 1.66 mmol) was added. The reaction mixture was 
stirred at 60°C for 3 h. Finally, it was quenched with H2O and extracted three times with 
EtOAc. The combined organic phase was washed with sat. NaCl-solution, dried over Na2SO4 
and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (CH2Cl2/MeOH = 95/5) to obtain the product (145.6 mg, 0.442 mmol, 53%). 
 
TLC: Rf = 0.45 (CH2Cl2/MeOH = 95/5) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.36 – 7.28 (m, 4H), 7.25 – 7.21 (m, 1H), 5.31 (d, J = 2.9 
Hz, 1H), 4.54 (dd, J = 7.0, 5.6 Hz, 1H), 4.16 – 4.04 (m, 2H), 3.98 (dd, J = 12.8, 1.9 Hz, 1H), 3.78 
(dd, J = 12.8, 1.1 Hz, 1H), 3.56 – 3.49 (m, 1H), 2.32 (s, 3H), 1.92 – 1.82 (m, 2H), 1.49 (s, 1H), 
1.35 (dd, J = 6.8, 0.9 Hz, 3H), 1.21 (td, J = 7.1, 4.4 Hz, 3H), 1.06 (t, J = 7.4 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 170.6, 168.1, 140.0, 128.6, 127.2, 93.4, 89.8, 79.8, 69.14, 
59.5, 51.6, 44.6, 29.0, 22.4, 19.2, 14.5, 9.7. 
 
MS (EI) m/z (%): 254.1 (100) [M+-C3H7O2], 163.0 (18), 106 (10) [BnNH], 91.1 (73) [Bn]. 
 
EXPERIMENTAL PART 
CATALYZED CASCADE REACTIONS, A WAY TOWARD FURAN COMPOUNDS 
 
139 
 
HRMS (ESI) m/z 330.2064 [330.2064 calcd. for C20H28NO3 (M
++H+)]. 
 
(E)-ethyl 3-((6-(butylamino)hept-4-yn-3-yl)oxy)but-2-enoate (I-86b) 
 
 
 
At 0°C, Et3N (49.2 mg, 0.832 mmol) and MsCl (71.5 mg, 0.624 mmol, 4 M in CH2Cl2) were 
added to vinyl propargyl alcohol I-72a (100 mg, 0.416 mmol) in CH2Cl2 (0.83 mL, 0.5 M). The 
reaction mixture was stirred at 0°C for 4 h. CH2Cl2 was added and the organic phase was 
washed with sat. NaHCO3-solution and sat. NaCl-solution, dried over Na2SO4 and 
concentrated under reduced pressure. At rt, the crude product was then dissolved in MeCN 
(0.47 mL, 1 M) and nButylamine (68.4 mg, 0.935 mmol) was added. The reaction mixture 
was then stirred at 60°C for 6 h. Finally, it was quenched with H2O and extracted three times 
with Et2O. The combined organic phase was washed with sat. NaCl-solution, dried over 
Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (Petroleum ether/EtOAc = 4/1  3/2) to obtain the product (71.6 mg, 0.242 
mmol, 58%). 
 
TLC: Rf = 0.07 (Petroleum ether/ EtOAc = 4/1) [UV] 
 
1H NMR (600 MHz, CDCl3)  [ppm] 5.24 (d, J = 2.4 Hz, 1H), 4.53 – 4.46 (m, 1H), 4.20 – 4.06 
(m, 2H), 3.52 (qdd, J = 6.8, 3.0, 1.6 Hz, 1H), 2.80 (dddd, J = 10.7, 8.4, 6.4, 4.0 Hz, 1H), 2.61 – 
2.52 (m, 1H), 2.29 (s, 3H), 1.88 – 1.79 (m, 2H), 1.52 – 1.39 (m, 4H), 1.33 (d, J = 6.8 Hz, 4H), 
1.26 (t, J = 7.1 Hz, 3H), 1.03 (t, J = 7.4 Hz, 3H), 0.91 (t, J = 7.3 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 170.6, 168.1, 93.3, 90.2, 79.4, 69.1, 59.4, 47.3, 45.4, 32.3, 
28.9, 22.4, 20.6, 19.2, 14.6, 14.1, 9.7. 
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MS (EI) m/z (%): 249.1 (16), 220.1 (100) [M+-C3H7O2], 206.1 (17), 135.1 (12), 56.0 (4) [C4H8]. 
 
HRMS (ESI) m/z 296.2219 [296.2220 calcd. for C17H30NO3 (M
++H+)]. 
 
ethyl 4-(but-1-en-1-yl)-2,5-dimethylfuran-3-carboxylate (I-81a)  
                                                   
(Procedure E) 
Under N2, AgBF4 (0.8 mg, 4.16 mol) was added to a solution of propargyl vinyl ether I-72a 
(50.5 mg, 0.208 mmol) in dry CH2Cl2 (2.1 mL, 0.1 M), then reaction mixture was heated to 
35°C for 12 h. After filtration over celite and concentration, the crude product was purified 
by flash chromatography (Cyclohexane/EtOAc= 95/5) to obtain the product (40.9 mg, 0.184 
mmol, 87%) as a E/Z mixture. 
 
TLC: Rf = 0.64 (Cyclohexane/EtOAc = 4/1) [UV/CAM]; 
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For the major isomer: 
 
Entry H C COSY (
1H-1H) HMBC (1H-13C) 
1 2.51 (s, 3H) 14.2 
 
 3, 2 
2 
 
157.5 
  3 
 
113.8 
  4 
 
164.7 
  5 4.25 (q, J = 7.1 Hz, 2H) 59.9 6 4, 6 
6 1.32 (t, J = 7.1 Hz, 3H) 14.4 5 5 
7 
 
117.2 
  8 6.20 (dd, J = 11.2, 0.9 Hz, 1H) 119.6 9 10, 12 
9 5.60 (dt, J = 11.2, 7.2 Hz, 1H) 134.6 8, 10 11, 10, 7  
10 2.00 - 1.90 (m, 2H) 22.4 9, 11 11, 9, 8 
11 0.96 (t, J = 7.5 Hz, 3H) 14.1 10 10, 9 
12 
 
146.3 
  13 2.11 (s, 3H) 12.6 
 
7, 12 
 
ethyl 4-butyl-2,5-dimethylfuran-3-carboxylate (I-83a) 
 
 
 
(Procedure F) 
 
Under N2, AgBF4 (0.6 mg, 3.32 mol) was added to a solution of propargyl vinyl ether I-72a 
(40 mg, 0.166 mmol) in dry CH2Cl2 (1.6 mL, 0.1 M), then reaction mixture was heated to 35°C 
for 12 h. After filtration over celite and concentration, the residue was dissolved in dry 
MeOH/ EtOAc (2/1, 1.1 mL, 0.15 M) and 5 mol% Pd/C (10.6 mg, 4.98 mol) was added. The 
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mixture was stirred at rt for 1 h under H2 atmosphere. It was filtered over celite and the 
crude product was purified by flash chromatography (Cyclohexane/EtOAc = 95/5) to obtain 
the product (26.8 mg, 0.120 mmol, 72%). 
 
TLC: Rf = 0.74 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3)  [ppm] 4.27 (q, J = 7.1 Hz, 2H), 2.53 – 2.45 (m, 5H), 2.16 (s, 3H), 
1.48 – 1.41 (m, 2H), 1.34 (t, J = 7.1 Hz, 3H), 1.33 – 1.28 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 165.0, 157.6, 146.0, 119.6, 113.3, 59.7, 33.0, 24.2, 22.7, 
14.4, 14.3, 14.1, 11.2. 
 
MS (EI) m/z (%): 224.1 (53) [M+], 195.1 (16) [M+-Et], 182.0 (100) [M+-nPr], 167.0 (18) [M+-
nBu], 153.0 (88), 137.0 (58).  
 
HRMS (ESI) m/z 225.1485 [225.1485 calcd. for C13H21O3 (M
++H+)]. 
 
ethyl 2,5-dimethyl-4-pentylfuran-3-carboxylate (I-83b) 
 
 
 
Following procedure F, substrat I-72b (30.1 mg, 0.118 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83b (19.0 mg, 79.7 mol, 68%). 
 
TLC: Rf = 0.8 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
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1H NMR (400 MHz, CDCl3)  [ppm] 4.27 (q, J = 7.1 Hz, 2H), 2.53 – 2.45 (m, 5H), 2.16 (s, 3H), 
1.53 – 1.41 (m, 2H), 1.40 – 1.23 (m, 7H), 0.88 (t, J = 7.0 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 165.0, 157.6, 146.0, 119.7, 113.3, 59.8, 31.9, 30.5, 24.5, 
22.8, 14.5, 14.4, 14.3, 11.3.  
 
MS (EI) m/z (%): 238.1 (43) [M+], 182.1 (100) [M+-C5H9], 153.0 (68), 137.0 (46).  
 
HRMS (ESI) m/z 239.1644 [239.1642 calcd. for C14H23O3 (M
++H+)]. 
 
ethyl 4-(3,3-dimethylbutyl)-2,5-dimethylfuran-3-carboxylate (I-83c) 
 
 
 
Following procedure F, substrat I-72c (40.0 mg, 0.149 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83c (24.9 mg, 98.7 mol, 66%). 
 
TLC: Rf = 0.8 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 4.28 (q, J = 7.1 Hz, 2H), 2.49 (s, 3H), 2.48 – 2.44 (m, 2H), 
2.16 (s, 3H), 1.36 – 1.29 (m, 5H), 0.95 (s, 9H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 165.0, 157.7, 145.7, 120.1, 113.3, 59.8, 45.2, 30.6, 29.4, 
19.6, 14.6, 14.4, 11.1. 
 
MS (EI) m/z (%): 252.1 (86) [M+], 181.0 (80) [M+-C5H11], 149.0 (100), 137.0 (65).  
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HRMS (ESI) m/z 253.1804 [253.1798 calcd. for C15H25O3 (M
++H+)]. 
 
ethyl 2,5-dimethyl-4-phenethylfuran-3-carboxylate (I-83d) 
 
 
 
Following procedure F, substrat I-72d (30.4 mg, 0.104 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83d (22.4 mg, 82.3 mol, 78%). 
 
TLC: Rf = 0.72 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.26 (dd, J = 8.1, 6.4 Hz, 2H), 7.23 – 7.11 (m, 3H), 4.32 (q, J 
= 7.1 Hz, 2H), 2.78 (s, 4H), 2.52 (s, 3H), 1.89 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 165.0, 157.8, 146.8, 142.3, 128.8, 128.3, 125.9, 118.4, 
113.1, 59.9, 36.9, 26.9, 14.6, 14.5, 10.9.  
 
MS (EI) m/z (%): 272.1 (67) [M+], 227.1 (14) [M+-EtO], 181.0 (100) [M+-Bn], 153.0 (75), 137.0 
(61), 91.0 (19).  
 
HRMS (ESI) m/z 295.1299 [295.1305 calcd. for C17H20O3Na (M
++Na+)]. 
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ethyl 4-butyl-5-isobutyl-2-methylfuran-3-carboxylate (I-83e) 
 
 
Following procedure F, substrat I-72e (39.7 mg, 0.142 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83e (24.0 mg, 90.1 mol, 64%). 
 
TLC: Rf = 0.8 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3)  [ppm] 4.27 (q, J = 7.1 Hz, 2H), 2.50 (s, 3H), 2.49 – 2.46 (m, 2H), 
2.37 (d, J = 7.2 Hz, 2H), 1.93 (dt, J = 13.6, 6.8 Hz, 1H), 1.44 (tt, J = 7.7, 6.3 Hz, 2H), 1.34 (t, J = 
7.1 Hz, 5H), 0.94 – 0.89 (m, 9H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 165.1, 157.8, 149.5, 120.4, 113.2, 59.8, 34.9, 33.3, 28.3, 
24.3, 23.0, 22.5, 14.5, 14.2. 
 
MS (EI) m/z (%): 266.2 (31) [M+], 223.1 (100) [M+-nPr], 181.0 (43), 153.0 (33), 137.0 (21). 
 
HRMS (ESI) m/z 267.1955 [267.1955 calcd. for C16H27O3 (M
++H+)]. 
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ethyl 5-isobutyl-2-methyl-4-phenethylfuran-3-carboxylate (I-83f) 
 
 
 
Following procedure F, substrat I-72f (47.5 mg, 0.144 mmol) gave after flash chroma-
tography (Petroleum Ether/EtOAc = 95/5) the furan I-83f (27.0 mg, 85.8 mol, 60%). 
 
TLC: Rf = 0.74 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3)  [ppm] 7.29 – 7.26 (m, 2H), 7.18 (dd, J = 11.8, 4.3 Hz, 3H), 4.32 (q, 
J = 7.1 Hz, 2H), 2.81 – 2.75 (m, 4H), 2.53 (s, 3H), 2.22 (d, J = 7.2 Hz, 2H), 1.84 (dt, J = 13.6, 6.8 
Hz, 1H), 1.37 (t, J = 7.1 Hz, 3H), 0.87 (d, J = 6.7 Hz, 6H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 165.0, 158.0, 150.0, 142.5, 128.7, 128.4, 125.9, 119.4, 
113.1, 59.9, 37.3, 34.6, 28.2, 26.9, 22.5, 14.6, 14.6. 
 
MS (EI) m/z (%): 314.2 (31) [M+], 223.1 (100) [M+-Bn], 91.0 (31).  
 
HRMS (ESI) m/z 337.1774 [337.1774 calcd. for C20H26O3Na (M
++Na+)]. 
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ethyl 4-butyl-2-methyl-5-phenylfuran-3-carboxylate (I-83g) 
 
 
 
Following procedure F, substrat I-72g (30.0 mg, 0.099 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83g (8.5 mg, 29.6 mol, 30%). 
 
TLC: Rf = 0.64 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3) 7.57 (dd, J = 8.3, 1.0 Hz, 2H), 7.41 (t, J = 7.8 Hz, 2H), 7.32 – 7.27 (m, 
1H), 4.33 (q, J = 7.1 Hz, 2H), 2.81 (dd, J = 8.8, 7.3 Hz, 2H), 2.61 (s, 3H), 1.62 (tt, J = 7.9, 6.4 Hz, 
2H), 1.43 (dd, J = 14.9, 7.4 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 164.8, 158.9, 147.6, 131.2, 128.7, 127.4, 126.2, 122.3, 
114.9, 60.0, 32.9, 24.6, 23.1, 14.7, 14.5, 14.1. 
 
MS (EI) m/z (%): 286.1 (100) [M+], 243.1 (47) [M+-nPr], 215.0 (23), 199.0 (25), 105.0 (20) 
[PhCO]. 
 
HRMS (ESI) m/z 309.1462 [309.1461 calcd. for C18H22O3Na (M
++Na+)]. 
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ethyl 2-methyl-4-phenethyl-5-phenylfuran-3-carboxylate (I-83h) 
 
 
 
Following procedure F, the substrat I-72h (40.0 mg, 0.114 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83h (24.7 mg, 73.9 mmol, 65%). 
 
TLC: Rf = 0.7 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3)  [ppm] 7.51 (dd, J = 8.3, 1.1 Hz, 2H), 7.39 (t, J = 7.8 Hz, 2H), 7.31 – 
7.26 (m, 3H), 7.26 – 7.24 (m, 2H), 7.21 – 7.17 (m, 1H), 4.36 (q, J = 7.1 Hz, 2H), 3.14 – 3.08 (m, 
2H), 2.98 – 2.92 (m, 2H), 2.64 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 164.7, 159.1, 148.2, 142.1, 131.0, 128.7, 128.6, 128.5, 
127.6, 126.2, 126.1, 121.2, 114.8, 60.2, 36.8, 27.0, 14.8, 14.6.  
 
MS (EI) m/z (%): 334.1 (46) [M+], 243.1 (100) [M+-Bn], 199.0 (21), 105.0 (20) [PhCO]. 
 
HRMS (ESI) m/z 357.1459 [357.1461 calcd. for C22H22O3Na (M
++Na+)]. 
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3-butyl-4-(ethoxymethyl)-2-methylfuran (I-83i) 
 
                                     
 
Following procedure F, substrat I-72i (30.5 mg, 0.135 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83i (8.9 mg, 42.3 mol, 31%). 
 
TLC: Rf = 0.76 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3)  [ppm] 7.83 (s, 1H), 4.27 (q, J = 7.1 Hz, 2H), 2.56 – 2.52 (m, 2H), 
2.22 (s, 3H), 1.48 (ddd, J = 15.2, 11.0, 7.5 Hz, 2H), 1.35 – 1.30 (m, 5H), 0.91 (t, J = 7.3 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 164.0, 149.7, 146.5, 119.4, 119.0, 60.0, 32.8, 23.6, 22.7, 
14.5, 14.1, 11.6. 
 
MS (EI) m/z (%): 210.1 (26) [M+], 168.0 (59) [M+-C3H6], 139.0 (100), 123.0 (25).  
 
HRMS (ESI) m/z 211.1329 [211.1329 calcd. for C12H19O3 (M
++H+)]. 
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Entry H C COSY (
1H-1H) HMBC (1H-13C) 
1 7.83 (s, 1H) 146.5 
 
 2, 11 
2 
 
119.0 
  3 
 
164.0 
  4 4.27 (q, J = 7.1 Hz, 2H) 60.0 5 3, 5 
5 1.35-1.30 (m, 5H) 14.5 4 
 6 
 
119.4 
  7 2.56 – 2.52 (m, 2H) 23.6 8 2, 6, 8, 9, 11 
8 1.48 (ddd, J = 15.2, 11.0, 7.5 Hz, 2H) 32.8 7, 9 6, 7, 9, 10 
9 1.35-1.30 (m, 5H) 22.7 8, 10 
 10 0.91 (t, J = 7.3 Hz, 3H) 14.1 9 8, 9 
11 
 
149.7 
  12 2.22 (s, 3H) 11.6 
 
6, 11 
 
ethyl 4-butyl-5-methyl-2-phenylfuran-3-carboxylate (I-83j) 
 
 
 
Following procedure F, substrat I-72j (37.0 mg, 0.125 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83j (20.5 mg, 71.6 mol, 59%). 
 
TLC: Rf = 0.71 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 7.75 – 7.71 (m, 2H), 7.41 – 7.30 (m, 3H), 4.27 (q, J = 7.1 
Hz, 2H), 2.59 – 2.52 (m, 2H), 2.28 (s, 3H), 1.49 (ddd, J = 8.7, 7.7, 3.9 Hz, 2H), 1.36 (dq, J = 
14.2, 7.1 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H), 0.93 (t, J = 7.3 Hz, 3H). 
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13C NMR (101 MHz, CDCl3) δ [ppm] 165.0, 155.1, 147.9, 130.8, 128.7, 128.3, 128.0, 121.3, 
114.4, 60.4, 33.0, 24.3, 22.7, 14.2, 14.1, 11.6.  
 
MS (EI) m/z (%): 286.1 (100) [M+], 244.1 (40) [M+-C3H6], 215.0 (47), 199.0 (20).  
 
HRMS (ESI) m/z 309.1462 [309.1461 calcd. for C28H22O3Na (M
++Na+)]. 
 
ethyl 5-ethyl-2-methyl-4-propylfuran-3-carboxylate (I-83k) 
 
 
 
Following procedure F, substrat I-72k (30.0 mg, 0.125 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83k (13.7 mg, 61.1 mol, 49%). 
 
TLC: Rf = 0.74 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3) 4.27 (q, J = 7.1 Hz, 2H), 2.57 – 2.44 (m, 7H), 1.54 – 1.43 (m, 2H), 
1.34 (t, J = 7.1 Hz, 3H), 1.17 (t, J = 7.5 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 165.1, 157.7, 151.5, 118.6, 113.2, 59.7, 26.3, 24.2, 19.2, 
14.5, 14.4, 14.1, 13.4. 
 
MS (EI) m/z (%): 224.1 (100) [M+], 209.1 (79) [M+-Me], 195.1 (93) [M+-Et], 167.0 (65) [M+-
C2H5-C2H4], 151.0 (51) [M
+-CO2Et]. 
 
HRMS (APCI) m/z 225.1510 [225.1485 calcd. for C13H21O3 (M
++H+)]. 
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ethyl 2-methyl-5-phenyl-4-propylfuran-3-carboxylate (I-83l) 
 
 
 
Following procedure F, substrat I-72l (30.0 mg, 0.104 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83l (7.2 mg, 26.4 mol, 25%). 
 
TLC: Rf = 0.67 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3) 7.59 – 7.54 (m, 2H), 7.41 (dd, J = 10.9, 4.5 Hz, 2H), 7.32 – 7.27 (m, 
1H), 4.32 (q, J = 7.1 Hz, 2H), 2.83 – 2.74 (m, 2H), 2.61 (s, 3H), 1.71 – 1.60 (m, 2H), 1.38 (t, J = 
7.1 Hz, 3H), 1.00 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 164.8, 158.9, 147.7, 131.2, 128.7, 127.4, 126.2, 122.2, 
114.9, 60.0, 26.9, 24.0, 14.7, 14.5, 14.4. 
 
HRMS (ESI) m/z 273.1484 [273.1485 calcd. for C17H21O3 (M
++H+)].  
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ethyl 5-ethyl-2-methyl-4-vinylfuran-3-carboxylate (I-83o) 
 
 
 
Following procedure E, substrat I-72o (30.0 mg, 0.132 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83o (11.8 mg, 56.7 mol, 43%). 
 
TLC: Rf = 0.71 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3) 6.86 – 6.76 (m, 1H), 5.29 (q, J = 1.9 Hz, 1H), 5.25 (dd, J = 4.2, 1.9 
Hz, 1H), 4.28 (q, J = 7.1 Hz, 2H), 2.69 (q, J = 7.5 Hz, 2H), 2.51 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H), 
1.22 (t, J = 7.5 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 164.8, 157.4, 152.5, 128.6, 118.2, 116.0, 112.9, 60.1, 
20.2, 14.5, 14.3, 12.9. 
 
HRMS (APCI) m/z 209.0849 [209.1172 calcd. for C12H17O3 (M
++H+)]. 
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ethyl 2-methyl-5-phenyl-4-vinylfuran-3-carboxylate (I-83p) 
 
 
 
Following procedure E, substrat I-72p (30.0 mg, 0.109 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83p (10.1 mg, 39.4 mol, 36%). 
 
TLC: Rf = 0.6 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3) 7.74 – 7.66 (m, 2H), 7.37 (tq, J = 3.5, 1.1 Hz, 2H), 7.32 – 7.28 (m, 
1H), 6.86 (dd, J = 17.8, 11.4 Hz, 1H), 5.53 (dd, J = 17.8, 1.9 Hz, 1H), 5.35 (dd, J = 11.4, 1.9 Hz, 
1H), 4.32 (q, J = 7.1 Hz, 2H), 2.60 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 164.6, 158.5, 148.3, 130.9, 128.6, 128.1, 127.9, 127.0, 
119.8, 119.3, 114.6, 60.3, 14.4, 14.4.  
 
HRMS (ESI) m/z 257.1172 [257.1172 calcd. for C16H16O3 (M)
+]. 
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ethyl 4-butyl-2-methylfuran-3-carboxylate (I-83q) 
 
 
 
Following procedure F, substrat I-72q (30.0 mg, 0.133 mmol) gave after flash chroma-
tography (Cyclohexane/EtOAc = 95/5) the furan I-83q (14.9 mg, 70.9 mol, 53%). 
 
TLC: Rf = 0.73 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3) 7.02 (s, 1H), 4.28 (q, J = 7.1 Hz, 2H), 2.60 – 2.55 (m, 2H), 2.53 (s, 
3H), 1.57 – 1.48 (m, 2H), 1.40 – 1.31 (m, 5H), 0.92 (t, J = 7.3 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 164.9, 160.9, 137.5, 126.5, 113.1, 59.9, 31.9, 24.6, 22.7, 
14.6, 14.5, 14.1. 
 
MS (EI) m/z (%): 181.9 (100) [M+-C2H4], 153.9 (62) [M
+-C4H8], 135.9 (84) [M
+-C3H6O2], 109.0 
(55), 79.0 (55). 
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ethyl 2-methyl-4-phenethylfuran-3-carboxylate (I-83r) 
 
 
 
Following procedure F, substrat I-72r (30.0 mg, 0.109 mmol) gave after flash chroma-
tography (Petroleum ether/EtOAc = 95/5) the furan I-83r (17.0 mg, 65.8 mol, 60%). 
 
TLC: Rf = 0.69 (Petroleum ether /EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3) 7.28 (t, J = 7.6 Hz, 2H), 7.19 (dd, J = 13.9, 7.2 Hz, 3H), 6.98 (s, 1H), 
4.32 (q, J = 7.1 Hz, 2H), 2.93 – 2.88 (m, 2H), 2.88 – 2.84 (m, 2H), 2.55 (s, 3H), 1.36 (t, J = 7.1 
Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 164.8, 160.4, 142.1, 137.8, 128.6, 128.4, 126.0, 125.6, 
113.0, 60.0, 36.2, 26.8, 14.6, 14.6. 
 
ethyl 5-isobutyl-2-methyl-4-styrylfuran-3-carboxylate (I-81f) 
 
 
Following procedure E, substrat I-72f (50.0 mg, 0.151 mmol) gave after flash chroma-
tography (Petroleum ether/EtOAc = 95/5) a diastereoisomeric mixture of furans I-81f (35.3 
mg, 113.0 mol, 75%, Z: E 2:1). 
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TLC: Rf = 0.78 (Petroleum ether/EtOAc = 4/1) [UV/CAM] 
 
For the major isomer: 
 
1H NMR (400 MHz, CDCl3) 7.21 – 7.17 (m, 4H), 7.13 (ddd, J = 9.6, 5.2, 3.0 Hz, 1H), 6.56 (d, J = 
12.0 Hz, 1H), 6.43 (d, J = 12.0 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 2.55 (s, 3H), 1.97 (d, J = 7.1 Hz, 
2H), 1.76 (td, J = 13.5, 6.7 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H), 0.74 (d, J = 6.6 Hz, 6H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 164.73, 157.9, 149.8, 137.9, 131.0, 128.5, 128.3, 126.9, 
121.7, 117.4, 113.6, 60.1, 35.5, 27.4, 22.4, 14.4, 14.3. 
 
MS (EI) m/z (%): 312.1 (28) [M+], 223.0 (79), 181.0 (100), 152 (46), 77 (24) [Ph]. 
 
HRMS (ESI) m/z 335.1619 [335.1618 calcd. for C20H24O3Na (M
++Na+)]. 
 
ethyl 4-(but-1-en-1-yl)-2-methyl-5-phenylfuran-3-carboxylate (I-81g) 
 
 
 
Following procedure E, substrat I-72g (50.0 mg, 0.165 mmol) gave after flash chroma-
tography (Petroleum ether/EtOAc = 95/5) a diastereoisomeric mixture of furans I-81g (16.0 
mg, 56.3 mol, 34 %, Z: E 3:1).  
 
TLC: Rf = 0.78 (Petroleum ether/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3) 7.73 (d, J = 7.6 Hz, 1.50H), 7.70 (d, J = 7.5 Hz, 0.50H), 7.34 (t, J = 
7.8 Hz, 2H), 7.24 (t, J = 7.4 Hz, 1H), 6.48 (d, J = 16.1 Hz, 0.25H), 6.42 (d, J = 11.2 Hz, 0.75H), 
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5.96 (dt, J = 16.1, 6.5 Hz, 0.25H), 5.69 (dt, J = 11.2, 7.2 Hz, 0.75H), 4.30 (dq, J = 11.5, 7.1 Hz, 
2H), 2.62 (s, 2.30H), 2.59 (s, 0.70H), 2.18 (qd, J = 7.5, 1.5 Hz, 0.50H), 1.79 (pd, J = 7.4, 1.5 Hz, 
1.50H), 1.36 (dt, J = 10.1, 7.1 Hz, 3H), 1.05 (t, J = 7.4 Hz, 1H), 0.79 (t, J = 7.5 Hz, 2H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] (164.5, 158.3), 147.2, (137.4, 136.5), 131.3, 128.5, 127.6, 
(127.4, 126.7), 125.5, (119.7, 119.2), 117.8, 115.6, (60.21, 60.15), 22.4, 14.5, 14.4, (13.4, 
13.3). 
 
MS (EI) m/z (%): 284.1 (100) [M+], 255.1 (34) [M+-Et], 223.0 (87), 199.0 (100), 105.0 (26) 
[PhCO], 77.0 (24) [Ph]. 
 
HRMS (APCI) m/z 285.1485 [285.1485 calcd. for C18H21O3 (M
++H+)]. 
 
ethyl 5-ethyl-2-methyl-4-(prop-1-en-1-yl)furan-3-carboxylate (I-81k) 
 
 
 
Following procedure E, substrat I-72k (29.8 mg, 0.125 mmol) gave after flash chroma-
tography (Petroleum ether/EtOAc = 95/5) a diastereoisomeric mixture of furans I-81k (15.6 
mg, 70.2 mol, 56 %, Z: E 2.5:1). 
 
TLC: Rf = 0.68 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3) 6.46 (dd, J = 15.9, 1.7 Hz, 0.30H), 6.27 (dd, J = 11.2, 1.0 Hz, 0.70H), 
5.76 – 5.69 (m, 1H), 4.26 (dq, J = 14.3, 7.1 Hz, 2H), 2.65 (q, J = 7.5 Hz, 0.70H), 2.52 (s, 2.10H), 
2.49 (s, 0.90H), 2.45 (q, J = 7.5 Hz, 1.50H), 1.85 (dd, J = 6.5, 1.7 Hz, 1H), 1.59 (dd, J = 6.9, 1.8 
Hz, 2H), 1.33 (dt, J = 14.2, 7.1 Hz, 3H), 1.19 (dt, J = 12.5, 7.5 Hz, 3H). 
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13C NMR (151 MHz, CDCl3) δ [ppm] (164.9, 164.8), (157.7, 157.2), (151.8, 151.1), (127.7, 
127.1), (122.2, 121.5), (117.9, 115.7), (113.6, 112.8), (60.0, 59.9), (20.3, 20.2), (19.0, 14.9), 
(14.47, 14.45), 14.3, (13.1, 12.1). 
 
HRMS (ESI) m/z 245.1127 [245.1148 calcd. for C13H18O3Na (M
++Na+)]. 
 
ethyl 4-(but-1-en-1-yl)-2-methylfuran-3-carboxylate (I-81q) 
 
 
 
Following procedure E, substrat I-72q (29.7 mg, 0.124 mmol) gave after flash chroma-
tography (Petroleum ether/EtOAc = 95/5) a diastereoisomeric mixture of furans I-81q (12.4 
mg, 59.5 mol, 45 %, Z: E 6:1). 
 
TLC: Rf = 0.69 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3) 7.30 (s, 0.15H), 7.22 (s, 0.80H), 6.53 (dd, J = 13.8, 8.5 Hz, 1H), 6.00 
(dt, J = 16.0, 6.4 Hz, 0.10H), 5.68 (dt, J = 11.5, 7.0 Hz, 0.90H), 4.30 (q, J = 7.1 Hz, 2H), 2.55 (s, 
2.70H), 2.53 (s, 0.40H), 2.20 (dqd, J = 15.1, 7.5, 1.5 Hz, 2H), 1.36 (dd, J = 13.7, 6.6 Hz, 3H), 
1.06 (dt, J = 15.1, 7.6 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 164.6, 159.7, 138.6, 134.8, 122.2, 118.1, 112.8, 60.2, 
22.7, 14.5, 14.5, 14.3. 
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(Z)-ethyl 2-methyl-4-styrylfuran-3-carboxylate (I-81r) 
 
 
 
Following procedure E, substrat I-72r (30.0 mg, 0.109 mmol) gave after flash chroma-
tography (Petroleum ether/EtOAc = 95/5) the furan I-81r (19.5 mg, 76.1 mol, 70 %). 
 
TLC: Rf = 0.66 (Petroleum ether/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3) 7.30 – 7.26 (m, 4H), 7.22 – 7.18 (m, 1H), 6.88 (d, J = 0.8 Hz, 1H), 
6.67 (dd, J = 12.2, 1.0 Hz, 1H), 6.61 (d, J = 12.2 Hz, 1H), 4.29 (q, J = 7.1 Hz, 2H), 2.54 (s, 3H), 
1.35 (t, J = 7.1 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 164.5, 159.6, 139.0, 138.0, 131.0, 128.6, 128.5, 127.2, 
121.7, 120.4, 113.0, 60.3, 14.5, 14.4. 
 
MS (EI) m/z (%): 155.0 (56), 106.0 (77), 105.0 (84) [PhCO], 90.9 (77) [Bn], 77 (100) [Ph]. 
 
HRMS (APCI) m/z 257.0926 [257.1172 calcd. for C16H17O3 (M
++H+)]. 
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ethyl 4-formyl-2,5-dimethylfuran-3-carboxylate (I-84a) 
 
 
 
At 0°C, NMO monohydrate (34.4 mg, 0.254 mmol), 2,6-lutidine (36.3 mg, 0.339 mmol) and 
OsO4 (43.1 mg, 6.78 mol, 4% in H2O) were added to furan I-81a (37.7 mg, 0.170 mmol) in 
acetone/H2O (1.7 mL, 0.1 M, 4/1). The reaction mixture was allowed to warm to room 
temperature and stirred for 1 h, then PhI(OAc)2 (81.9 mg, 0.254 mmol) was added. The 
mixture was stirred for 2h, quenched with H2O and extracted three times with EtOAc. The 
combined organic phase was washed with sat. NaCl-solution, dried over Na2SO4 and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography (Petroleum ether/EtOAc = 9/1) to obtain the product (20.8 mg, 106.0 mol, 
63%). 
 
TLC: Rf = 0.71 (Cyclohexane/EtOAc = 7/3) [UV/KMnO4] 
 
1H NMR (600 MHz, CDCl3) 10.36 (s, 1H), 4.35 (q, J = 7.1 Hz, 2H), 2.55 (s, 3H), 2.55 (s, 3H), 1.37 
(t, J = 7.1 Hz, 3H). 
 
13C NMR (151 MHz, CDCl3) δ [ppm] 189.2, 163.7, 158.3, 158.1, 120.1, 112.7, 60.8, 14.5, 14.1, 
13.9. 
 
MS (EI) m/z (%): 196.0 (62) [M+], 167.0 (49) [M+-Et], 150.0 (100) [M+-EtOH], 139.0 (47), 122.0 
(44) [M+-HC(O)OEt]. 
 
HRMS (ESI) m/z 219.0621 [219.0628 calcd. for C10H12O4Na (M
++Na+)]. 
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ethyl 1-benzyl-4-(but-1-en-1-yl)-2,5-dimethyl-1H-pyrrole-3-carboxylate (I-87a) 
 
 
 
Under N2, AuCl (1.4 mg, 6.07 mol) was added to a solution of propargyl vinyl ether I-86a 
(20.0 mg, 60.7 mol) in dry DCE (0.6 mL, 0.1 M), the reaction mixture was heated  to 50°C for 
18 h. After filtration over celite and concentration, the crude product was purified by flash 
chromatography (Cyclohexane/EtOAc = 98/2) to obtain a diastereoisomeric mixture of 
pyrroles (15.1 mg, 48.5 mol, 80%, Z: E 8:1). 
 
TLC: Rf = 0.54 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3) 7.34 – 7.28 (m, 2H), 7.28 – 7.24 (m, 1H), 6.90 (d, J = 7.0 Hz, 2H), 
6.68 (d, J = 16.5 Hz, 0.10H), 6.42 (dd, J = 11.1, 0.7 Hz, 0.90H), 5.66 (dt, J = 16.0, 6.4 Hz, 
0.10H),  5.54 (dt, J = 11.1, 7.1 Hz, 0.90H), 5.06 (s, 2H), 4.30 – 4.22 (m, 2H), 2.44 (s, 3H), 1.97 
(s, 3H), 1.93 (ddd, J = 14.8, 7.4, 1.7 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H), 1.09 (t, J = 7.4 Hz, 0.30H), 
0.96 (t, J = 7.5 Hz, 2.70H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 166.3, 137.3, 135.2, 132.8, 129.0, 127.5, 125.7, 125.5, 
122.9, 118.4, 110.8, 59.3, 47.1, 22.4, 14.6, 14.2, 11.7, 11.1.  
 
MS (EI) m/z (%): 311.1 (68) [M+], 282.1 (14) [M+-Et], 250.1 (36), 238.1 (25) [M+-CO2Et], 91.0 
(100) [Bn]. 
 
HRMS (ESI) m/z 334.1772 [334.1778 calcd. for C20H25NO2Na (M
++Na+)]. 
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ethyl 1-benzyl-4-butyl-2,5-dimethyl-1H-pyrrole-3-carboxylate (I-88a) 
 
 
 
Under H2, 5% Pd/C (5.4 mg, 2.53 mol) was added to a solution of pyrrole I-87a (24.9 mg, 
80.0 mol) in dry MeOH/EtOAc (2/1, 0.56 mL, 0.15 M), then reaction mixture was stirred at 
rt for 2 h. After filtration over celite and concentration, the crude product was purified by 
flash chromatography (Cyclohexane/EtOAc = 95/5) to obtain the product (20.3 mg, 64.7 
mol, 81%). 
 
TLC: Rf = 0.57 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (600 MHz, CDCl3) 7.30 (t, J = 7.5 Hz, 2H), 7.24 (t, J = 7.3 Hz, 1H), 6.88 (d, J = 7.4 Hz, 
2H), 5.03 (s, 2H), 4.28 (q, J = 7.1 Hz, 2H), 2.69 – 2.64 (m, 2H), 2.44 (s, 3H), 2.04 (s, 3H), 1.48 
(ddd, J = 12.3, 8.6, 6.5 Hz, 2H), 1.35 (t, J = 7.1 Hz, 5H), 0.92 (t, J = 7.3 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 166.6, 137.5, 135.2, 129.0, 127.4, 125.7, 124.9, 121.5, 
110.2, 59.1, 47.0, 34.2, 25.7, 22.9, 14.6, 14.3, 11.8, 9.8. 
 
MS (EI) m/z (%): 313.2 (7) [M+], 270.0 (13) [M+-nPr], 91.0 (100) [Bn]. 
 
HRMS (ESI) m/z 336.1934 [336.1934 calcd. for C20H27NO2Na (M
++Na+)]. 
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ethyl 4-(but-1-en-1-yl)-1-butyl-2,5-dimethyl-1H-pyrrole-3-carboxylate (I-87b) 
 
 
 
Under N2, AuCl (3.1 mg, 1.35 mol) was added to a solution of propargyl vinyl ether I-86a 
(20.0 mg, 67.7 mol) in dry DCE (0.7 mL, 0.1 M), the reaction mixture was heated to 70°C for 
18 h. After filtration over celite and concentration, the crude product was purified by flash 
chromatography (Cyclohexane/EtOAc = 98/2) to obtain a diastereoisomeric mixture of 
pyrroles (5.5 mg, 19.8 mol, 29%, Z: E 1:2). 
 
Rf = 0.54 (Cyclohexane/EtOAc = 4/1) [UV/CAM] 
 
1H NMR (400 MHz, CDCl3) 6.36 (d, J = 11.1 Hz, 1H), 5.50 (dt, J = 11.1, 7.1 Hz, 1H), 4.23 (q, J = 
7.1 Hz, 2H), 3.79 – 3.72 (m, 2H), 2.50 (s, 3H), 2.04 (s, 3H), 1.96 – 1.87 (m, 2H), 1.60 (ddd, J = 
15.3, 10.9, 7.6 Hz, 2H), 1.44 – 1.27 (m, 5H), 0.95 (dd, J = 14.0, 7.4 Hz, 6H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 166.3, 134.6, 132.5, 124.8, 123.0, 118.1, 110.3, 59.2, 
43.8, 32.9, 22.4, 20.3, 14.6, 14.2, 13.9, 11.7, 11.2. 
 
MS (EI) m/z (%): 277.1 (99) [M+], 248.0 (28) [M+-Et], 216.0 (100), 204.1 (93) [M+-CO2Et], 
162.0 (43), 91.0 (40), 57.0 (36) [nBu]. 
 
HRMS (ESI) m/z 300.1934 [300.1934 calcd. for C17H27NO2Na (M
++Na+)]. 
 
 
 
 
EXPERIMENTAL PART 
CATALYZED CASCADE REACTIONS, A WAY TOWARD FURAN COMPOUNDS 
 
165 
 
(Z)-3-acetyl-4-(but-1-en-1-yl)-5-isobutylfuran-2(5H)-one (P2) 
 
 
 
I-72e (30.0 mg, 0.106 mmol) in dry toluene (1 mL, 0.1 M) was heated to 120°C in microwave 
for 5.5h. Toluene was evaporated and the residue was purified by flash chromatography 
(Petroleum ether/EtOAc = 9/1) to obtain the product (11.4 mg, 48.2 µmol, 46%).  
 
1H NMR (600 MHz, CDCl3) 7.33 (d, J = 16.5 Hz, 1H), 6.43 (dt, J = 16.5, 6.5 Hz, 1H), 5.25 (dd, J = 
10.4, 1.9 Hz, 1H), 2.60 (s, 3H), 2.38 (qd, J = 7.5, 1.3 Hz, 2H), 2.11 – 2.01 (m, 2H), 1.75 (ddd, J = 
14.4, 9.6, 2.2 Hz, 1H), 1.15 (t, J = 7.4 Hz, 3H), 1.07 (d, J = 6.6 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ [ppm] 195.7, 170.9, 170.6, 150.3, 121.5, 120.8, 78.6, 45.4, 30.5, 
27.3, 25.6, 23.6, 21.6, 12.6. 
 
MS (EI) m/z (%): 236.2 (2) [M+], 207.1 (100) [M+-Et], 151.0 (13), 79.0 (6), 77.0 (7). 
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3) Catalyzed cascade reactions, a way toward pyridine 
derivatives 
 
N-tosylformamide (I-120) 
 
 
 
N-tosylamine (1 g, 5.84 mmol) was added to a freshly prepared NaOMe solution (12 mL, 
0.73 M). The reaction mixture was heated to 40°C for 30 min, ethylformate (2.35 mL, 29.2 
mmol) was introduced. The reaction mixture was heated to 50°C for 3 h. Finally, it was 
quenched with a 1M HCl-solution and methanol was evaporated. After concentration, the 
residue was dissolved in MTBE and water, the solution was acidified to pH = 2, and the 
aqueous phase was extracted three times with MTBE. The combined organic phase was 
washed with sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified by recristallisation with MTBE (5 mL) to the product 
(942.0 mg, 4.73 mmol, 81%) as a white solid.  
 
TLC: Rf = 0.27 (CH2Cl2/Et2O = 5/1) [UV] 
 
1H NMR (250 MHz, CDCl3) ppm] 8.65 (s, 1H), 8.06 (s, 1H), 7.81 (d, J = 8.3 Hz, 2H), 7.38 (d, J 
= 8.1 Hz, 2H), 2.46 (s, 3H). 
 
The analytical data are identical to the literature data.[76b] 
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N-(2-methylallyl)-N-tosylformamide (I-121) 
 
 
 
N-tosylformamide (100 mg, 0.502 mmol) and K2CO3 (104.1 mg, 0.753 mmol) were added to a 
solution of methylallychloride (45.2 mg, 0.502 mmol) in dry THF/DMSO (2/1) (0.7 mL, 0.7 M). 
The reaction mixture was stirred at reflux for 2 h. Finally, it was quenched with water and 
extracted three times with Et2O. The combined organic phase was washed with sat. NaHCO3-
solution, dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash chromatography (Pentanes/Et2O = 9/1) to obtain the product (61.2 mg, 
0.242 mmol, 48%) as a white solid.  
 
TLC: Rf = 0.46 (Pentanes/Et2O = 9/1) [UV/KMnO4] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 9.16 (s, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.2 Hz, 
2H), 4.80 (d, J = 8.8 Hz, 2H), 4.08 (s, 2H), 2.46 (s, 3H), 1.55 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 161.4, 145.6, 138.4, 135.5, 130.3, 127.7, 113.7, 47.7, 21.8, 
19.9. 
 
The analytical data are identical to the literature data.[76b] 
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N-(2,2-dichlorovinyl)-4-methyl-N-(2-methylallyl)benzenesulfonamide (I-122) 
 
 
 
At 55°C, CCl4 (1.54 mL, 15.8 mmol) was added to the N-methylallyl-N-tosylformamide I-121 
(400 mg, 1.58 mmol) and PPh3 (1.24 g, 4.74 mmol) in dry THF (16 mL, 0.1 M), over a period 
of 3 h. The reaction mixture was stirred at 55°C for an additional hour. Finally it was 
quenched with sat. NaHCO3-solution and extracted three times with Et2O. The combined 
organic phase was washed with sat. NaCl-solution, dried over Na2SO4 and concentrated 
under reduced pressure. The residue was purified by flash chromatography (Pentanes/Et2O = 
99/1) to obtain the product (235.5 mg, 0.735 mmol, 47%) as a white solid. 
 
TLC: Rf = 0.74 (Pentanes/Et2O = 9/1) [UV/KMnO4] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.70 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 6.21 (s, 
1H), 4.88 (d, J = 14.5 Hz, 2H), 3.88 (s, 2H), 2.44 (s, 3H), 1.75 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 144.3, 139.6, 135.8, 130.0, 127.5, 124.9, 115.2, 55.3, 21.8, 
20.0. 
 
The analytical data are identical to the literature data.[76b] 
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N-ethynyl-4-methyl-N-(2-methylallyl)benzenesulfonamide (I-123) 
 
 
 
At -78°C, nBuLi (1.37 mL, 3.44 mmol, 2.5 M in hexanes) was slowly added to a solution of 
dichlorovinyl compound I-122 (500 mg, 1.56 mmol) in dry THF (7.8 mL, 0.2 M). The reaction 
mixture was allowed to warm to -20°C and stirred for 1 h. Then MeOH (0.30 mL) was added. 
Finally the reaction mixture was diluted with Et2O and washed with sat. NaHCO3-solution. 
The organic phase was dried over Na2SO4 and concentrated under reduced pressure. The 
residue was purified by flash chromatography (Pentanes/Et2O = 9/1) to obtain the product 
(311 mg, 1.25 mmol, 80%) as a white solid. 
 
TLC: Rf = 0.38 (Pentanes/Et2O = 9/1) [UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.81 (d, J = 8.3 Hz, 2H), 7.42 – 7.31 (m, 2H), 4.94 (d, J = 8.9 
Hz, 2H), 3.86 (s, 2H), 2.70 (s, 1H), 2.46 (s, 3H), 1.72 (s, 3H) 
 
13C NMR (63 MHz, CDCl3)  [ppm] 144.9, 138.6, 134.8, 129.9, 127.9, 115.9, 76.1, 59.2, 57.7, 
21.8, 19.8. 
 
The analytical data are identical to the literature data.[76b] 
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4-methyl-N-(2-methylallyl)-N-(phenylethynyl)benzenesulfonamide (I-124) 
 
 
 
Phenyl iodide (47.9 mg, 0.235 mmol) was dissolved in a degassed solution of DIPEA (2.8 mL) 
and toluene (1.2 mL). The mixture was in turn degassed. Then Pd(PPh3)4 (20.8 mg, 18.0 
µmol), CuI (2.4 mg, 18.0 µmol) and I-123 (45 mg, 0.180 mmol) were added. After stirring at rt 
for 2.5h, the reaction mixture was diluted with CH2Cl2 and filtered through celite. The filtrate 
was concentrated under reduced pressure and the residue was purified by flash 
chromatography (Pentanes/Et2O = 95/5) to obtain the product (45.5 mg, 0.140 mmol, 77%).  
 
TLC: Rf = 0.38 (Pentanes/Et2O = 9/1) [UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.85 (d, J = 8.3 Hz, 2H), 7.39 – 7.25 (m, 7H), 4.98 (s, 2H), 
3.95 (s, 2H), 2.45 (s, 3H), 1.76 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 144.8, 138.9, 131.4, 129.9, 128.4, 129.9, 128.4, 116.0, 
82.5, 71.0, 58.1, 21.8, 19.9. 
 
The analytical data are identical to the literature data.[94] 
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4-methyl-N-(2-methylallyl)benzenesulfonamide (I-126) 
 
 
 
Methylallyl chloride (2.38 g, 26.3 mmol) and K2CO3 (3.63 g, 26.3 mmol) were added to 
tosylamide (3 g, 17.5 mmol) in acetone (88 mL, 0.2 M). The reaction mixture was stirred at 
70°C (reflux) for 24 h. It was diluted with water and CH2Cl2 and the aqueous phase was 
extracted three times with CH2Cl2. The combined organic phase was washed with sat. NaCl-
solution, dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash chromatography (Pentanes/Et2O = 4/1) to obtain the product (1.76 g, 7.81 
mmol, 45%). 
 
TLC: Rf = 0.40 (Pentanes/Et2O = 9/1) [KMnO4] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.75 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 4.95 – 4.76 
(m, 2H), 4.40 (s, 1H), 3.49 (d, J = 6.4 Hz, 2H), 2.43 (s, 3H), 1.68 (d, J = 0.4 Hz, 3H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 143.6, 140.7, 137.2, 129.8, 127.3, 112.9, 49.2, 21.7, 20.3. 
 
The analytical data are identical to the literature data.[95] 
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4-methyl-N-(2-methylallyl)-N-(phenylethynyl)benzenesulfonamide (I-124) 
 
 
 
Bromophenyl acetylene (441.9 mg, 2.44 mmol) was dissolved in dry toluene (2.4 mL, 1 M), 
N-methylallyl-N-tosylamide I-126 (500 mg, 2.22 mmol), K2CO3 (613.4 mg, 4.44 mmol), 
CuSO4
.5H2O (54.9 mg, 0.22 mmol) and phenanthroline (80.0 mg, 0.44 mmol) were added. 
The reaction mixture was sonicated at 60°C for 7 h. It was diluted with CH2Cl2 and filtered 
through celite. The filtrate was concentrated under reduced pressure and the residue was 
purified by flash chromatography (Pentanes/Et2O = 99/1) to obtain the product (562.5 mg, 
1.42 mmol, 86%).  
 
4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide (I-135) 
 
 
 
At rt, propargyl amine (100 mg, 1.82 mmol) was stirred in pyridine for 30 min, then TsCl 
(519.2 mg, 2.72 mmol) was added portionwise. The reaction mixture was stirred at rt for 
2.5 h. It was quenched with a 1M HCl-solution and extracted three times with EtOAc. The 
combined organic phase was washed with sat. NaCl-solution, dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by flash chromatography 
(Pentanes/Et2O = 9/1) to obtain the product (394.9 mg, 1.89 mmol, 99%). 
 
TLC: Rf = 0.35 (Pentanes/Et2O = 9/1) [UV] 
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1H NMR (360 MHz, CDCl3)  [ppm] 7.77 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 4.57 (s, 
1H), 3.83 (dd, J = 6.1, 2.5 Hz, 2H), 2.43 (s, 3H), 2.11 (t, J = 2.5 Hz, 1H). 
 
13C NMR (91 MHz, CDCl3)  [ppm] 144.0, 136.7, 129.9, 127.6, 78.1, 73.2, 33.0, 21.7. 
 
The analytical data are identical to the literature data.[96] 
 
4-methyl-N-(phenylethynyl)-N-(prop-2-yn-1-yl)benzenesulfonamide (I-131) 
 
 
 
Bromophenyl acetylene (324.6 mg, 1.79 mmol) was dissolved in dry toluene (2.4 mL, 0.5 M), 
propargyl tosylamide I-135 (250 mg, 1.20 mmol), K2CO3 (330.2 mg, 2.39 mmol), CuSO4
.5H2O 
(29.8 mg, 0.12 mmol) and phenanthroline (43.1 mg, 0.24 mmol) were added. The reaction 
mixture was sonicated at 65°C for 20 h. It was diluted with CH2Cl2 and filtered through celite. 
The filtrate was concentrated under reduced pressure and the residue was purified by flash 
chromatography (Pentanes/Et2O = 9/1) to obtain the product (48.4 mg, 0.156 mmol, 13%). 
 
TLC: Rf = 0.78 (Pentanes/Et2O = 9/1) [UV] 
 
1H NMR (250 MHz, CDCl3)  [ppm] 7.88 (d, J = 8.3 Hz, 2H), 7.45 – 7.27 (m, 7H), 4.34 (d, J = 2.5 
Hz, 2H), 2.46 (s, 3H), 2.22 (t, J = 2.5 Hz, 1H). 
 
13C NMR (63 MHz, CDCl3)  [ppm] 145.1, 134.3, 131.7, 129.8, 128.4, 128.2, 122.7, 81.7, 76.0, 
74.8, 42.0. 
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I)  Introduction 
 
1) A definition with a long history 
 
The term alkaloids was first employed in 1819 by Carl Friedrich Wihelm Messner to 
qualify natural products contained in plants, that showed alkaline properties.[1] It derives 
from the Arabic word, “al qali”, which is the plant from which the soda was first extracted. 
The suffix “oid” refers to the resemblance of it’s structure and activity. As no clear definition 
was given, the term was used during the whole 19th century to characterize several molecule 
types.[2] 
Almost one century after Messner, Winterstein and Trier attempted to define the 
term. They used the expression “true alkaloids” to name natural products that have a 
nitrogen atom included in a heterocyclic system, present a complex structure, possess 
potent pharmaceutical activities, and belong to the plant kingdom. In spite of the 
remarkable effort in precision, this definition proved to be too restrictive. Compounds 
commonly recognized as alkaloids were not presenting all the necessary characteristics.[3] 
In the 1960s, Hegnauer divided alkaloids into three classes: the true alkaloids; the 
pseudoalkaloids; and the protoalkaloids. The first category described the compounds arising 
from the condensation between a decarboxylate amino acid and a non-nitrogenous partner. 
The pseudoalkaloids are products without a link to amino acids, and the last class, the 
protoalkaloids, concerns amino-acid related compounds, where the nitrogen atom is not 
part of a heterocyclic system.[4] 
However, the distinction between the different types is often difficult to apply, and in 
1983, Pelletier suggested a simple and suitable definition: “An alkaloid is a cyclic compound 
containing nitrogen in a negative oxidation state which is of limited distribution on living 
organisms”.[5] 
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2) Natural products of prime interest 
 
Alkaloids belong to an important type of secondary metabolites mainly produced by 
plants. They are essential for their defense against herbivores and predators. They are also 
applied as herbicides against competing plants. Often one alkaloid is multifunctional, 
showing more than one biological activity. Furthermore, it never occurs alone, but in a 
mixture of alkaloids deriving from a specific biosynthetic unit.  
 
Alkaloids are as central in the plant kingdom, as in human history: for early 
civilizations, they were recognized to be useful medicines, stimulants, or poisons. Cleopatra’s 
consumption of atropine (II-1) containing henbane to dilate her pupils is one example.[6] Or 
the preparation from the bark Cinchona officinalis that holds the antimalarial drug quinine 
(II-2) and helped European exploration and inhabitation of the tropics.[7] Approximately 
13 000 plant species have been used around the world as drugs, and nowadays about 25% of 
medicines have a plant source.[8]  
 
                                
Figure 1. Presentation of selected alkaloids. 
 
 Since the first alkaloid synthesis with the poisonous (+)-coniine (II-3) by 
Ladenburg in 1886,[9] other chemists have been encouraged by this wealth of 
pharmacologically active compounds amongst alkaloids to synthesize this group of natural 
products.[10]  
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3) Melohenine B, a unique alkaloid from Melodinus Henryi 
 
Melodinus plants have shown to be good sources of indole and quinoline alkaloids, 
which exhibit interesting pharmaceutical properties.[11] They are also used in Chinese and 
Thai traditional medicine to cure meningitis in children and rheumatic heart diseases.[11a] 
These advantages have attracted the attention of several groups, among them the Luo 
group, who investigated the Melodinus Henryi plant.[12] In 2009, the group isolated and 
characterized two novel alkaloids, melohenine A and B.[12] Both were tested for cytotoxycity 
against five human cell cancers. Unfortunately they showed inactivity with IC50 values 
superior to 40 M.[13] However, melohenine B (Figure 2) presents an interesting ketolactam 
derivative, with an unprecedented 6/9/6/6 tetracyclic ring system. 
 
 
Figure 2. The melohenine B. 
 
4) The biosynthesis: from monoterpenoid indole alkaloids to 
quinoline alkaloids 
 
As the alkaloids encompass a considerable class of secondary metabolites with 
several structural families, their biosyntheses differ from one to another. Here, I choose to 
report the biosynthesis of monoterpenoid indole alkaloids and quinoline alkaloids, with 
regard to melohenine B. Both can be seen as true alkaloids, following the definition of 
Hegnauer, they find their origins in the condensation of a decarboxylate amino acid and a 
non-nitrogenous partner. The monoterpenoid indole alkaloids are a large family of alkaloids, 
with a great number of various structures. However, only two enzymes catalyze the early 
steps in the biosynthesis of all these alkaloids, the tryptophan decarboxylase and the 
strictosidine synthase.[14] 
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As its name informs us, the tryptophan decarboxylase catalyzes the decarboxylation 
of the amino acid L-tryptophan to give the tryptamine, which in turn acts as a substrate for 
the enzyme strictosidine synthase. The latter catalyzes the stereospecific condensation of 
the amino moiety from tryptamine and the aldehyde group of the monoterpene secologanin 
to produce the 3(S)-strictosidine (Scheme 1).  
Scheme 1. The early steps of the biosynthesis of monoterpenoid indole alkaloids. 
 
From the 3(S)-strictosidine, a rich diversity of monoterpenoid indole alkaloids is 
accessible. Among them, we can name the antineoplastic chemotherapeutic agents 
vincristine and vinblastine,[15] the rat poison and homeopathic drug strychnine,[16] or the 
aphrodisiac yohimbine[17] (Scheme 2).  
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Scheme 2. From the 3α(S)-strictosidine, a gain in diversity. 
 
On the side of the quinoline alkaloids, some, such as quinine, have been found to 
derive from the rearrangement of monoterpenoid indole alkaloids (Scheme 3).[18] 
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Scheme 3. An access to quinoline alkaloids. 
 
In 2009, when Luo and coworkers isolated melohenine B, they suggested that the 
molecule could be seen as a key intermediate from indole to quinoline alkaloids.[12] More 
recently, various novel alkaloids were isolated from the Melodinus yunnanensis, a plant of 
the genus Melodinus. Among them is a quinolone alkaloid, Meloyunine C, in presence of its 
biosynthetic precursors, the keto-lactam II-18 and the eburnane-type alkaloid II-17 (Scheme 
4).[19] 
 
Scheme 4. Proposed biosynthesis from indole to quinolone alkaloids in Melodinus plant. 
 
 Furthermore, as illustrated in Scheme 5, the first total synthesis of melohenine B (II-
4) was designed by Westwood et al. on the basis of this biogenetic relationship. As 
eburnamine (II-21) is an indole alkaloid also present in Melodinus Henryi,[20] they have 
developed a method to oxidatively cleave the C2-C7 indole bond and therefore obtain II-4 as 
a single diastereoisomer in quantitative yield.[21]  
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Scheme 5. The synthesis of melohenine B (Westwood et al., 2012).[21] 
 
The racemic eburnamonine (±)-II-20 was prepared following a modified version of the 
Sclessinger approach (Scheme 6).[22]  
 
Scheme 6. Synthesis of eburnamonine (±)-II-20 (Westwood et al., 2012).[21] 
 
In addition to the synthesis of melohenine B, Westwood and coworkers investigated 
the intramolecular aldol reaction to the quinolone alkaloid (Scheme 7).  
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Scheme 7. Synthesis of quinolone from melohenine B (Westwood et al., 2012).[21]  
 
Using sodium methoxide, they were able to isolate the desired condensation product 
as a 3:1 mixture of diastereoisomers.  
 
 
RESULTS AND DISCUSSION 
THE RETROSYNTHESIS 
 
192 
 
II) Results and Discussion 
 
1) The retrosynthesis 
 
In 2009, intrigued by this unprecedented 6/9/6/6 tetracyclic ketolactam derivative 
we decided to launch a study toward the total synthesis of melohenine B.  Although the first 
investigations have not demonstrated any biological effects,[12,19,20] a concise synthesis of 
this molecule is nevertheless an interesting challenge from a synthetic chemist’s point of 
view and could be a road to improve its pharmacological properties via the synthesis of 
analogues and to test its activity against other targets. The retrosynthesis analysis for II-4 is 
outlined in Scheme 8. 
 
Scheme 8. Retrosynthesis of melohenine B. 
 
Melohenine B was expected to arise from an intramolecular lactamization of the 
lacton with primary amine II-29. The latter should be formed by Michael addition[23] of the 
Heck reaction product II-31 to the α,β-unsaturated carbonyl compound II-30, directly 
followed by reduction of the nitro group to the amine. The intramolecular Heck cross-
coupling[24] on the iodoallyl aminodihydro-2H-pyranone would be the key step as the 
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emergence of two stereogenic centers will occur at this stage. Finally, the five-step synthesis 
to melohenine B should start with the simple building block II-33. In fact, the road to this 
goal was demanding and at this point in the investigations, several strategies have been 
tested. The first plan was to use a ring-closing metathesis to produce the lacton ring 
(Strategy A), then our attention was steered toward carbohydrate chemistry as they can 
provide a direct access to the dihydropyranone structure (Strategy B). Two other alternatives 
were also proposed, one ending with a lactonization, the second with an enyne metathesis. 
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2) Studies toward the synthesis of building block II-33 
 
2.1) Ring closing metathesis strategy (Strategy A) 
 
Our first plan was to obtain molecule II-34 via a ring-closing metathesis (RCM) 
(Scheme 9).  
 
 
Scheme 9. Ring-closing metathesis strategy to access the building block. 
 
In recent years, this method has been commonly involved in total synthesis to 
fashion complex rings.[25] A case in point is the total synthesis of epothilone C by Nicolaou 
and coworkers,[26] where a macrocylization was performed in 85% yield, despite the 
presence of an unprotected hydroxyl group and a thiazole unit (Scheme 10).  
 
Scheme 10. Ring-closing metathesis reaction in the total synthesis of epothilone C 
(Nicolaou et al., 1997).[26] 
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2.1.1) The Michael-type reaction. 
 
Our first approach was to reach the metathesis substrate II-35 using a Michael-type 
reaction between nitro allylester II-42 and pentanone (Scheme 12). As featured in Scheme 
11, II-42 was synthesized in three steps with an overall yield of 43%. The process was 
initiated with the cheap starting material nitromethane, which after self-condensation[27] 
and esterification,[28] gave the desired nitro allylester.  
 
Scheme 11. The synthetic route to nitro allyl ester II-42. 
 
Nevertheless, after initial experiments, no trace of the expected product II-44 was 
found and this route was investigated no further.  
 
 
Scheme 12. The unsuccessful Michael-type reaction. 
 
2.1.2) The transesterification 
 
As the first method, described above, was aborted, another angle of attack was to 
reverse the synthesis and terminate with the introduction of the allyl ester via a 
transesterification[29] from nitro ethyl ester II-49 to nitro allyl ester II-50. Compound II-49 
was formed in four steps starting with pentanone and ethyl-2-(diethoxyphosphoryl)acetate. 
A Horner-Wadsworth-Emmons reaction,[30] followed by nitration[31] gave II-47 in good yield. 
After deconjugation,[32] this latter produced nitro ethyl ester II-49 in excellent yield (Scheme 
13). 
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Scheme 13. Synthesis of the nitro compound II-49. 
 
To eventually produce the allylic ester, the transesterification was investigated. As 
shown in Scheme 14, this convenient method to prepare esters was tested using different 
conditions.[33] With the exception of the Conditions 1, which gave us the product in a 27% 
unreproducible yield, they were, to our disappointment, all fruitless. Another member of the 
group, M. Sc. Chem. P. Klahn tried the same conditions on the amino starting material 
without improving on previous results.  
 
 
Scheme 14. A problematic transesterification. 
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We reasoned that the methyl ester may have a better reactivity than the ethyl ester. 
The nitro methyl ester II-55 was synthesized employing the same reaction conditions as for 
the nitro ethyl ester II-49 (Scheme 15).  
 
Scheme 15. Change of plan, from nitro ethyl ester II-49 to nitro methyl ester II-55. 
 
 We subsequently examined different conditions for the transesterification (Scheme 
16) and were pleased to obtain the nitro allylic ester II-56 using Bu2SnO as a catalyst,
[34] 
albeit in low yield (Eq 1).  
 
 
Scheme 16. Transesterification of the nitro methyl ester II-55 into the nitro allyl ester II-56 
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However, having compound II-56 in hand, RCM could be tested. Attempting to avoid 
an unconvenient protecting group, the metathesis was first tested on the compound 
containing the nitro group[35] in presence of various ruthenium catalysts: Grubbs I,[36] Grubbs 
II,[37] with or without the additive Ti(OiPr)4,
[38] or Grubbs-Hoveyda II[39]. 
 
 
Entry Catalyst (10 mol%) Solvent (0.01M) Temperature (°C) Result 
1 Grubbs II CH2Cl2  Rfl - 
2 Grubbs II/ 
Ti(OiPr)4 
CH2Cl2  Rfl SM + CM 
3 Grubbs II DCE  60 to Rfl SM + CM 
4 Grubbs II Benzene  70 - 
5 Grubbs I CH2Cl2  Rfl SM 
6 Grubbs-Hoveyda II CH2Cl2 Rfl - 
CM: cross-metathesis compound, SM: recovery of the starting material. 
Table 1. Attempts at ring-closing metathesis on II-56. 
 
As shown in Table 1, the only significant isolated compound was the cross-metathesis (CM) 
product when using the Grubbs II catalyst (Scheme 17).  
 
 
Scheme 17. The cross-metathesis product. 
 
From previous results, we deduced that we may need two terminal olefins. A new 
nitro methyl ester was synthesized employing the reactions conditions as previously 
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described (Scheme 18). However, here the transesterification was performed prior to the 
isomerization to avoid the presence of the acidic proton alpha to the nitro group. Indeed, 
when the previous order was maintained, II-61 underwent an isomerization of the double 
bond in tandem with the transesterification. 
 
Scheme 18. Synthesis of compound II-63. 
 
Compound II-63 was then available to be tested with typical metathesis conditions. 
As for compound II-56, only the cross-metathesis product was found, sometimes with 
observed isomerization of the double bond (Table 2, Scheme 19). 
 
Entry Catalyst (10 mol%) 
Solvent 
(0.01M) 
Temperature Result 
1 Grubbs II CH
2
Cl
2
  Rfl CM+ isomerisation 
2 Grubbs II/ 
Ti(OiPr)
4
 
CH
2
Cl
2
  Rfl CM+ isomerisation 
3 Grubbs-Hoveyda II CH
2
Cl
2
   Rfl CM 
4 Grubbs I CH
2
Cl
2
  Rfl SM 
5 Grubbs II Toluene Rfl CM+ isomerisation 
6 Grubbs- Hoveyda II Toluene Rfl CM+ isomerisation 
CM: cross-metathesis compound, SM: recovery of the starting material. 
Table 2. Attempts at ring-closing metathesis on II-63. 
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Scheme 19. The cross-metathesis products. 
 
We concluded that the nitro-moiety could be the reason for the unsuccessful 
metathesis and decided to make other attempts on the amine protected compound II-67. 
From intermediate II-63, product II-67 was produced in two steps through reduction with 
zinc[40] and tert-butyloxycarbonyl protection of the amine, with 32% overall yield (Scheme 
20).  
 
Scheme 20. Synthetic approach to Boc-amino allylic ester II-67. 
 
To our delight, the RCM product was detected and isolated in 16 % yield (22% brsm). 
The yield was low and during the reaction, the cross-metathesis compound was also 
produced in a rather short time, even at extremely low concentration (0.005 M). The RCM 
might fail due to the sterically-hindered or electronically deactivated alkene moiety.[41] Some 
other groups have also had trouble closing dihydropyranone derivatives and have employed 
a relay RCM to overcome the problem.[42] However, at this point, we considered changing 
our initial plan, and to start with a completely new approach to synthesize the building block 
II-33.  
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2.2) The carbohydrate strategy (Strategy B) 
 
2.2.1) Starting with D-(+)-xylose 
  
 Carbohydrate chemistry has been successfully applied to several total syntheses. As 
carbohydrates are rich in stereochemistry and functionality, they represent an excellent 
class of starting materials for total synthesis.[43] To name one example, Tatsuta et al. have 
reported the stereoselective construction of the pyranonaphthoquinone antibiotic, 
nanaomycin D, starting with the carbohydrate methyl L-rhamnoside (Scheme 21).[44] 
 
 
Scheme 21. Total synthesis of nanaomycin D from methyl L-rhamnoside (Tatsuta et al., 
1985).[44] 
 
 Recognizing that carbohydrate chemistry can be an excellent chiral pool for a 
stereoselective synthesis of melohenine B, a new strategy was launched, starting with the 
natural sugar, D-(+)-xylose.  
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Scheme 22. An enantioselective synthesis of the methoxy dihydropyranol II-78. 
 
The already well-known reactions on monosaccharides allow us to have an easy 
access to the methoxy dihydropyranol product (II-78). As shown in Scheme 22, acetyl 
protection of the D-(+)-xylose, substitution with a bromine on the anomeric position[45] and 
elimination with zinc gave the diacetate dihydropyran in good yield. The standard procedure 
to obtain glycal II-76 involves treating bromide II-75 with zinc in acetic acid,[46] but in this 
case high yield was not reproducible. Instead, a mild and efficient reaction developed by 
Zhao et al. was employed, using NaH2PO4 and zinc dust in ethyl acetate at room 
temperature.[47] Finally, Ferrier rearrangement[48] and acetate deprotection afforded product 
II-78. However, it is worth noting that the rearrangement did not provide a pure 
diastereoisomer, but instead a diastereoisomeric mixture with a ratio of 5 to 1. 
Nevertheless, both diastereoisomers were easily separated.  
 
The next step, oxidation of alcohol II-78, was more demanding. It required the 
screening of different oxidation methods (Table 3). Finally, IBX was found to be the best 
oxidant for this reaction (Entry 5). Thus, by stirring II-78 in DMSO in the presence of 2.5 
equivalents of IBX, II-79 was isolated in 80% yield.  
 
 
 
 
 
 
RESULTS AND DISCUSSION 
STUDIES TOWARD THE SYNTHESIS OF BUILDING BLOCK II-33 
 
203 
 
Entry Oxidant Solvent Temp. (°C) Yielda (%) 
1 Py.SO3, Et3N DMSO rt - 
2 Swern CH2Cl2 -78 21 
4 IBX (1 equiv.) DMSO (0.3 M) rt 28 
5 IBX (2.5 equiv.) DMSO (0.3 M) rt 80 
6 Ac2O (35 equiv.) DMSO (0.2 M) rt 56 
7 NMO (2 equiv.)/TPAP (5 
mol%) 
CH2Cl2 (0.1 M) rt 25 
a: Isolated yield after flash chromatography. 
Table 3. Oxidation of the alcohol II-78. 
 
In order to introduce the ethyl group, the Negishi reaction[49] was tested on molecule 
II-80, obtained by -iodination[50] of the methoxy dihydropyranone (Scheme 23). 
 
 
Scheme 23. Synthesis of iodo compound II-80. 
 
Regrettably, several attempts led us to believe that the Negishi cross coupling does 
not work on substrate II-80 (Scheme 24).  
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Scheme 24. Unsuccessful Negishi cross-coupling on II-80. 
 
-Iodoenone II-80 was then reduced under Luche conditions[51] and the alcohol 
moiety was protected with trichloroacetonitrile (Scheme 25), in order to proceed to the 
Overman rearrangement.[52] With the reduction step, two diastereoisomers were formed (cf. 
experimental part 3., p 244), both were separated by flash chromatography and the major 
isomer was used for the next step. 
 
 
Scheme 25. Formation of the trichloroacetimidate II-83. 
 
Trichloroacetimidate II-83 was tested with the Overman rearrangement. Despite the 
optimization phase, the yield remained moderate (51%, 58% brsm). The presence of the 
bulky iodine moiety and the methoxy group[53] could be one explanation of this result.  
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Entry Solvent (0.1 M) Additive 
(equiv.) 
Mode Temperature 
(°C) 
Time 
(h)  
Yielda (%) 
1 o-dichlorobenzene K2CO3 (0.2) Mw 200 8 5 
2 o-dichlorobenzene K2CO3 (0.2) Mw 180 12 19 
3 o-dichlorobenzene K2CO3 (0.2) Thermal 180 2 23 
4 o-dichlorobenzeneb / Thermal 170 3 11 
5 xylene K2CO3 (0.2) Thermal 135 48 35 
6 xylene K2CO3 (1) Thermal 135 48 51 (58% brsm) 
7 xylene K2CO3 (2) Thermal 135 48 34 (39 % brsm) 
a: Isolated yield after flash chromatography; b: 0.08 M. 
Table 4. Overman rearrangement. 
 
2.2.2) A shortcut 
 
Parallel to the work on the [3,3]-sigmatropic rearrangement, a shorter, but racemic 
approach to II-79 was investigated. Lefebvre et al. have further developed an interesting 
rearrangement found by Achmatowicz and coworkers,[54] using 2-furfuryl alcohol with m-
CPBA to afford hydroxyl-pyranone.[55] As depicted in Scheme 26, with the same conditions as 
Lefebvre we were able to isolate product II-86 in 78% yield, saving 5 steps in comparison to 
the previous route. 
 
 
Scheme 26. The oxidative rearrangement of 2-furfuryl alcohol. 
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The next step was the glycosidation of the obtained hydroxypyranone II-86 into 
methyl glycoside. Unfortunately, the reaction with trimethyl formate and Lewis or Brønsted 
acids gave the desired compound only in a poor yield. However, the treatment with acetic 
anhydride and pyridine at 0°C delivered, to our delight, o-acetyl derivative II-87[51] in high 
yield. Iodination and reduction of the ketone moiety provided compound II-90 after 
formation of the trichloroacetimidate, ready for the Overman rearrangement. It should be 
noted that the acetyl group was substituted by a methoxy group[56] during the course of the 
reduction, giving the trans-product as the major isomer. 
 
 
Scheme 27. Formation of the trichloroacetimidate II-90. 
 
The conditions applied on II-83 were reproduced on II-90, and the Overman 
rearrangement gave trans-trichloroacetamide3 II-91 in 77% yield by refluxing II-90 in o-
dichlorobenzene for 1h in presence of 0.2 equivalents K2CO3 (Scheme 28). Eventually, a 
procedure[57] was employed to cleave away the trichloroacetamide group and to provide the 
primary amine compound II-92. 
 
                                                          
3
 The thermal Overman rearrangement occurs suprafacially.
[52a,d]
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Scheme 28. The Overman rearrangement of II-90. 
2.2.3) Cross-coupling reaction to introduce the ethyl chain 
  
 At this point, the ethyl group was the only remaining motif necessary for completion 
of building block II-33. As previously described, the introduction of this alkyl chain had first 
been attempted on the reactant II-80 via a Negishi cross-coupling reaction without success 
(Scheme 22). Since this attempt, several experiments have been undertaken on various 
stages of the synthesis. Thus the Negishi reaction was also investigated on the substrate II-
84, two different palladium catalysts have been employed in THF at diverse temperatures 
without significant results (Scheme 29). Either starting material II-84, was reisolated or 
decomposition products were found, but no trace of an ethyl group was detected. 
 
 
Scheme 29. The unsuccessful Negishi cross-coupling reactions on II-84. 
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As the Negishi cross-coupling reaction seemed to be inefficient in bringing the 
desired alkyl moiety, the Suzuki cross-coupling[58] was carried out on II-84. To our delight, the 
Suzuki reaction delivered the right product. However, as illustrated in Table 5, the yield 
stayed low due to a poor conversion or the hydrolysis of the trichloroacetamide group 
(Entries 2 and 3).  
 
 
Entry Cat. Loading 
(mol%) 
Base 
(1.8 equiv.) 
Solvent 
(0.3 M) 
Temp. (°C) Time (h) Resulta 
1 5 NaOHb THFc 30  20 SM + II-93 (15%) 
2 20 NaOHb THFc 50 20 SM + II-93 (11%) + 
II-94 (13%) 
3 10 Cs2CO3 DMF  30 20 II-94 (17%) 
4 10 K2CO3 DMF  80 2 decomposition 
5 10 K2CO3  Tol rt 24 II-93 (41% not 
pure) 
6 10 Et3N THF 50 24 SM 
a: Isolated yield after flash chromatography; b: 2.2 equiv.; c: 0.5 M. 
Table 5. The Suzuki cross-coupling reactions on II-84. 
 
Despite this, the result was encouraging and further experiments could be explored. 
In particular at room temperature or employing KF[59] to avoid the product of hydrolysis. 
Regrettably, batch II-84 (cis-isomer) was no longer available and II-91 (trans-isomer) was 
used instead, and surprisingly, when the working Suzuki conditions were applied on II-91, no 
trace of the required product was found (Scheme 30, Eq 1 and Eq 2). As the route to II-91 
was much shorter than the one to II-84, some additional efforts were made on this 
diastereoisomer, in particular using other bases. However, neither sodium acetate nor the 
booster-base Tl2CO3
[60] were appropriate to promote the coupling of the ethyl group to II-91 
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(Scheme 30, Eq 3 and Eq 4). It appears that the trans-isomer does not favour the cross-
coupling reaction, for which the steric hindrance of the bulky trichloroacetamide group may 
be responsible.  
 
 
Scheme 30. Suzuki cross-coupling reactions on II-91. 
 
At this time, two other possibilities remained viable: indeed, cross-coupling reactions 
were still practicable on II-89 and II-92. In the case of iodo-dihydropyranol, a copper(I) 
catalyzed cross-coupling between the ethyl Grignard reagent and the vinyl iodide was 
carried out at -20°C in tetrahydrofuran,[61] producing traces of the desired ethyl-
dihydropyranol II-95 (Scheme 31, Eq 1). Changing from Grignard cross-coupling to a Suzuki 
reaction with the palladium-catalyzed cross-coupling between the triethylborane and the 
alcohol II-89 in the presence of NaOH or K2CO3 as base in THF proved to be encouraging, as 
II-95 was isolated in 15% yield when using NaOH (Scheme 31, Eq 2).   
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Scheme 31. Cross-coupling reactions on II-89. 
 
 In parallel, the Suzuki cross-coupling was investigated on the stage of II-92. Various 
bases (NaOH, K2CO3, Cs2CO3) were tested in the presence of Pd(dppf)Cl2 or Pd(PPh3)4 in DMF 
at room temperature or higher (Table 6). Unfortunately, none of these conditions led to the 
desired product.  
 
Entry Catalyst (5 mol%) Base (2.2 equiv.) Temperature (°C) Result 
1 Pd(dppf)Cl2 NaOH rt →60  - 
2 Pd(PPh3)4 NaOH rt →60  - 
3 Pd(PPh3)4 K2CO3 rt →60  - 
4 Pd(PPh3)4 Cs2CO3 rt →60  - 
Table 6. Suzuki cross-coupling reactions on II-92. 
 
 Based on these findings, the iododihydropyranol II-89 seemed to be the most 
appropriate subject for an efficient cross-coupling reaction. Consequently, Negishi cross-
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coupling and even a Sonogashira reaction[62] were tested, yielding the best results so far. 
Particularly with the Sonogashira reaction as shown in Scheme 32.  
 
 
Scheme 32. Further cross-coupling on II-89. 
 
 However, in the case of the Sonogashira product, two additional steps were required 
to access the alkyl chain. Although TBAF was sufficient to remove the TMS-protecting group, 
efforts were required for the selective reduction of the triple bond, leaving the double bond 
unchanged.[63] Therefore, the conditions of the Negishi cross-coupling were further 
optimized. As depicted in Table 7, the yield was remarkably improved when II-89 was 
reacted in the presence of 10 mol% Pd(dppf)Cl2 in THF at room temperature. At 50°C, the 
reaction time was accelerated considerably (Entry 4-5, Table 7). However, the yield was 
reduced and thus improvement must be done in this direction.  
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Entry Catalyst (mol%) Temperature (°C) Time (h) Yielda (%) 
1 Pd(PPh3)Cl2 (10) rt 18 32 
2 Pd(dppf)Cl2 (10) rt 18 61 
3 Pd(PPh3)4 (20) rt → 50 24 66 
4 Pd(PPh3)4 (10) 50 1 55 
5 Pd(dppf)Cl2 (10) 50 3 46 
a: Isolated yield after flash chromatography. 
Table 7. Condition screening for Negishi reaction on II-89. 
 
As the ethyl group was finally introduced on II-89, Overman rearrangement had to be 
repeated on structure II-95. As featured in Scheme 33, formation of the trichloroacetimidate 
and Overman rearrangement gave the desired building block II-98, albeit in a low overall 
yield. Optimization is still left to be conducted, but with II-98 in hand, only six steps remain 
until the natural product, melohenine B. 
 
 
Scheme 33. Formation of the building block. 
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2.3) Two other approaches to the building block 
 
Two alternative routes to the building block (II-33) were envisaged. One relied on a 
lactonization reaction to deliver lactone ring product II-33. In addition, the use of chiral 
auxiliary, (S)-1-amino-2-methoxymethylpyrrolidine (SAMP),[64] should lead to II-33 asym-
metrically (Scheme 34).  
 
 
Scheme 34. The lactonization approach to II-33. 
 
Unfortunately, this strategy quickly turned out to be in vain. The poor stability of the 
aldehyde II-99 did not allow the condensation of the Enders auxiliary, the 
organomagnesium-, or lithium reaction (Scheme 35). 
 
Scheme 35. A dead-end road. 
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The second approach employed an enyne metathesis as the key step to form the 
ring.[65] With regard to the difficulty of introducing the ethyl group, the enyne metathesis 
may be a response to this problem, while delivering the lactone ring. Nevertheless, a 
regioselective alkene reduction must be performed (Scheme 36).[66] 
 
Scheme 36. Enyne metathesis plan. 
 
We anticipated that the synthesis of compound II-107 would be straightforward 
starting from the amino acid, Boc-serine.  However, the oxidation of the N-Boc-O-allyl-serine 
to the corresponding aldehyde failed (Scheme 37). 
 
 
Scheme 37. Difficulties to oxidize the alcohol. 
  
 Thereafter, a literature precedent from Meffre et al. regarding the synthesis of β,γ--
alkynylglycine derivatives was found,[67] and from N-Boc-β,γ-alkynylglycine a simple esteri-
fication should give the desired substrate for the enyne metathesis (Scheme 38). 
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Scheme 38. Access to the enyne metathesis substrate. 
 
 The group devised the synthesis starting from L-serine. As illustrated in Scheme 39, 
methylation of the Boc-protected amino acid followed by protection of both the alcohol and 
secondary amine, via formation of an oxazolidine ring, gave the product II-113 in good 
overall yield. Then, reduction of the ester with DIBAl-(H) produced the aldehyde II-114, 
which was subject to a Seyfert-Gilbert homologation[68] in the presence of the Bestmann-
Ohira reagent and potassium carbonate.[69] A final deprotection sequence delivered the 
alcohol II-117 in good yield.  
 
Scheme 39. Formation of II-117 via Meffre’s route. 
 
Finally, a Jones oxidation[70] of the alcohol to form the corresponding acid was performed 
employing the conditions described by Meffre and coworkers. However, in our hands the 
reaction did not work. 
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III) Summary 
 
In 2009, the Luo group isolated and characterized two novel alkaloids from the 
Melodinus Henryi plant,[12] the melohenines A and B. The same year, intrigued by the 
unprecedented 6/9/6/6 tetracyclic ketolactam structure of the melohenine B (Figure 3), we 
decided to launch a study toward the total synthesis of this alkaloid.  
 
 
Figure 3. Melohenine B. 
 
The retrosynthesis plan to reach II-4 is outlined in Scheme 40. Nevertheless, the 
investigations up to this point, have focused on the production of the aminolactone building 
block II-33. 
 
 Scheme 40. Retrosynthesis of melohenine B.  
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Our initial strategy was to close the lacton ring through a ring-closing metathesis. 
Regrettably the reaction on II-67 delivered the desired product in poor yield (Scheme 41).  
 
 
Scheme 41. Ring-closing metathesis to synthesize the building block. 
 
The alternative solution was to start with a preformed lactone and to functionalize 
the ring. To this end, D-(+)-xylose was employed as the starting material and after five 
known steps, methoxy dihydropyranol II-78 was isolated in an overall good yield, as featured 
in Scheme 42. Then II-78 was functionalized with iodine in three additional steps in order to 
proceed to a cross-coupling reaction to introduce the ethyl group.  
 
 
Scheme 42. Carbohydrate chemistry to form the ring structure. 
 
 A shorter, but racemic route to II-82 was also developed starting with furfuryl alcohol 
to form the trans-isomer II-89 in only four reactions (Scheme 43). 
 Scheme 43. A shorter alternative. 
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Then, in order to install the amine functionality, an Overman rearrangement was 
examinated after formation of the trichloroacetimidate on II-82 or II-89. For the ethyl 
moiety, cross-coupling reactions on vinyl iodide compounds were explored. After various 
experiments on diverse stages of the synthesis, we finally found that the ethyl chain was 
best introduced via a Negishi reaction on II-89. Thus, Overman rearrangement was repeated 
on structure II-95. As featured in Scheme 44, formation of the trichloroacetimidate and the 
Overman rearrangement gave the desired building block II-98. Eventually, only six more 
steps are remaining until melohenine B. 
 
 
Scheme 44. The final steps for the building block synthesis. 
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IV) Experimental part 
 
1) General procedures 
 
Air and water sensitive reactions were performed in flame-dried glassware under an 
argon or nitrogen atmosphere. Air and moisture sensitive reagents were introduced via 
argon or nitrogen pre-filled plastic syringes, dry glass syringes or cannula.  
At low temperature, the reactions were carried out in a dewar filled with ice-water 
(0°C) or acetone/dry ice (-78°C). Under 0°C, reactions were accomplished with a cryostat 
(Thermo Haake, EK90).  
 
1.1) Solvents and reagents 
 
Dichloromethane (CH2Cl2), diethyl ether (Et2O), tetrahydrofuran (THF) were dried 
using a solvent purification system SPS-800 from M.Braun GmbH: 
 CH2Cl2: Merck Emsure®, p. a., 99.8%, <0.03% H2O, Column 2 × MB-KOL-A. 
 Et2O: Merck Emsure®, p. a., 99.7%, <0.03% H2O, Column 1 × MB-KOL-A, 1 × 
MB-KOL-M Typ 2. 
 THF: Merck Emsure®, p. a., 99.8%, <0.03% H2O, Column 2 × MB-KOL-M Typ 
2. 
Other solvents and reagents were purchased dry:  
 Acetonitrile: Acros Organics, Extra Dry, 99.9% over molecular sieves,           
< 0.005% H2O. 
 Dimethylsulfoxide: Sigma-Aldrich, puriss., 99.5% over molecular sieves,     
< 0.01% H2O or Acros Organics, Extra Dry, 99.9% over molecular sieves,           
< 0.005% H2O. 
 Methanol: Acros Organics, Extra Dry, 99.8% over molecular sieves,                    
< 0.005% H2O. 
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 N,N-Dimethylformamide: Sigma-Aldrich, puriss., 99.5% over molecular 
sieves, < 0.01% H2O or Acros Organics, Extra Dry, 99.9% over molecular 
sieves, < 0.005% H2O. 
 Toluene: Acros Organics, Extra Dry, 99.8% over molecular sieves, < 0.005% 
H2O. 
 1,2-dichloroethane: Acros Organics, Extra Dry, 99.8% over molecular 
sieves, < 0.005% H2O. 
 N,N-Diisopropylethylamine: Sigma-Aldrich, puriss., 99.5% over molecular 
sieves, < 0.05% H2O. 
 Pyridine: Acros Organics, Extra Dry, 99.8% over molecular sieves, < 0.005% 
H2O or Sigma-Aldrich, puriss., 99.8% over molecular sieves, < 0.005% H2O 
 Triethylamine: Distillated from molecular sieves and used immediately 
after distillation.  
Solvents used for thin layer chromatography (TLC), flash chromatography or work up 
(CH2Cl2, Et2O, THF, ethyl acetate, acetone, ethanol, methanol, pentanes, cyclohexane, 
petroleum ethers) were simply distilled. All other solvents and reagents were purchased 
from Aldrich, Acros, Fluka and Merck and used without further purification. 
 
1.2) Analytical techniques and apparatus 
 
Analytical thin-layer chromatography (TLC)  
TLC was performed with Merck Kieselgel 60 F254, 0.25 mm precoated glass-backed TLC 
plates. TLC plates were visualized using UV254, cerium ammonium molybdate (CAM) solution, 
or potassium permanganate (KMnO4) solution. CAM solution was prepared using 2.0 g 
cerium (IV) sulfate, 25.0 g ammonium heptamolybdate, 50 mL H2SO4 and 300 mL water. 
KMnO4 was prepared using 3 g potassium permanganate, 20.0 g potassium carbonate and 5 
mL 5% sodium hydroxide in 300 mL water.   
 
Flash Chromatography 
 Flash chromatography was carried out using 60 silica gel (40-63 µm, 230-400 mesh 
ASTM) available from Merck.  
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Gas chromatography (GC and GC-MS) 
 GC-MS spectra were recorded on an Agilent gas chromatography, Agilent 
Technologies 7890 A equipped with column HP-5MS (30 m x 250 µm x 0.25 µm), an Agilent 
Technologies 5975C inert MSD with triple-axis detector and helium as the carrier gas. 
 
Infrared spectroscopy (IR) 
 Infrared spectra were recorded on a JASCO IR-4100 spectrometer. Samples were 
analysed neat with attenuated total reflection (ATR). Characteristic bands are reported in 
wave length (cm-1).  
 
Mass Spectroscopy (MS) 
 Mass spectroscopic data were recorded using Finnigan MAT 8200 and an Agilent 
Technologies 5975C (electron ionization, EI 70 eV), or using a MAT 95S and a Bruker 
micrOTOF Agilent 1100 Series (high resolution mass spectroscopy, HRMS). 
 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
1H NMR spectra were obtained on Bruker 600 MHz FT-NMR, 400 Mhz FT-NMR, 500 
MHz FT-NMR, 360 MHz FT-NMR and 250 MHz FT-NMR spectrometers. 13C NMR spectra were 
recorded at 151.1 Mhz, 100.7 MHz, 90.6 MHz or 62.9 Mhz. Chemical shifts are reported in 
ppm relative to solvent signal. Multiplicity is indicated as follows: s (singlet); d (doublet); t 
(triplet); m (multiplet); dd (doublet of doublets).  
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2) Ring closing metathesis strategy (Strategy A) 
 
Dipotassium salt of nitroacetic acid (II-40) 
 
 
 
Nitromethane (10 g, 163.8 mmol) was added dropwise to a solution of potassium hydroxide 
(36.7 g, 654.8 mmol) in water (20 mL, 8 M). The solution turned yellow to brown and a 
precipitate was suddenly formed. The reaction mixture was heated to reflux for 1h. After 
cooling to room temperature, the precipitate was filtered, washed with methanol and dried 
under vacuum to give a brown solid (13.95 g, 77.0 mmol, 93%). It was directly used for the 
next step without further purification.   
 
2-nitroacetic acid (II-41) 
 
 
 
At 0°C, a 37% HCl-solution (11.1 mL, 135.4 mmol) was slowly added to a solution of 
dipotassium nitro acetate (5.0 g, 27.6 mmol) in water (7 mL, 4 M), so that the temperature 
of the reaction mixture did not exceed 0°C. After complete addition, the reaction mixture 
was allowed to warm to room temperature. The precipitate was filtered and the filtrate was 
extracted three times with Et2O. The combined organic phase was washed with sat. NaCl-
solution, dried over Na2SO4 and concentrated under reduced pressure, to give a brown solid 
(1.85 g, 17.6 mmol, 65%). It was directly used for the next step without further purification.   
 
IR (neat) cm-1: 1719, 1550, 1387. 
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m.p. 94 °C 
 
13C NMR (63 MHz, (CD3)2SO)  ppm] 123.84, 62.99.  
 
The analytical data are identical to the literature data.[71] 
 
Allyl 2-nitroacetate (II-42) 
 
 
 
Allyl alcohol (1.46 mL, 21.4 mmol) was added to a solution of nitroacetic acid II-41 (2.25 g, 
21.4 mmol) in THF (110 mL, 0.2 M). After cooling to 0°C, a solution of DCC (4.42 g, 21.4 
mmol) in THF (40 mL, 0.5 M) was slowly added, so that the temperature did not exceed 0°C. 
The reaction mixture was allowed to warm to room temperature and stirred for 20 h. It was 
then extracted three times with CH2Cl2. The combined organic phase was washed with sat. 
NaCl-solution, dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash chromatography (Pentanes/EtOAc = 9/1) to obtain the product (2.21 g, 15.2 
mmol, 71%).  
 
1H NMR (250 MHz, CDCl3)  ppm] 6.00 – 5.79 (m, 1H), 5.38 (dd, J = 2.7, 1.4 Hz, 1H), 5.33 – 
5.25 (m, 1H), 5.16 (s, 2H), 4.72 (d, J = 5.9 Hz, 2H). 
 
13C NMR (91 MHz, CDCl3)  ppm]161.6, 130.4, 120.4, 76.4, 67.6. 
 
 The analytical data are identical to the literature data.[72] 
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Ethyl 3-ethylpent-2-enoate (II-46) 
 
 
 
At 0°C, triethyl phosphonoacetate (2.99 mL, 15.1 mmol) was slowly added to a suspension of 
NaH (60% in paraffin oil) (0.604 g, 15.1 mmol) in dry THF (30 mL, 0.5 M). After stirring for 30 
min, pentan-3-one (1.23 mL, 11.6 mmol) was added dropwise. The reaction mixture was 
heated to 40 °C. After 20 h, it was quenched with sat. NH4Cl-solution and extracted three 
times with Et2O. The combined organic phase was washed with sat. NaCl-solution, dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by flash 
chromato-graphy (Pentanes/EtOAc = 99/1) to obtain the product (1.30 g, 8.31 mmol, 71%) as 
an oil.  
 
Rf = 0.26 (Pentanes/EtOAc = 99/1) [UV] 
 
1H NMR (360 MHz, CDCl3)  ppm] 5.60 (s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 2.61 (q, J = 7.5 Hz, 
2H), 2.19 (qd, J = 7.4, 1.3 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H), 1.07 (td, J = 7.5, 1.4 Hz, 6H). 
 
13C NMR (91 MHz, CDCl3)  ppm] 167.4, 166.8, 113.8, 59.6, 30.9, 25.6, 14.5, 13.2, 12.2.  
 
The analytical data are identical to the literature data.[73]  
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Ethyl 3-ethyl-2-nitropent-2-enoate (II-47) 
 
 
 
At 0°C, a 90 % nitric acid solution (2.41 mL) was carefully added to water (330 L). After slow 
addition of ethyl 3-ethylpent-2-enoate II-46 (1.0 g, 6.40 mmol) over a period of 90 min, the 
green solution was stirred for 1 h at 0°C and at room temperature for 2 h. The yellow 
reaction mixture was quenched with ice-water and extracted three times with CH2Cl2. The 
combined organic phase was washed with sat. NaHCO3-solution and sat. NaCl-solution, dried 
over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash 
chromatography (Pentanes/EtOAc = 9/1) to obtain the product (791.0 g, 3.93 mmol, 61%) as 
a yellow oil.   
 
Rf = 0.58 (Pentanes/Et2O = 95/5) [UV/KMnO4] 
 
1H NMR (360 MHz, CDCl3)  ppm] 4.28 (q, J = 7.1 Hz, 2H), 2.61 (q, J = 7.5 Hz, 2H), 2.21 (q, J = 
7.5 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H), 1.16 (td, J = 7.5, 3.5 Hz, 6H). 
 
13C NMR (91 MHz, CDCl3)  ppm]163.9, 159.4, 158.4, 62.3, 27.1, 24.7, 14.1, 12.6, 12.3. 
 
MS (EI) m/z (%): 156.1 (52) [M+-EtO], 127.1 (32) [M+-EtCHO2], 110.0 (20) [M
+-EtO-NO2], 94.1 
(68), 81.0 (79), 70.1 (65), 67.0 (100).  
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Ethyl 3-ethyl-2-nitropent-3-enoate (II-49) 
 
 
 
II-47 (700.0 mg, 3.48 mmol) dissolved in dry THF (0.88 mL, 4 M) was slowly added to a 
suspension of potassium hydride (140.0 mg, 3.48 mmol) in dry THF (1.74 mL, 2 M) at 0°C. 
After stirring for 30 min, THF was added, and after 1 h at 0°C, the reaction mixture was 
stirred at rt for 2 h. The formed precipitate was filtered, washed with Et2O and dried under 
vacuum to give a brown solid (552 mg, 2.31 mmol, 66%).  
 
The potassium salt (500 mg, 2.09 mmol) was dissolved in water (6.33 mL) and a 1M HCl-
solution was added. After stirring at rt for 10 min, the reaction mixture was extracted three 
times with Et2O. The combined organic phase was washed with sat. NaHCO3-solution and 
sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced pressure to give the 
product (376 mg, 1.87 mmol, 90%). It was directly used for the next step without further 
purification.   
 
1H NMR (250 MHz, CDCl3)  ppm] 5.79 (q, J = 6.9 Hz, 1H), 5.56 (s, 1H), 4.36 – 4.21 (m, 2H), 
2.41 – 2.11 (m, 2H), 1.78 (d, J = 6.9 Hz, 3H), 1.31 (t, J = 7.1 Hz, 3H), 1.00 (t, J = 7.6 Hz, 3H). 
 
13C NMR (91 MHz, CDCl3): δ [ppm] 163.8, 133.6, 132.1, 92.9, 63.1, 22.1, 14.2, 14.1, 12.9. 
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Methyl 3-ethylpent-2-enoate (II-52) 
 
 
 
Following the same procedure as for II-46, pentan-3-one (2.0 g, 23.2 mmol) was reacted with 
methyl diethyl phosphonoacetate (6.34 g, 30.2 mmol) in the presence of NaH (1.25 g, 31.1 
mmol). After flash chromatography (Pentanes/Et2O = 99/1), the product (1.93 g, 13.5 mmol, 
58%) was obtained.  
 
Rf = 0.55 (Cyclohexane/EtOAc = 95/5) [UV/KMnO4]. 
 
1H NMR (250 MHz, CDCl3) ppm] 5.61 (s, 1H), 3.68 (s, 3H), 2.62 (q, J = 7.5 Hz, 2H), 2.19 (dt, J 
= 8.7, 6.8 Hz, 2H), 1.07 (td, J = 7.5, 0.9 Hz, 6H). 
 
13C NMR (63 MHz, CDCl3)  ppm] 167.8, 167.2, 113.4, 50.9, 30.9, 25.6, 13.2, 12.2.  
 
The analytical data are identical to the literature data.[74] 
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Methyl 3-ethyl-2-nitropent-2-enoate (II-53) 
 
 
 
Following the same procedure as for II-47, II-52 (4.7 g, 33.1 mmol) was nitrated with a 90 % 
nitric acid solution (12.6 mL). After flash chromatography (Pentanes/Et2O = 99/1) the 
product (2.62 g, 14.0 mmol, 42%) was obtained.  
 
Rf = 0.53 (Pentanes/Et2O= 95/5) [UV/KMnO4] 
 
1H NMR (250 MHz, CDCl3)  ppm] 3.81 (s, 3H), 2.62 (q, J = 7.5 Hz, 2H), 2.22 (q, J = 7.5 Hz, 
2H), 1.16 (td, J = 7.5, 3.7 Hz, 6H). 
 
13C NMR (63 MHz, CDCl3)  ppm] 165.1, 159.7, 159.0, 52.9, 27.1, 24.7, 12.6, 12.3. 
 
Methyl 3-ethyl-2-nitropent-3-enoate (II-55) 
 
 
 
Following the same procedure as for II-49, II-53 (1.07 g, 5.71 mmol) was reacted with 
potassium hydride (236.0 mg, 5.88 mmol). After acidic work up, the product (509.3 mg, 2.72 
mmol, 48%) was isolated.   
 
Rf = 0.71 (Cyclohexane/EtOAc = 95/5) [UV/KMnO4] 
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1H NMR (360 MHz, CDCl3)  ppm] 5.79 (q, J = 6.9 Hz, 1H), 5.58 (s, 1H), 3.84 (s, 3H), 2.38 – 
2.14 (m, 2H), 1.78 (d, J = 6.9 Hz, 3H), 1.00 (t, J = 7.6 Hz, 3H). 
 
13C NMR (91 MHz, CDCl3)  ppm] 165.0, 133.6, 132.0, 92.6, 53.5, 22.0, 14.0, 12.7. 
 
Allyl 3-ethyl-2-nitropent-3-enoate (II-56) 
 
 
 
Bu2SnO (6.65 mg, 26.7 mol) was added to a solution of methyl 3-ethyl-2-nitropent-3-
enoate II-55 (49.0 mg, 267 mol) in allyl alcohol (2.3 mL, 0.01 M). The reaction mixture was 
heated to reflux for 15 h. It was quenched with sat. NaHCO3-solution and extracted three 
times with EtOAc. The combined organic phase was filtered through celite and the filtrate 
was concentrated under reduced pressure. The residue was purified by flash 
chromatography (Pentanes/Et2O = 95/5) to obtain the product (17.5 mg, 82.0 mol, 31%). 
 
Rf= 0.48 (Pentanes/Et2O = 95/5) [UV/KMnO4] 
 
1H NMR (250 MHz, CDCl3)  ppm] 6.00 – 5.73 (m, 2H), 5.84 – 5.75 (m, 1H), 5.59 (s, 1H), 5.43 
– 5.25 (m, 1H), 4.72 (d, J = 5.9 Hz, 2H), 2.44 – 2.10 (m, 2H), 1.78 (d, J = 6.9 Hz, 3H), 1.00 (t, J = 
7.6 Hz, 3H). 
 
13C NMR (63 MHz, CDCl3)  ppm] 164.2, 133.6, 131.9, 130.8, 112.0, 92.7, 67.3, 22.0, 14.0, 
12.8. 
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Methyl 3-methylpent-2-enoate (II-60) 
 
 
 
Following the same procedure as for II-46, butanone (8.0 g, 0.110 mol) was reacted with 
methyl diethyl phosphonoacetate (26.3 g, 0.114 mol) in the presence of NaH (5.32 g, 0.144 
mol). After flash chromatography (Pentanes/Et2O = 95/5), the product (9.85 g, 76.9 mmol, 
69%) was obtained as a mixture of E and Z isomers.  
 
Rf = 0.69 (Pentanes/Et2O = 95/5) [UV/KMnO4]. 
 
1H NMR (250 MHz, CDCl3)  ppm] 5.66 (d, J = 1.2 Hz, 0.7H), 5.63 (s, 0.3H), 3.68 (s, 2H), 3.67 
(s, 1H), 2.63 (q, J = 7.5 Hz, 0.6H), 1.21 – 1.10 (m, 3.4H), 1.88 (d, J = 1.3 Hz, 1H), 1.07 (t, J = 7.5 
Hz, 3H). 
 
13C NMR (63 MHz, CDCl3)  ppm] 167.5, 166.9, 162.6, 162.0, 115.2, 114.2, 50.9, 33.9, 31.0, 
26.7, 24.7, 18.9, 12.7, 12.1.  
 
The analytical data are identical to the literature data.[75] 
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Methyl 3-methyl-2-nitropent-2-enoate (II-61) 
 
 
 
Following the same procedure as for II-47, II-60 (9.0 g, 70.3 mmol) was nitrated with a 90 % 
nitric acid solution (24.5 mL). After flash chromatography (Pentanes/EtOAc = 95/5) the 
product (7.35 g, 42.4 mmol, 60%) was obtained as a mixture of E and Z isomers.  
 
Rf = 0.43 (Pentanes/Et2O = 9/1) [UV/KMnO4] 
 
1H NMR (360 MHz, CDCl3)  ppm] 3.82 (s, 3H), 2.63 (q, J = 7.5 Hz, 1H), 2.25 (s, 1.3H), 2.20 (q, 
J = 7.6 Hz, 1H), 1.97 (s, 1.7H), 1.21 – 1.10 (m, 3H). 
 
13C NMR (91 MHz, CDCl3)  ppm]160.0, 159.7), (154.3, 154.0), 141.6, (52.9, 52.9), (29.7, 
27.4), (20.2, 18.3), (12.1, 12.0).  
 
MS (EI) m/z (%): 173.0 (2) [M+], 156.1 (41) [M+-OH], 142.0 (30) [M+-MeO], 67.0 (70), 59.0 
(100). 
 
IR (neat) cm-1: 2981, 2958, 2883, 1732, 1530, 1270, 1214, 1120, 1053, 769. 
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Allyl 3-methyl-2-nitropent-2-enoate (II-62) 
 
 
 
Following the same procedure as for II-56, II-60 (2.0 g, 11.5 mmol) was transesterificated in 
presence of Bu2SnO (287.0 mg, 1.15 mmol) in allylic alcohol (115 mL). After flash chromato-
graphy (Pentanes/Et2O = 95/5) the product (1.24 g, 6.22 mmol, 53%) was obtained as a 
mixture of E and Z isomers. 
 
Rf = 0.31 (Cyclohexane/EtOAc= 95/5) [UV/KMnO4] 
 
1H NMR (250 MHz, CDCl3)  ppm] 5.98 – 5.80 (m, 1H), 5.41 – 5.21 (m, 2H), 4.71 (ddd, J = 5.6, 
2.2, 1.3 Hz, 2H), 2.63 (q, J = 7.5 Hz, 1H), 2.28 – 2.14 (m, 2.5H), 1.98 (s, 1.5H), 1.16 (td, J = 7.5, 
3.5 Hz, 3H). 
 
 13C NMR (91 MHz, CDCl3)  ppm] (159.2, 158.9), (154.4, 154.1), (130.98, 130.96), (119.3, 
119.2), 100.1, (66.5, 66.4), (29.7, 27.5), (20.2, 18.3), (12.1, 12.0). 
 
MS (EI) m/z (%): 199.0 (4) [M+], 158.0 (36) [M+-Allyl], 142.0 (42) [M+-CH2CHCH2O], 81.0 (64), 
67.1 (77), 57.1 (100) [CH2CHCH2O].  
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Allyl 3-methylene-2-nitropentanoate (II-63) 
 
 
 
Following the same procedure as for II-49, II-62 (1.0 g, 5.02 mmol) was reacted with 
potassium hydride (302.0 mg, 7.53 mmol). After acidic work up and flash chromatography 
(Pentanes/Et2O = 95/5) the product (708.7 mg, 3.56 mmol, 71%) was obtained.  
 
Rf = 0.31 (Cyclohexane/EtOAc = 95/5) [UV/KMnO4] 
 
1H NMR (250 MHz, CDCl3)  ppm] 5.98 – 5.81 (m, 1H), 5.67 (s, 1H), 5.44 – 5.26 (m, 4H), 4.74 
(dt, J = 5.9, 1.2 Hz, 2H), 2.24 (ddd, J = 8.6, 5.4, 1.3 Hz, 2H), 1.12 (t, J = 7.4 Hz, 3H). 
 
13C NMR (63 MHz, CDCl3)  ppm] 163.5, 140.0, 130.6, 120.5, 120.2, 91.9, 67.4, 26.1, 11.9.  
 
MS (EI) m/z (%): 158.0 (26) [M+-Allyl], 142.0 (28) [M+-CH2CHCH2OH], 81.0 (51), 67.0 (70), 57.0 
(100) [CH2CHCH2O].  
 
HRMS (ESI) m/z 222.0738 [222.0737 calcd. for C9H13NO4Na (M
++Na+)]. 
 
IR (neat) cm-1: 3090, 2974, 2883, 1751, 1561, 1534, 1360, 1266, 1210, 990, 930, 748. 
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Allyl 2-amino-3-methylenepentanoate (II-66) 
 
 
 
At 0°C, a conc. HCl-solution (11.5 mL, 0.5 M) was slowly added to a solution of allyl 3-
methylene-2-nitropentanoate II-63 (1.14 g, 5.75 mmol) in allyl alcohol (57.5 mL, 0.1 M). Then 
zinc powder (3.76 g, 57.5 mmol) was added portionwise to the reaction mixture under 
strong stirring. At the end of the addition, the suspension was filtered over celite and the 
filtrate was quenched with sat. NaHCO3-solution and extracted three times with EtOAc. The 
combined organic phase was washed with sat. NaCl-solution, dried over Na2SO4 and 
concentrated under reduced pressure to give the product (874.4 mg, 5.17 mmol, 90%). It 
was directly used for the next step without further purification.   
 
Rf = 0.25 (Pentanes/EtOAc = 6/4) [UV/KMnO4] 
 
1H NMR (360 MHz, CDCl3)  ppm] 5.90 (ddt, J = 17.1, 10.4, 5.7 Hz, 1H), 5.39 – 5.19 (m, 2H), 
5.06 (s, 1H), 4.96 (d, J = 1.4 Hz, 1H), 4.62 (dd, J = 5.7, 1.3 Hz, 2H), 4.05 (s, 1H), 2.21 – 2.01 (m, 
2H), 1.69 (s, 2H), 1.07 (t, J = 7.4 Hz, 3H). 
 
13C NMR (63 MHz, CDCl3)  ppm] 173.5, 149.4, 131.9, 118.7, 111.5, 65.9, 59.7, 25.8, 12.2. 
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Allyl 2-((tert-butoxycarbonyl)amino)-3-methylenepentanoate (II-67) 
 
 
 
At rt, triethylamine (271.1 mg, 2.68 mmol) and Boc anhydride (438.7 mg, 2.01 mmol) were 
added to a solution of allyl 2-amino-3-methylenepentanoate (226.7 mg, 1.34 mmol) in 
CH2Cl2 (2.68 mL, 0.5 M). After stirring for 21 h, the reaction mixture was quenched with sat. 
NaHCO3-solution and extracted three times with EtOAc. The combined organic phase was 
washed with sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified by flash chromatography (Pentanes/EtOAc = 9/1) to 
obtain the product (166.3 mg, 617.4 mol, 46%) as an oil.  
 
Rf = 0.31 (Cyclohexane/EtOAc = 95/5) [UV/KMnO4] 
 
1H NMR (360 MHz, CDCl3)  ppm] 5.89 (ddt, J = 17.1, 10.5, 5.7 Hz, 1H), 5.37 – 5.22 (m, 3H), 
5.08 (s, 1H), 5.01 (t, J = 1.6 Hz, 1H), 4.78 (d, J = 7.8 Hz, 1H ), 4.64 (dd, J = 7.5, 3.3 Hz, 2H), 2.11 
(ddd, J = 20.6, 13.9, 5.9 Hz, 2H), 1.44 (s, 9H), 1.07 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3)  ppm] 171.0, 159.0, 132.7, 131.7, 118.8, 112.4, 73.3, 66.1, 39.3, 
28.5, 26.3, 12.0. 
 
MS (EI) m/z (%): 269.1 (1) [M+], 196.1 (4) [M+-tBuO], 154.0 (18) [M+-tBuOC(O)N], 128.1 (100), 
84.1 (62), 57.1 (56) [CH2CHCH2O].  
 
HRMS (ESI) m/z 292.1520 [292.1519 calcd. for C14H23O4NNa (M
++Na+)]. 
 
IR (neat) cm-1: 3382, 3090, 2974, 2935, 1713, 1492, 1366, 1246, 1154, 1050, 988, 907. 
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Tert-butyl (4-ethyl-2-oxo-3,6-dihydro-2H-pyran-3-yl)carbamate (II-33) 
 
 
 
Grubbs II catalyst (31.3 mg, 36.9 mol) was added to II-67 (99.3 mg, 368.7 mol) dissolved in 
degassed toluene (37 mL, 0.01M). The reaction mixture was heated to reflux and stirred for 
24 h. After cooling to rt, the solution was filtered through celite. The filtrate was 
concentrated under reduced pressure. The residue was purified by flash chromatography 
(Pentanes/EtOAc = 8/2) to obtain the product (13.9 mg, 57.6 mol, 16%, 22% brsm) as an oil.  
 
Rf = 0.26 (Pentanes/EtOAc = 8/2) [UV/KMnO4] 
 
1H NMR (360 MHz, CDCl3)  ppm] 5.78 – 5.70 (m, 1H), 5.30 (s, 1H), 4.90 – 4.75 (m, 3H), 2.23 
– 2.11 (m, 2H), 1.46 (s, 9H), 1.06 (t, J = 7.3 Hz, 3H). 
 
13C NMR (91 MHz, CDCl3)  ppm] 170.7, 156.2, 142.6, 116.2, 80.6, 66.9, 53.2, 28.4, 23.6, 
11.5. 
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3) The carbohydrate strategy (Strategy B) 
 
(3R,4S,5R)-tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate (II-74) 
 
 
 
At 0°C, acetic acid (12.6 mL, 133.2 mmol) was added dropwise to a solution of D-(+)-xylose 
(5.0 g, 33.3 mmol) in pyridine (16 mL, 2 M). After the addition, the reaction mixture was 
allowed to warm to rt and stirred for 18 h. It was quenched with water and extracted three 
times with CH2Cl2. The combined organic phase was washed with sat. NaHCO3-solution and 
sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced pressure. The residue 
was purified by flash chromatography (CH2Cl2/EtOH = 100/3) to obtain the product (9.98 g, 
31.4 mmol, 94%) as a colorless syrup.  
 
Rf = 0.56 (Pentanes/EtOAc = 1/1) [CAM] 
 
1H NMR (250 MHz, CDCl3)  ppm] 6.26 (d, J = 3.7 Hz, 1H), 5.72 (d, J = 6.9 Hz, 1H), 5.47 (t, J = 
9.8 Hz, 1H), 5.21 (t, J = 8.3 Hz, 1H), 5.01 (tdd, J = 8.2, 6.8, 4.0 Hz, 4H), 4.15 (dd, J = 12.1, 5.0 
Hz, 1H), 3.94 (dd, J = 11.2, 5.9 Hz, 1H), 3.71 (t, J = 11.0 Hz, 1H), 3.52 (dd, J = 12.0, 8.4 Hz, 1H), 
2.17 (s, 13H), 2.11 (s, 3H), 2.05 (d, J = 0.5 Hz, 12H), 2.02 (s, 3H).  
 
The analytical data are identical to the literature data.[76] 
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(3R,4S,5R)-2-bromotetrahydro-2H-pyran-3,4,5-triyl triacetate (II-75) 
 
 
 
At 0°C, HBr (10 mL, 62.8 mmol, 33% solution in acetic acid) was added dropwise to 
tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate II-74 (10 g, 31.4 mmol) in solution in CH2Cl2 
(52 mL, 0.6 M). After stirring at 0°C for 30 min, the reaction mixture was quenched with ice 
water and extracted three times with CH2Cl2. The combined organic phase was washed with 
sat. NaHCO3-solution and sat. NaCl-solution, dried over Na2SO4 and concentrated under 
reduced pressure. Diethyl ether was added at 0°C to precipitate  the product, which was 
dried under vacuum to give white crystals (16.75 g, 49.4 mmol, 86%).  
 
Rf = 0.75 (Pentanes/EtOAc = 2/3) [CAM] 
 
1H NMR (250 MHz, CDCl3)  ppm] 6.15 (d, J = 3.7 Hz, 1H), 5.25 (t, J = 9.5 Hz, 1H), 5.04 – 4.92 
(m, 1H), 3.90 (dd, J = 11.2, 5.7 Hz, 1H), 3.85 – 3.76 (m, 1H), 3.62 (t, J = 10.8 Hz, 1H), 2.19 (s, 
3H), 2.12 (s, 3H), 2.05 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  ppm] 171.6, 169.9, 169.5, 91.8, 72.8, 70.2, 68.3, 60.9, 21.1, 21.0, 
20.8. 
 
 The analytical data are identical to the literature data.[76] 
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(3R,4R)-3,4-dihydro-2H-pyran-3,4-diyl diacetate (II-76) 
 
 
 
Pyranose bromide II-75 (50.7 mg, 149.5 mol) was dissolved in EtOAc (0.3 mL, 0.5 M). Sat. 
NaH2PO4 solution (0.6 mL, 0.25 M) and zinc dust (120 mg, 1.83 mmol) were added. The 
reaction mixture was stirred at room temperature for 3 h. The solution was extracted three 
times with EtOAc. The combined organic phase was washed with water, sat. NaHCO3-
solution and sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified by flash chromatography (Pentanes/EtOAc = 8/2) to 
obtain the product (25.3 mg, 126.4 mol, 85%) as colorless syrup.  
 
Rf = 0.33 (Pentanes/EtOAc = 9/1) [CAM] 
 
1H NMR (360 MHz, CDCl3)  ppm] 6.60 (d, J = 5.8 Hz, 1H), 4.98 (tdd, J = 9.2, 5.4, 3.4 Hz, 3H), 
4.20 (ddd, J = 12.0, 3.1, 1.5 Hz, 1H), 3.98 (dd, J = 12.2, 1.8 Hz, 1H), 2.10 (s, 3H), 2.07 (s, 3H). 
 
 13C NMR (91 MHz, CDCl3)  ppm] 170.1, 170.0, 148.2, 97.6, 67.4, 63.8, 63.6, 21.3, 21.1.  
 
The analytical data are identical to the literature data.[77] 
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6-methoxy-3,6-dihydro-2H-pyran-3-yl acetate (II-77) 
 
 
 
At rt, abs. methanol (1.09 mL, 33.9 mmol) and tin (IV) chloride (0.85 mL, 0.847 mmol, 1M in 
CH2Cl2) were added to 3,4-dihydro-2H-pyran-3,4-diyl diacetate II-76 (3.39 g, 16.9 mmol) 
dissolved in dry CH2Cl2 (85 mL, 0.2 M). After 45 min, the purple reaction was quenched with 
sat. NaHCO3-solution and extracted three times with CH2Cl2. The combined organic phase 
was washed with sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified by flash chromatography (Pentanes/EtOAc = 8/2) to 
obtain the product (2.56 g, 14.8 mmol, 88%) as a mixture of both diastereoisomers.  
 
Cis-diastereoisomer (minor) (II-77a) 
 
Rf = 0.43 (Pentanes/EtOAc= 4/1) [CAM] 
 
1H NMR (250 MHz, CDCl3)  ppm] 6.01 – 5.80 (m, 2H), 5.33 – 5.22 (m, 1H), 4.85 (s, 1H), 3.92 
– 3.72 (m, 2H), 3.45 (s, 3H), 2.07 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  ppm] 170.7, 129.2, 129.1, 95.5, 65.1, 60.4, 56.0, 21.1. 
 
Trans-diastereoisomer (major) (II-77b) 
 
Rf = 0.32 (Pentanes/EtOAc = 4/1) [CAM] 
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1H NMR (500 MHz, CDCl3)  ppm] 6.04 (qd, J = 10.1, 3.9 Hz, 2H), 4.98 – 4.92 (m, 1H), 4.89 (d, 
J = 2.6 Hz, 1H), 4.13 (dd, J = 13.0, 2.8 Hz, 1H), 3.83 (d, J = 13.0 Hz, 1H), 3.43 (s, 3H), 2.09 (s, 
3H). 
 
13C NMR (63 MHz, CDCl3)  ppm] 170.7, 130.9, 125.2, 94.2, 63.5, 61.4, 55.9, 21.2. 
 
The analytical data are identical to the literature data.[77] 
 
(3S,6R)-6-methoxy-3,6-dihydro-2H-pyran-3-ol (II-78) 
 
 
 
At rt, trans methoxy-3,6-dihydro-2H-pyran-3-yl acetate II-77b (451.0 mg, 2.62 mmol) was 
added to a fresh solution of sodium methoxide (1.75 mmol) in methanol (17.5 mL, 0.1 M). 
After 45 min, acetic acid (1.5 mL) was added dropwise and the reaction mixture was 
concentrated under reduce pressure. The residue was purified by flash chromatography 
(Pentanes/EtOAc = 1/1) to obtain the product (291.0 mg, 2.24 mmol, 85%) as a white solid.  
 
Rf = 0.09 (Pentanes/EtOAc = 4/1) [KMnO4] 
 
1H NMR (360 MHz, CDCl3)  ppm] 6.17 – 6.10 (m, 1H), 5.92 – 5.86 (m, 1H), 4.86 – 4.81 (m, 
1H), 4.09 (dd, J = 12.2, 2.5 Hz, 1H), 3.85 – 3.76 (m, 2H), 3.43 (s, 3H), 1.93 (s, 1H). 
 
13C NMR (91 MHz, CDCl3)  ppm] 129.4, 128.6, 94.4, 64.4, 61.7, 55.8. 
 
 The analytical data are identical to the literature data.[78] 
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(R)-6-methoxy-2H-pyran-3(6H)-one (II-79) 
 
 
 
At rt, IBX (3.81 g, 13.6 mmol) was added to 6-methoxy-3,6-dihydro-2H-pyran-3-ol II-78 
(709.2 mg, 5.45 mmol) in DMSO (18 mL, 0.3 M). After 2 h, CH2Cl2 (10 × 18 mL) was added to 
the solution, which was then stirred for 15 min. The precipitate was filtered and the filtrate 
was quenched with sat. NaHCO3-solution and extracted three times with CH2Cl2. The 
combined organic phase was washed with sat. NaCl-solution, dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by flash chromatography 
(Pentanes/EtOAc = 9/1) to obtain the product (560.2 mg, 4.37 mmol, 80%) as a white solid.  
 
Rf = 0.71 (Pentanes/EtOAc = 3/2) [KMnO4] 
 
1H NMR (250 MHz, CDCl3)  ppm] 6.89 (dd, J = 10.4, 3.3 Hz, 1H), 6.14 (d, J = 10.4 Hz, 1H), 
5.11 (d, J = 3.3 Hz, 1H), 4.45 (d, J = 16.9 Hz, 1H), 4.11 (d, J = 16.9 Hz, 1H), 3.53 (s, 3H). 
 
13C NMR (63 MHz, CDCl3)  ppm] 194.7, 144.3, 128.0, 94.4, 66.4, 56.8.  
 
The analytical data are identical to the literature data.[79] 
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(R)-4-iodo-6-methoxy-2H-pyran-3(6H)-one (II-80) 
 
 
 
I2 (87.2 mg, 0.343 mmol) was added to 6-methoxy-2H-pyran-3(6H)-one II-79 (20 mg, 0.156 
mmol) dissolved in dry pyridine (61.7 mg, 0.780 mmol) and dry CH2Cl2 (0.78 mL, 0.2 M) at 
0°C. The reaction mixture was stirred at 0°C. After 1 h, it was quenched with sat. Na2S2O3-
solution and sat. NH4Cl-solution. The solution was extracted three times with Et2O and the 
combined organic phase was washed with sat. NH4Cl-solution and with sat. NaCl-solution, 
dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by 
flash chromatography (Pentanes/EtOAc = 9/1) to obtain the product (29.6 mg, 0.117 mmol, 
75%) as a yellow liquid.  
 
Rf = 0.67 (Pentanes/EtOAc = 4/1) [KMnO4] 
 
1H NMR (360 MHz, CDCl3)  ppm] 7.62 (d, J = 3.7 Hz, 1H), 4.99 (d, J = 3.6 Hz, 1H), 4.64 (d, J = 
16.7 Hz, 1H), 4.34 (d, J = 16.7 Hz, 1H), 3.51 (s, 3H). 
 
13C NMR (91 MHz, CDCl3)  ppm] 188.2, 153.0, 103.1, 96.3, 65.8, 56.8. 
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4-iodo-6-methoxy-3,6-dihydro-2H-pyran-3-ol (II-82) 
 
 
At 0°C, cerium (III) chloride heptahydrate (147.3 mg, 0.395 mmol) and NaBH4 (14.95 mg, 
0.395 mmol) were added to iodopyranone II-80 (99.8 mg, 0.394 mmol) in dry methanol (0.7 
mL, 0.6 M). The reaction mixture was allowed to warm to rt. After stirring for 1 h, the 
reaction was quenched with water and extracted three times with Et2O. The combined 
organic phase was washed with sat. NaCl-solution, dried over Na2SO4 and concentrated 
under reduced pressure. The residue was purified by flash chromatography (Pentanes/EtOAc 
9/1) to obtain the product (66.5 mg, 0.260 mmol, 66%) as a diastereoisomeric mixture.  
 
Cis- diastereoisomer (Major) (II-82a) 
NOESY contact: 
 
 
Rf = 0.23 (Cyclohexane/EtOAc= 4/1) [KMnO4] 
 
1H NMR (400 MHz, CDCl3)  ppm] 6.48 (dd, J = 2.8, 1.4 Hz, 1H), 4.73 (dd, J = 2.8, 1.2 Hz, 1H), 
4.16 (dt, J = 6.8, 5.6 Hz, 1H), 3.89 (qd, J = 11.2, 6.7 Hz, 2H), 3.42 (s, 3H), 2.01 (d, J = 7.1 Hz, 
1H). 
 
13C NMR (101 MHz, CDCl3)  [ppm] 137.7, 108.6, 97.4, 68.4, 63.8, 55.9. 
 
MS (EI) m/z (%): 238.9 (65) [M+-OH], 224.9 (64) [M+-MeO], 129.0 (81) [M+-H-HI], 97.0 (100). 
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IR (neat) cm-1: 3426, 2978, 2925, 2830, 1637, 1355, 1328, 1232, 1121, 1058, 946, 891, 640, 
550. 
 
Trans-diastereoisomer (minor) (II-82b)  
 
NOESY contact: 
 
 
Rf = 0.19 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (400 MHz, CDCl3)  ppm] 6.51 (d, J = 3.3 Hz, 1H), 4.76 (d, J = 3.1 Hz, 1H), 4.22 – 4.16 
(m, 1H), 3.93 – 3.89 (m, 1H), 3.87 (dd, J = 12.1, 1.4 Hz, 1H), 3.41 (s, 3H), 2.25 (d, J = 8.5 Hz, 
1H). 
 
13C NMR (101 MHz, CDCl3)  [ppm] 137.7, 102.3, 96.2, 70.9, 64.2, 55.8.  
 
(3S,6R)-4-iodo-6-methoxy-3,6-dihydro-2H-pyran-3-yl 2,2,2-trichloroacetimidate (II-83) 
 
 
 
At 0°C, DBU (59.4 mg, 0.390 mmol), 4Å molecular sieves (cat.) and trichloroacetonitrile (50.7 
mg, 0.351 mmol) were added into a solution of cis iodopyranol II-82a (50 mg, 0.195 mmol) in 
dry CH2Cl2 (1.0 mL, 0.2 M). The reaction mixture was stirred at rt. After 12 h, it was 
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quenched with sat. NH4Cl-solution and extracted three times with CH2Cl2. The combined 
organic phase was washed with sat. NaCl-solution, dried over Na2SO4 and concentrated 
under reduced pressure. The residue was purified by flash chromatography (Pentanes/EtOAc 
= 9/1) to obtain the product (73.7 mg, 0.184 mmol, 94%) as a white solid. 
 
Rf = 0.46 (Cyclohexane/EtOAc = 4/1) [KMnO4] 
 
1H NMR (400 MHz, CDCl3)  ppm] 8.45 (s, 1H), 6.59 (dd, J = 2.9, 1.6 Hz, 1H), 5.47 (ddt, J = 
7.0, 5.4, 1.4 Hz, 1H), 4.74 (dd, J = 2.8, 1.3 Hz, 1H), 3.97 (dtd, J = 9.4, 7.6, 2.9 Hz, 2H), 3.37 (s, 
3H). 
13C NMR (101 MHz, CDCl3)  ppm] 162.0, 140.2, 98.9, 97.2, 91.0, 73.2, 60.6, 55.8. 
 
MS (EI) m/z (%): 238.9 (64) [M+-CCl3C(NH)O], 178.0 (32) [M
+-CCl3C(NH)O-MeOCH2O], 129.0 
(69), 107.9 (100), 97.0 (95).  
 
IR (neat) cm-1: 3340, 2932, 2887, 2831, 1663, 1281, 1056, 966, 835, 795, 645. 
 
2,2,2-trichloro-N-((2R,3R)-4-iodo-2-methoxy-3,6-dihydro-2H-pyran-3-yl)acetamide (II-84) 
 
 
 
Trichloroacetimidate II-83 (499 mg, 1.25 mmol) and K2CO3 (172.2 mg, 1.25 mmol) were 
heated to reflux in dry xylene (12,5 mL, 0.1 M) for 60 h. The solution was cooled to rt and 
filtered. The filtrate was concentrated and the residue was purified by flash chromate-
graphy (Cyclohexane/EtOAc = 9/1) to obtain the product (256.7 mg, 0.641 mmol, 51%, 58% 
brsm) as a white solid. 
 
Rf = 0.46 (Cyclohexane/EtOAc = 4/1) [CAM] 
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1H NMR (400 MHz, CDCl3)  ppm] 6.93 (d, J = 8.0 Hz, 1H), 6.62 (dt, J = 4.0, 2.1 Hz, 1H), 4.89 
(d, J = 4.1 Hz, 1H), 4.81 (tdd, J = 6.2, 4.3, 2.5 Hz, 1H), 4.19 (ddd, J = 17.0, 3.6, 2.1 Hz, 1H), 4.04 
(ddd, J = 16.7, 3.6, 2.6 Hz, 1H), 3.50 (s, 3H). 
 
13C NMR (101 MHz, CDCl3)  ppm] 161.7, 138.9, 99.5, 96.9, 91.8, 62.2, 56.4, 53.2. 
 
IR (neat) cm-1: 3329, 2959, 2933, 2853, 2839, 1712, 1522, 1382, 1299, 1093, 1047, 836, 816, 
721, 674, 602, 561. 
 
6-hydroxy-2H-pyran-3(6H)-one (II-86) 
 
 
 
At 0°C, m-CPBA (26.9 g, 112.1 mmol) was added portionwise to a solution of furfuryl alcohol 
(10 g, 101.9 mmol) in dry CH2Cl2 (204 mL, 0.5 M). The reaction mixture was allowed to warm 
to room temperature and was stirred for 4 h. The precipitate was filtered at -10°C, the 
filtrate was concentrated to 1/3 of its volume and cooled to -10°C, the formed solid was 
filtered. Finally, hexane was added to the filtrate to give the product as a white precipitate 
(9.11 g, 79.8 mmol, 78%).  
 
Rf = 0.08 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (600 MHz, CDCl3)  ppm] 6.95 (dd, J = 10.4, 3.1 Hz, 1H), 6.17 (d, J = 10.4 Hz, 1H), 
5.65 (dd, J = 3.0, 0.6 Hz, 1H), 4.58 (d, J = 16.8 Hz, 1H), 4.14 (d, J = 16.8 Hz, 1H). 
 
13C NMR (101 MHz, CDCl3)  ppm] 195.0, 146.2, 127.9, 88.3, 66.7.  
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The analytical data are identical to the literature data.[80] 
 
5-oxo-5,6-dihydro-2H-pyran-2-yl acetate (II-87) 
 
 
At 0°C, pyridine (3 mL, 37.2 mmol) was added to II-86 (3 g, 26.3 mmol) in acetic anhydride 
(9 mL, 95.4 mmol). The reaction mixture was stirred at 0°C. After 3 h, it was concentrated 
under reduced pressure and the residue was purified by flash chromatography 
(Cyclohexane/EtOAc = 4/1) to obtain the product (3.12 g, 20.0 mmol, 76%) as a yellow liquid. 
 
Rf = 0.22 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (600 MHz, CDCl3)  ppm] 6.92 (dd, J = 10.4, 3.6 Hz, 1H), 6.49 (d, J = 3.6 Hz, 1H), 6.27 
(d, J = 10.4 Hz, 1H), 4.51 (d, J = 17.0 Hz, 1H), 4.22 (d, J = 17.0 Hz, 1H), 2.14 (s, 3H). 
 
13C NMR (151 MHz, CDCl3)  ppm] 193.4, 169.6, 142.4, 128.9, 86.8, 67.6, 21.0.  
 
The analytical data are identical to the literature data.[54] 
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4-iodo-5-oxo-5,6-dihydro-2H-pyran-2-yl acetate (II-88) 
 
 
 
I2 (17.9 g, 70.5 mmol) was added portionwise to II-87 (5 g, 32.0 mmol) in solution in dry 
CH2Cl2 (160 mL, 0.2 M) and dry pyridine (12.9 mL, 160.1 mmol) at 0°C. The reaction mixture 
was stirred at 0°C for 3 h. Finally, it was quenched with sat. NH4Cl-solution and sat. Na2S2O3-
solution and extracted three times with Et2O. The combined organic phase was washed with 
sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced pressure. The residue 
was purified by flash chromatography (Cyclohexane/EtOAc = 4/1) to obtain the product (6.57 
g, 23.3 mmol, 73%) as a white solid. 
 
Rf = 0.4 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
1H NMR (600 MHz, CDCl3)  ppm] 7.68 (d, J = 3.9 Hz, 1H), 6.36 (d, J = 3.9 Hz, 1H), 4.73 (d, J = 
16.8 Hz, 1H), 4.49 (d, J = 16.8 Hz, 1H), 2.18 (s, 3H). 
 
13C NMR (151 MHz, CDCl3)  ppm] 187.1, 169.3, 150.9, 103.9, 88.6, 67.1, 20.9. 
 
IR (neat) cm-1: 3074, 3004, 1749, 1699, 1604, 1368, 1328, 1312, 1209, 1153, 997, 929, 906, 
895, 591, 524, 503. 
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4-iodo-6-methoxy-3,6-dihydro-2H-pyran-3-ol (II-89) 
 
 
 
At -78°C, cerium (III) chloride heptahydrate (687.0 mg, 1.84 mmol) and NaBH4 (69.8 mg, 1.84 
mmol) were added to -iodoketon II-88 (400 mg, 1.42 mmol) dissolved in dry methanol 
(2.36 mL, 0.6 M). The reaction mixture was then allowed to warm to rt and was stirred for 10 
min. Finally, it was quenched with water and extracted three times with EtOAc. The 
combined organic phase was washed with sat. NaCl-solution, dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by flash chromatography 
(Cyclohexane/EtOAc = 4/1) to obtain two diastereoisomers as a white solid, II-89a (186.7 mg, 
0.729 mmol, 51%) and II-89b (38.2 mg, 0.149 mmol, 11%). 
 
Trans-diastereoisomer (major) (II-89a) 
 
Rf = 0.19 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
 1H NMR (600 MHz, CDCl3)  ppm] 6.51 (d, J = 3.3 Hz, 1H), 4.76 (d, J = 3.3 Hz, 1H), 4.19 (dd, J 
= 12.2, 2.7 Hz, 1H), 3.93 – 3.89 (m, 1H), 3.87 (dd, J = 12.2, 1.4 Hz, 1H), 3.41 (s, 3H), 2.19 (d, J = 
8.6 Hz, 1H). 
 
13C NMR (151 MHz, CDCl3)  ppm] 137.7, 102.2, 96.3, 70.9, 64.2, 55.8. 
 
MS (EI) m/z (%): 238.9 (68) [M+-H3O], 224.9 (72) [M
+-MeO], 129.0 (90) [M+-I], 97 (100) [M+-
I-MeOH].  
 
IR (neat) cm-1: 3427, 2977, 2965, 2935, 2829, 1744, 1629, 1346, 1248, 1048, 934, 821, 571. 
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Cis-diastereoisomer (minor) (II-89b) 
 
Rf = 0.24 (Cyclohexane/EtOAc = 4/1) [CAM] 
 
 1H NMR (400 MHz, CDCl3)  ppm] 6.48 (dd, J = 2.8, 1.4 Hz, 1H), 4.74 (dd, J = 2.7, 1.1 Hz, 1H), 
4.21 – 4.12 (m, 1H), 3.89 (qd, J = 11.2, 6.7 Hz, 2H), 3.42 (s, 3H), 1.96 (d, J = 7.1 Hz, 1H). 
 
 13C NMR (101 MHz, CDCl3)  ppm] 137.7, 108.7, 97.4, 68.3, 63.8, 55.9. 
 
MS (EI) m/z (%): 238.9 (60) [M+-H3O], 224.9 (60) [M
+-MeO], 129.0 (78) [M+-I], 97 (100) [M+-
I-MeOH].  
 
(±)-4-iodo-6-methoxy-3,6-dihydro-2H-pyran-3-yl 2,2,2-trichloroacetimidate (II-90) 
 
 
 
At 0°C, DBU (213.7 mg, 1.37 mmol), 4Å molecular sieves (cat.) and trichloroacetonitrile 
(197.4 mg, 1.37 mmol) were added to a solution of II-89a (175.1 mg, 0.684 mmol) in dry 
CH2Cl2 (3.4 mL, 0.2 M). The reaction mixture was stirred at 0°C. After 3 h, it was quenched 
with sat. NH4Cl-solution and extracted three times with CH2Cl2. The combined organic phase 
was washed with sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified by flash chromatography (Cyclohexane/EtOAc = 9/1) to 
obtain the product (206.3 mg, 0.515 mmol, 75%). 
 
Rf = 0.58 (Cyclohexane/EtOAc = 4/1) [CAM/KMnO4] 
 
EXPERIMENTAL PART 
THE CARBOHYDRATE STRATEGY (STRATEGY B) 
 
252 
 
1H NMR (600 MHz, CDCl3)  ppm] 8.49 (s, 1H), 6.73 (d, J = 3.4 Hz, 1H), 5.30 (d, J = 2.3 Hz, 
1H), 4.87 (d, J = 3.4 Hz, 1H), 4.26 (dd, J = 13.2, 2.8 Hz, 1H), 4.06 (dd, J = 13.2, 1.0 Hz, 1H), 3.42 
(s, 3H). 
 
13C NMR (151 MHz, CDCl3)  ppm] 162.1, 140.8, 100.4, 96.2, 94.0, 75.2, 61.1, 55.9. 
 
MS (EI) m/z (%): 254.9 (6) [M+-CCl3C(NH)], 238.9 (82) [M
+-CCl3C(NH)O], 224.9 (81), 129.0 
(84), 96.9 (100).  
 
(±)-2,2,2-trichloro-N-(-4-iodo-2-methoxy-3,6-dihydro-2H-pyran-3-yl)acetamide (II-91) 
 
 
 
Trichloroacetimidate II-90 (105.3 mg, 0.263 mmol) and K2CO3 (7.3 mg, 52.6 µmol) were 
heated to 170°C in dry o-dichlorobenzene (2.6 mL, 0.1 M) for 3h. The solution was cooled to 
rt and filtered. The filtrate was purified by flash chromatography (Cyclohexane/EtOAc = 9/1) 
to obtain the product (81.4 mg, 0.203 mmol, 77%) as a white solid. 
 
Rf = 0.42 (Cyclohexane/EtOAc= 4/1) [CAM/KMnO4] 
 
1H NMR (600 MHz, CDCl3)  ppm] 6.69 – 6.66 (m, 2H), 4.77 (d, J = 0.9 Hz, 1H), 4.48 – 4.43 
(m, 1H), 4.26 (dt, J = 16.9, 2.2 Hz, 1H), 4.08 (ddd, J = 16.8, 3.8, 0.6 Hz, 1H), 3.48 (s, 3H). 
 
13C NMR (151 MHz, CDCl3)  ppm] 161.8, 140.0, 100.1, 99.5, 86.5, 61.7, 57.0, 56.3.  
 
MS (EI) m/z (%): 338.9 (22) [M+-MeOCH2O], 271.9 (18) [M
+-HI], 237.9 (4) [M+-Cl3C(O)NH2], 
211.9 (100), 177.9 (47), 176.9 (46), 78.0 (47).  
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HRMS (ESI) m/z 421.8585 [421.8585 calcd. for C8H9Cl3INNaO3 (M
++Na+)]. 
 
IR (neat) cm-1: 3268, 2957, 2935, 2906, 2839, 1694, 1520, 1343, 1308, 1250, 1136, 1100, 818, 
654, 590, 547. 
 
(±)-4-iodo-2-methoxy-3,6-dihydro-2H-pyran-3-amine (II-92) 
 
 
 
A 3M NaOH-solution (2.1 mL, 6.24 mmol) was added to II-91 (500 mg, 1.25 mmol) in MeOH 
(12.5 mL, 0.1 M), and the solution was heated to reflux. After 24 h, a 1M HCl-solution was 
added dropwise into the reaction mixture until pH = 1-2, and the mixture was extracted 
three times with CH2Cl2. The aqueous phase was basified with NaOH-solution and extracted 
with three times Et2O. The combined organic phase was washed with sat. NaCl-solution, 
dried over Na2SO4 and concentrated under reduced pressure. The crude product was 
purified by flash chromatography (Petroleum ether/EtOAc 1/1) to obtain the product (144.2 
mg, 0.565 mmol, 45%) as oil. 
 
Rf = 0.11 (Cyclohexane/EtOAc= 4/1) [KMnO4] 
 
1H NMR (400 MHz, CDCl3)  ppm] 6.39 (dd, J = 3.4, 2.3 Hz, 1H), 4.73 (d, J = 1.7 Hz, 1H), 4.20 
(dt, J = 16.5, 2.1 Hz, 1H), 4.02 (ddd, J = 16.5, 3.5, 1.0 Hz, 1H), 3.46 (s, 3H), 3.19 (s, 1H), 1.56 (s, 
2H). 
 
13C NMR (101 MHz, CDCl3)  [ppm] 135.4, 102.5, 98.3, 62.3, 58.4, 56.1. 
 
MS (EI) m/z (%): 195.9 (6), 194.9 (100), 126.9 (2), 68.0 (27), 67.0 (6).  
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(±)-4-ethyl-6-methoxy-3,6-dihydro-2H-pyran-3-ol (II-95) 
 
 
 
At rt, Pd(dppf)Cl2 (6.4 mg, 7.81 µmol) was added to a degassed solution of II-89a (20 mg, 
78.1 µmol) in dry THF (0.31 mL, 0.25 M) The reaction mixture was cooled to 0°C and Et2Zn 
(78.1 µL, 78.1 µmol, 1 M in hexanes) was added dropwise. The reaction mixture was then 
allowed to warm to rt and was stirred for 16 h. Finally, it was quenched with sat. NH4Cl-
solution and extracted three times with Et2O. The combined organic phase was washed with 
sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced pressure. The residue 
was purified by flash chromatography (Cyclohexane/EtOAc = 4/1) to obtain the product (7.5 
mg, 47.4 µmol, 61%).  
 
Rf = 0.15 (Petroleum ether/EtOAc = 4/1) [KMnO4] 
 
1H NMR (400 MHz, CDCl3)  ppm] 5.53 (dt, J = 3.2, 1.7 Hz, 1H), 4.85 (dt, J = 2.7, 1.2 Hz, 1H), 
4.03 (dd, J = 12.2, 2.1 Hz, 1H), 3.79 (dd, J = 12.1, 1.2 Hz, 1H), 3.64 (d, J = 9.7 Hz, 1H), 3.43 (s, 
3H), 2.36 – 2.23 (m, 1H), 2.21 – 2.10 (m, 1H), 1.84 (d, J = 10.2 Hz, 1H), 1.08 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3)  ppm] 143.4, 120.7, 95.2, 64.9, 64.5, 55.7, 26.7, 11.6. 
 
MS (EI) m/z (%): 157.1 (6) [M+-H], 141.1 (71) [M+-OH], 128.1 (66), 127.1 (100) [M+-MeO], 
97.1 (44) [M+-MeOCH2O], 81.1 (50), 69.1 (45).  
 
HRMS (APCI) m/z 157.0861 [157.0859 calcd. for C8H13O3 (M-H)
+]. 
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(±)-4-ethyl-6-methoxy-3,6-dihydro-2H-pyran-3-yl 2,2,2-trichloroacetimidate (II-96) 
 
 
 
At 0°C, DBU (6.1 mg, 40.3 µmol) and trichloroacetonitrile (64.0 mg, 443.8 µmol) were added 
to a solution of II-95 (63.8 mg, 403.3 µmol) in dry CH2Cl2 (1.6 mL, 0.25 M). The reaction 
mixture was stirred at 0°C. After 1 h, it was quenched with H2O and extracted three times 
with CH2Cl2. The combined organic phase was washed with sat. NaCl-solution, dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by flash 
chromatography (Cyclohexane/EtOAc = 9/1) to obtain the product (77.6 mg, 256.5 µmol, 
64%). 
 
Rf = 0.59 (Cyclohexane/EtOAc = 4/1) [KMnO4] 
 
1H NMR (400 MHz, CDCl3)  ppm] 8.39 (s, 1H), 5.79 (dt, J = 3.2, 1.6 Hz, 1H), 5.12 (d, J = 2.3 
Hz, 1H), 4.98 – 4.95 (m, 1H), 4.12 (dd, J = 13.3, 2.7 Hz, 1H), 4.03 (dd, J = 13.3, 1.0 Hz, 1H), 
3.44 (s, 3H), 2.29 – 2.08 (m, 2H), 1.09 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3)  ppm] 162.7, 138.6, 124.1, 95.1, 91.6, 70.7, 60.5, 55.8, 26.6, 
11.4. 
 
 
 
 
 
 
EXPERIMENTAL PART 
THE CARBOHYDRATE STRATEGY (STRATEGY B) 
 
256 
 
(±)-2,2,2-trichloro-N-(4-ethyl-2-methoxy-3,6-dihydro-2H-pyran-3-yl)acetamide (II-97) 
 
 
 
Trichloroacetimidate II-96 (20 mg, 66.1 µmol) and K2CO3 (1.8 mg, 13.2 µmol) were heated to 
170°C in dry o-dichlorobenzene (0.70 mL, 0.1 M) for 5 h. The solution was cooled to rt and 
filtered. The filtrate was purified by flash chromatography (Cyclohexane/EtOAc = 9/1) to 
obtain the product (17.4 mg, 57.5 µmol, 87%). 
 
Rf = 0.40 (Cyclohexane/EtOAc= 4/1) [KMnO4] 
 
1H NMR (400 MHz, CDCl3)  ppm] 6.58 (d, J = 7.6 Hz, 1H), 5.69 (dd, J = 3.3, 1.6 Hz, 1H), 4.72 
(s, 1H), 4.25 – 4.08 (m, 3H), 3.48 (s, 3H), 2.14 – 2.01 (m, 2H), 1.07 (t, J = 7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3)  [ppm] 161.9, 133.4, 122.5, 100.2, 99.3, 59.4, 56.2, 50.0, 27.1, 
11.6. 
 
HRMS (ESI) m/z 323.9929 [323.9931 calcd. for C10H14Cl3NNaO3 (M
++Na+)]. 
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4) Enyne metathesis strategy (Strategy C) 
 
methyl 2-((tert-butoxycarbonyl)amino)-3-hydroxypropanoate (II-112) 
 
 
 
At 0°C, K2CO3 (1.48 g, 10.7 mmol) and methyl iodide (2.77 g, 19.5 mmol) were added to Boc-
serine (2.0 g, 9.75 mmol) in dry DMF (16.0 mL, 0.6 M). The reaction mixture was stirred at rt. 
After 18 h, it was concentrated, quenched with H2O and extracted three times with EtOAc. 
The combined organic phase was washed with H2O and with sat. NaCl-solution, dried over 
Na2SO4 and concentrated under reduced pressure. The crude product (1.78 g, 8.11 mmol, 
83%) was used for the next step without further purification.  
 
1H NMR (400 MHz, CDCl3)  [ppm] 5.43 (br s, 1H), 4.38 (br s, 1H), 3.93 (qd, J = 11.2, 4.1 Hz, 
2H), 3.79 (s, 3H), 2.29 (br s, 1H), 1.45 (s, 9H). 
 
13C NMR (151 MHz, CDCl3)  [ppm] 171.4, 162.7, 80.4, 63.7, 55.9, 52.8, 28.4. 
 
The analytical data are identical to the literature data.[81] 
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3-tert-butyl 4-methyl 2,2-dimethyloxazolidine-3,4-dicarboxylate (II-113) 
 
 
 
A solution of O-methyl-N-Boc serine II-112 (1.74 g, 8.48 mmol), 2,2-dimethoxypropane (2.21 
g, 21.2 mmol) and PTSA (32.3 mg, 0.170 mmol) in dry benzene (14.1 mL, 0.6 M) was heated 
to reflux. After 2h, the reaction mixture was allowed to cool to rt then it was quenched with 
sat. NaHCO3-solution and extracted three times with EtOAc. The combined organic phase 
was washed with sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced 
pressure. The crude product (1.77 g, 6.82 mmol, 81%) was used for the next step without 
further purification. 
 
1H NMR (400 MHz, CDCl3)  [ppm] 4.49 (dd, J = 6.7, 2.6 Hz, 0.4H), 4.38 (dd, J = 7.0, 3.1 Hz, 
0.6H), 4.14 (td, J = 9.0, 7.0 Hz, 1H), 4.04 (td, J = 9.4, 2.9 Hz, 1H), 3.76 (s, 3H), 1.67 (s, 1.7H), 
1.64 (s, 1.3H), 1.57 (s, 1H), 1.54 (s, 2H), 1.50 (s, 4H), 1.41 (s, 5H). 
 
The analytical data are identical to the literature data.[81] 
 
tert-butyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate (II-114) 
 
 
 
At -78°C, DIBAl-(H) (5.46 mL, 6.56 mmol, 1.2 M in toluene) was slowly added to II-113 (1 g, 
3.86 mmol) in dry toluene (7.7 mL, 0.5 M). The reaction mixture was stirred at -78°C for 3 h. 
Then MeOH (1.5 mL) was added, after 15 minutes the suspension was poured in a 1M HCl-
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solution and extracted three times with EtOAc. The combined organic phase was washed 
with sat. NaCl-solution, dried over Na2SO4 and concentrated under reduced pressure. The 
residue was purified by flash chromatography (Cyclohexane/EtOAc = 4/1) to obtain the 
product (657.3 mg, 2.87 mmol, 74%) as a rotameric mixture. 
 
Rf = 0.31 (Cyclohexane/EtOAc = 4/1) [KMnO4]  
 
1H NMR (400 MHz, CDCl3)  [ppm] 9.61 (br s, 0.4H), 9.55 (d, J = 2.1 Hz, 0.6H), 4.33 (br s, 
0.4H), 4.19 (br s, 0.6H), 4.14 – 4.02 (m, 2H), 1.68 – 1.40 (m, 15H). 
 
13C NMR (101 MHz, CDCl3)  [ppm] 199.6, 160.8, 95.2, 81.3, 64.9, 64.1, 28.4, (26.9, 26.0), 
(24.9, 24.0). 
 
The analytical data are identical to the literature data.[81] 
 
dimethyl (1-diazo-2-oxopropyl)phosphonate (II-115) 
 
 
 
At 0°C, the solution of dimethyl (2-oxopropyl)phosphonate (3.0 g, 18.1 mmol) in benzene (14 
mL, 1.3 M) was slowly added to the suspension of NaH (455.1 mg, 19.0 mmol) in benzene 
(63 mL, 0.3 M) and THF (11.1 mL, 1.7 M), the reaction mixture was stirred for 1 h, before 
tosyl azide (3.9 g, 19.9 mmol, 1.4 M in benzene) was added. After stirring at rt for 15 h; the 
suspension was filtered through celite and the filtrate was concentrated under reduced 
pressure. The residue was purified by flash chromatography (Cyclohexane/EtOAc 2/3) to 
obtain the product (2.38 g, 12.3 mmol, 69%). 
 
1H NMR (400 MHz, CDCl3)  [ppm] 3.85 (s, 3H), 3.82 (s, 3H), 2.26 (s, 3H). 
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13C NMR (101 MHz, CDCl3)  [ppm] 190.1, 189.9, 53.7, 53.7, 27.3. 
 
The analytical data are identical to the literature data.[82] 
 
tert-butyl 4-ethynyl-2,2-dimethyloxazolidine-3-carboxylate (II-116) 
 
 
 
At 0°C, K2CO3 (2.17 g, 15.7 mmol) was added to a solution of II-114 (1.8 g, 7.85 mmol) and 
dimethyl (1-diazo-2-oxopropyl)phosphonate II-115 (2.26 g, 11.8 mmol) in dry MeOH (26 mL, 
0.3 M). After 1 h at 0°C, the reaction mixture was stirred at rt for 20 h. It was quenched with 
sat. NH4Cl-solution, MeOH was evaporated and the residue was extracted three times with 
EtOAc. The combined organic phase was washed with sat. NaCl-solution, dried over Na2SO4 
and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (Cyclohexane/EtOAc 95/5) to obtain the product (1.03 g, 4.58 mmol, 58%) 
as a rotameric mixture. 
 
Rf = 0.52 (Cyclohexane/EtOAc= 4/1) [KMnO4] 
 
1H NMR (400 MHz, CDCl3)  [ppm] 4.61 (br s, 0.5H), 4.49 (br s, 0.5H), 4.08 – 3.99 (m, 2H), 
2.26 (s, 1H), 1.63 (s, 3H), 1.49 (s, 12H). 
 
13C NMR (101 MHz, CDCl3)  [ppm] 160.8, 94.6, 81.1, 80.6, 70.3, 68.9, 48.5, 28.6. 
 
The analytical data are identical to the literature data.[67] 
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tert-butyl (1-hydroxybut-3-yn-2-yl)carbamate (II-117) 
 
 
At 0°C, II-116 (1.03 g, 4.56 mmol) in MeOH (4 mL, 1.1 M) was added to TFA (41 mL, 0.1 M), 
the reaction mixture was stirred at room temperature for 1 h. Et2O was added and the 
solution was concentrated under reduced pressure, this operation was repeated three 
times, before dioxane (23 mL, 0.2 M) was introduced and sat. NaHCO3-solution was added 
until pH = 7-8. The solution was cooled to 0°C, then Na2CO3 (1.21 g, 11.4 mmol) and Boc 
anhydride (2.49 g, 11.4 mmol) were added. After 1 h at 0°C and 1 h at room temperature, 
the reaction mixture was filtered and the filtrate was extracted three times with EtOAc. The 
combined organic phase was washed with sat. NaCl-solution, dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by flash chromatography 
(Cyclohexane/EtOAc = 7/3 → 6/4) to obtain the product (592 mg, 3.19 mmol, 70%) as a 
white solid. 
 
Rf = 0.38 (Cyclohexane/EtOAc = 1/1) [KMnO4]  
 
1H NMR (400 MHz, CDCl3)  [ppm] 5.01 (br s, 1H), 4.53 (br s, 1H), 3.77 – 3.69 (m, 2H), 2.33 (d, 
J = 2.4 Hz, 1H), 1.46 (s, 9H). 
 
13C NMR (101 MHz, CDCl3)  [ppm] 146.9, 85.3, 80.6, 72.7, 65.8, 45.4, 28.5. 
 
The analytical data are identical to the literature data.[67] 
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Abbreviations 
 
Ac Acetyl 
Ac2O Acetic anhydride 
Aq. Aqueous 
Ar Aryl 
b. p. Boiling point 
Bn Benzyl 
Boc2O Di-tbutyl dicarbonate 
n-BuLi n-Butyllithium 
brsm Based on recovering starting material 
Bu Butyl 
Bz Benzoyl 
calcd. Calculated 
CAM Cerium ammonium molybdate 
Cat. Catalyst, catalytic 
COD 1,5-cyclooctadiene 
Conc. Concentrated 
COSY Correlated spectroscopy 
m-CPBA meta-Chloroperoxybenzoic acid 
 Chemical shift 
D Doublet (NMR) 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCC N,N'-dicyclohexylcarbodiimide 
DCE Dichloroethane 
DIBAL(H) Diisobutylaluminium hydride 
DIPEA Diisopropylamine 
DHP 2,3-Dihydropyran 
DMAP 4-Dimethylaminopyridine 
DMF N,N’-dimethylformamide 
DMPU 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
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DMSO Dimethyl sulfoxide 
Dppf 1,1'-Bis(diphenylphosphino)ferrocene 
d.r. Diastereomeric ratio 
EI Electron ionization 
Eq Equation 
Equiv. Equivalent 
ESI Electrospray ionization 
Et Ethyl 
EtOAc Ethyl acetate 
Et2O Diethyl ether 
GC Gas chromatography 
G Gram 
h Hour(s) 
HMBC Heteronuclear multiple-bond-coherence 
HMQC Heteronuclear multiple-quantum-coherence 
HRMS High resolution mass spectroscopy 
Hz Herz 
IBX 2-Iodoxybenzoic acid 
Im Imidazole 
iPr Iso-propyl 
iPrOH Isopropanol 
J Coupling constant 
M Molar 
m Multiplet 
m/z Ratio mass/charge 
Me Methyl 
MeOH Methanol 
mg Milligram 
MHz Megaherz 
Min Minute(s) 
mL Milliliter 
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mmol Millimole 
m.p Melting point 
MS Mass spectroscopy 
Mw Microwave 
nBu nButyl 
NIS N-Iodosuccinimide 
NMO N-Methylmorpholine-N-oxide 
nPr nPropyl 
Pd/C Palladium on charcoal 
Pent Pentyl 
Ph Phenyl 
PhH Benzene 
Ppm parts-per-million 
PPTS Pyridinium p-toluenesulfonate 
PTSA para-Toluenesulfonic acid 
Py Pyridine 
Py.SO3 Sulfur trioxide pyridine complex 
Q quadruplet 
Quant. Quantitative 
RCM Ring closing metathesis 
Rf Retention factor 
Rfl Reflux 
rt Room temperature 
s Singlet 
Sat. Saturated 
SM Starting material 
t Triplet 
TBSCl tert-Butyldimethylsilyl chloride 
tBu tert-Butyl 
Temp. Temperature 
TFA Trifluoroacetic acid 
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THF Tetrahydrofuran 
THP Tetrahydropyran 
TLC Thin layer chromatography 
Tol Toluene 
TPAP Tetrapropylammonium perruthenate 
UV Ultra violet 
 
 
 
 
 
